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Cardiac arrhythmia leads to 325,000 cases of sudden cardiac death annually 
in adults alone (Clinic 2017). Long QT Syndrome (LQTS) is an arrhythmogenic 
disorder that is caused by mutations (or channelopathies) in voltage-gated ion 
channels expressed in the cardiomyocyte. Polyunsaturated fatty acids (PUFAs) 
have emerged as a potential therapeutic for the treatment of LQTS because they 
modulate the activity of voltage-gated ion channels involved in LQTS pathology. 
PUFAs are amphipathic molecules with a hydrophilic head group, as well as long, 
polyunsaturated hydrophobic tail. In this work, we demonstrate that the position of 
the double bonds in the hydrophobic tail influence the apparent binding affinity of 
the PUFA to the cardiac Kv7.1/KCNE1 channel complex. We also find that 
alterations to the hydrophilic head group (i.e. substituting a carboxyl head for a 
glycine or taurine group) result in a range of Kv7.1/KCNE1 channel activators. 
Lastly, we find that PUFAs range in their selectivity for different voltage-gated 
channels expressed in the heart (e.g. Nav1.5, Cav1.2, and Kv7.1/KCNE1). 
Specifically, PUFA analogues with taurine head groups tend to have broad effects 
on multiple voltage-gated ion channels including Nav1.5, Cav1.2, and 
Kv7.1/KCNE1. However, PUFA analogues with glycine head groups tend to have 
more selective effects on Kv7.1/KCNE1 channels. PUFA analogues with glycine 
 head groups such as pinoleoyl glycine and DHA-glycine are able to partially restore 
a prolonged ventricular action potential and prevent arrhythmia in simulated 
cardiomyocytes. These results suggest a therapeutic role of polyunsaturated fatty 
acid analogues in the treatment of cardiac arrhythmia.
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CHAPTER 1: Introduction 
1.1. Overview of the electrical activity of the heart and Long QT Syndrome. 
The human heart operates as a pump, allowing blood to circulate throughout the 
body (Mohrman and Heller 2010). The normal cardiac cycle depends on 
precisely timed electrical activity of cardiac muscle cells (cardiomyocytes) 
(Malanga 2007). The cardiac action potential is the electrical signal that is 
propagated through the heart, leading ultimately to the coordinated contraction of 
the heart muscle (Feher 2012) (Figure 1.1). The initiation of the cardiac cycle 
begins in the sinoatrial (SA) node of the heart, which contains pacemaker cells 
that allow spontaneous, rhythmic, action potential firing (Feher 2012; Prinzen et 
al. 2017; Mohrman and Heller 2010). The action potential that is initiated in the 
SA node travels through the atrial muscle and then reaches the atrioventricular 
(AV) node (Feher 2012; Prinzen et al. 2017; Mohrman and Heller 2010). From 
the AV node, the action potential is conducted into the ventricular muscle via 
Purkinje fibers (Feher 2012; Prinzen et al. 2017; Mohrman and Heller 2010). 
There is a notable change in the action potential waveform when the action 
potential reaches the Purkinje fibers and ventricles, including a long plateau 
phase following the initial depolarization phase (Feher 2012; Prinzen et al. 2017; 
Mohrman and Heller 2010). During this long plateau phase, calcium enters the 
cells allowing the synchronized contraction of the ventricular muscle, allowing 
blood to be pumped from the heart to the rest of the body and circulate 
systemically (Feher 2012; Prinzen et al. 2017; Mohrman and Heller 2010; Bers 
and Perez-Reyes 1998). The timing and duration of the cardiac action potential is 
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determined by the expression profile of cardiac ion channels that have distinct 
voltage-dependent and kinetic properties. 
 
  
Figure 1.1. The cardiac action potential measured in different regions of the 
heart and the electrocardiogram (ECG). The cardiac action potential measured in 
the sinoatrial (SA) node, the atrioventricular (AV) node, and in the ventricular muscle 
as they correspond to the electrocardiogram (ECG). The P wave indicates 
depolarization of the atrium and aligns with the initiation of the action potential in the 
SA node. The QRS complex indicates depolarization of the ventricles and aligns with 
the initiation of the action potential in the ventricular muscle. The T wave indicates 
repolarization of the ventricles and aligns with the repolarization/termination of the 
action potential in the ventricular muscle. 
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The cardiac cycle can be measured using the electrocardiogram (ECG) 
(Mohrman and Heller 2010; Carroll 2007) (Figure 1.1). In the ECG, the P wave 
indicates depolarization of the atrial muscle; the QRS complex indicates 
depolarization of the ventricular muscle; and the T wave indicates repolarization 
of the ventricular muscle (Mohrman and Heller 2010; Carroll 2007). The QT 
interval, or the time between depolarization and repolarization of the ventricular 
muscle, closely corresponds to the action potential duration in the ventricular 
muscle (Mohrman and Heller 2010; Carroll 2007). The ventricular action potential 
is divided into four phases: Phases 0 – 3 (Figure 1.2). Each of these phases are 
mediated by the activation and inactivation of different voltage-dependent 
currents (Mohrman and Heller 2010). Phase 0 is the point at which the ventricular 
action potential is initiated and an inward Na+ current, mediated by Nav1.5, leads 
to rapid depolarization of the membrane potential (Mohrman and Heller 2010; 
Carroll 2007; Feher 2012). Phase 1, which appears as a “notch” in the ventricular 
action potential, occurs as a result of the rapid inactivation of Nav1.5 and also the 
activation of a transient outward K+ current (ITo) (Mohrman and Heller 2010; 
Carroll 2007; Feher 2012). Phase 2, which appears as a plateau in the 
membrane potential, is mediated by the influx of Ca2+ ions by the L-type Ca2+ 
channel, Cav1.2 (Mohrman and Heller 2010; Carroll 2007; Feher 2012). Phase 3, 
or the repolarization of the ventricular action potential, is initiated when the efflux 
of K+ dominates over Ca2+ influx, due to the slow inactivation of Cav1.2 and the 
activation the delayed rectifier currents, IKr and IKs (Mohrman and Heller 2010; 
Carroll 2007; Feher 2012; Nerbonne and Kass 2005). The IKr current is the rapid 
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component of the delayed rectifier K+ current and is comprised of the Kv11.1 
channel co-assembled with the KCNE2 auxiliary subunit (Nerbonne and Kass 
2005). The IKs current is the slow component of the delayed rectifier K+ current 
and is mediated by the Kv7.1 channel co-assembled with the KCNE1 auxiliary 
subunit (Nerbonne and Kass 2005). 
 
 
  Figure 1.2. Phases of the ventricular action potential and underlying channel 
currents. (Adapted from website image. What-when-how: The Cardiac Ion Channels 
(Cardiac Arrhythmias) Part 1)). Phases 0-4 of the cardiac ventricular action potential. 
Phase 0 is mediated by activation of Nav1.5 channels and inward Na+ current. Phase 1 
is mediated by the inactivation of Nav1.5 channels. Phase 2 is mediated by activation 
of Cav1.2 channels and inward Ca2+ current. Phase 3 is mediated by the inactivation of 
Cav1.2 channels and the activation of delayed rectifier potassium channels 
Kv7.1/KCNE1 (IKs current) and Kv11.1 (IKr current) and outward K+ current. 
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Disruption of the cardiac action potential can lead to various forms of cardiac 
arrhythmia (Schwartz, Crotti, and Insolia 2012; Wu, Ding, and Horie 2016). Long 
QT Syndrome (LQTS) is an arrhythmogenic disorder that results from the 
aberrant activity of various cardiac ion channels (Balse and Boycott 2017; Clancy 
and Kass 2005; Kass and Cabo 2000; Sanguinetti 1999; Sanguinetti et al. 1995; 
Schwartz, Crotti, and Insolia 2012). LQTS is characterized by a prolongation of 
the QT interval – the time between depolarization and repolarization of the 
ventricular muscle – which, in turn, corresponds to a prolongation of the 
ventricular action potential duration (Alders and Christiaans 2003; Bohnen et al. 
2017; Roden 2008; Rossenbacker and Priori 2007; Schwartz, Crotti, and Insolia 
2012; Waddell-Smith and Skinner 2016). A prolonged QT interval is diagnosed 
when it is longer than 440 ms in men and longer than 460 ms in women 
(Rossenbacker and Priori 2007). There are several different subtypes of LQTS 
(LQ1-LQT15) which are caused my mutations in different ion channels or other 
proteins (Alders and Christiaans 2003; Bohnen et al. 2017; Roden 2008; 
Schwartz, Crotti, and Insolia 2012; Fernandez-Falgueras et al. 2017; Schwartz, 
Ackerman, and Wilde 2017). LQTS predisposes patients to a particularly 
dangerous form of cardiac arrhythmia known as Torsades de Pointes (TdP), 
which is a re-entrant arrhythmia resulting in abnormal T/U waves giving the 
appearance of a “twisting of the points” (Yap and Cam 2003; Viskin 1999). 
Torsades de Pointes that is non-terminating can degenerate into ventricular 
fibrillation and sudden cardiac death (Yap and Cam 2003; Viskin 1999; 
Fernandez-Falgueras et al. 2017; Schwartz, Ackerman, and Wilde 2017). 
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Common treatments for LQTS include by the prescription of b-blockers and the 
implantation of a cardioverter defibrillator, both of which act to prevent the 
likelihood of an arrhythmic event, either by reducing adrenergic tone of the heart 
or by delivering an electrical impulse to terminate arrhythmia (Cho 2016; 
Schwartz, Crotti, and Insolia 2012; Waddell-Smith and Skinner 2016). However, 
these treatments do not target the underlying channelopathies that lead to LQTS. 
 
1.2. Cardiac voltage-gated ion channels. 
The voltage-gated Na+ channel, Nav1.5, is a TTX insensitive Nav channel that is 
expressed in cardiac tissue (DeMarco and Clancy 2016). Nav1.5 contains four 
non-identical linked domains which are called DI-DIV (Catterall 2000; Yu and 
Catterall 2003; Catterall, Wisedchaisri, and Zheng 2017) (Figure 1.3A). Each of 
these domains contain 6 transmembrane helices, called S1-S6, which are 
divided into a voltage-sensing domain and a pore domain (Yu and Catterall 2003; 
DeMarco and Clancy 2016). The voltage sensing domain is made up of the S1-
S4 transmembrane segments (DeMarco and Clancy 2016). The S4 helix 
contains 4 positively charged amino acid residues (R1-R4; 3 arginines and 1 
lysine), allowing it to act as the voltage sensor where it detects and responds to 
changes in membrane potential (Bezanilla 2008; Moreau et al. 2015). S5-S6 form 
the pore domain. The Nav1.5 α-subunit can be modulated by being co-
assembled with auxiliary β-subunits, including β1 and β3 (Barro-Soria, Liin, and 
Larsson 2017; Catterall 2000; Yu and Catterall 2003). In the ventricles of the 
heart, Nav1.5 is assembled with the β3 subunit (Ko et al. 2005). In some cases, 
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co-expression of Nav1.5 with β-subunits has been shown to alter the 
pharmacology of Nav1.5 (Xiao et al. 2000). Nav1.5 activates upon membrane 
depolarization, allowing the influx of Na+ ions before it quickly inactivates 
(Armstrong and Bezanilla 1977; Bezanilla and Armstrong 1977; Capes et al. 
2013; Chanda and Bezanilla 2002). Work characterizing the contributions of 
different domains to fast inactivation of Nav channels have shown that the 
movement of the domain IV voltage sensor is necessary and sufficient to 
produce fast inactivation (Capes et al. 2013). Gain-of-function mutations of the 
Nav1.5 channel lead to Long QT Syndrome Type 3 (LQT3) (Calloe et al. 2013; 
Fernandez-Falgueras et al. 2017).  
 
The voltage-gated Ca2+ channel, Cav1.2, is a voltage-activated, L-type Cav 
channel expressed in cardiac tissue (Hofmann et al. 2014). Cav1.2, like Nav1.5, 
contains four non-identical linked domains, DI-DIV (Figure 1.3B). Each domain 
contains S1-S6 helices and the S4 helix behaves as the voltage sensor in each 
of these domains (Hofmann et al. 2014; Pantazis et al. 2014). The Cav1.2 
channel exists as a large macromolecular complex comprising the Cav1.2 α-
subunit, as well as β1 and α2δ auxiliary subunits (Rougier and Abriel 2016). 
These auxiliary subunits, β1 and α2d alter channel expression and the activation 
and deactivation kinetics, respectively (Rougier and Abriel 2016; Savalli et al. 
2016). Cav1.2 channel is activated upon depolarization and Cav1.2 current is 
active during the plateau phase of the ventricular action potential, allowing Ca2+ 
influx that is required for excitation-contraction coupling in the cardiac muscle 
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(Bers and Perez-Reyes 1998; Mohrman and Heller 2010). Cav1.2 channels 
undergo two forms of inactivation: voltage-dependent inactivation and calcium-
dependent inactivation, which is a mechanism to restrict excessive calcium influx 
(Stotz, Jarvis, and Zamponi 2003; Zhang et al. 1994; Abderemane-Ali et al. 
2019). Cav1.2 channels are sensitive to dihydropyridines (DHPs), which inhibit 
the activity of Cav1.2 channels through an allosteric mechanism (Tang et al. 
2016). Gain-of-function mutations in Cav1.2 channels lead to Long QT Syndrome 
Type 8 (LQT8) (Dick et al. 2016; Drum et al. 2014).  
 
The slow component of the delayed rectifier K+ current, IKs current, is mediated 
by Kv7.1 and the KCNE1 auxiliary β-subunit (Barhanin et al. 1996; Salata et al. 
1996; Sanguinetti 1996) (Figure 1.3C). Kv7.1 is a voltage-gated K+ channel that 
is encoded by the KCNQ1 gene and assembles as a tetrameric channel (Smith 
et al. 2007; Sun and MacKinnon 2017). A single Kv7.1 subunit is made up of 6 
transmembrane spanning helices, where S1-S4 make up the voltage sensing 
domain (VSD), S4 acts as the voltage sensor, and S1-S6 make up the pore 
domain (PD) (Peroz et al. 2008; Smith et al. 2007; Sun and MacKinnon 2017). 4 
Kv7.1 subunits form a homotetrameric channel which is activated by 
depolarization and allows the selective efflux of K+ ions (Smith et al. 2007; Sun 
and MacKinnon 2017). KCNE1 (also called minK) is a single transmembrane 
spanning protein that is necessary to recapitulate physiological IKs current. 
KCNE1 is suggested to localize in the lipophilic cleft between adjacent voltage 
sensing domains of Kv7.1 (Chung et al. 2009; Murray et al. 2016; Nakajo et al. 
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2010; Westhoff et al. 2017; Gofman 2012). In this position, KCNE1 is able to alter 
the voltage-dependence of Kv7.1, causing it to open at more positive potentials 
(Gofman 2012; Osteen et al. 2010; Barro-Soria et al. 2014). In addition, KCNE1 
slows the activation kinetics of Kv7.1 and also increases the single channel 
conductance (Yang and Sigworth 1998; Panaghie, Tai, and Abbott 2006). Loss-
of-function mutations of the Kv7.1/KCNE1 (IKs) channel lead to Long QT 
Syndrome Type 1 (LQT1), which is the most common form of LQTS (Eldstrom et 
al. 2010; Wu, Ding, and Horie 2016; Crotti et al. 2007; Huang et al. 2018; Ma et 
al. 2015). 
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  Figure 1.3. Membrane topology and auxiliary subunits of cardiac voltage-gated 
ion channels. A) Topology of the cardiac Nav1.5 α-subunit (light blue) and auxiliary β1 
subunit (green). B) Topology of the cardiac Cav1.2 α-subunit (light gray) and auxiliary 
β3 (mint green) and α2δ (yellow and lime green) subunits. C) Topology of the cardiac 
Kv7.1 α-subunit (cyan) and auxiliary β-subunit KCNE1 (dark gray). 
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1.3. Polyunsaturated fatty acids (PUFAs). 
Polyunsaturated fatty acids (PUFAs) are amphipathic molecules that have both a 
hydrophilic head group and a hydrophobic tail group (Benatti et al. 2004; 
Foundation 1992) (Figure 1.4A). The hydrophobic tail of the PUFA molecule can 
range from 14-22 carbons in length and contains 2 or more double bonds in 
order to be classified as polyunsaturated (Benatti et al. 2004; Foundation 1992). 
In naturally occurring PUFAs, the hydrophilic head group is a –COOH, or 
carboxyl, group (Benatti et al. 2004; Foundation 1992). This carboxyl group has 
the potential to be negatively charged when the PUFA head group is 
deprotonated (Benatti et al. 2004; Foundation 1992). Polyunsaturated fatty acids 
(PUFAs), for example, docosahexaenoic acid (DHA) has well-documented roles 
in the development of the nervous system and is also suggested to reduce the 
risk of coronary artery disease (Horrocks and Yeo 1999) (Figure 1.4A). PUFAs 
became of clinical interest historically when researchers found that there was an 
Inuit population with a very low incidence of cardiovascular disease (Horrocks 
and Yeo 1999; Bang, Dyerberg, and Hjoorne 1976). This population consumed a 
diet that was enriched in fish oil and therefore had elevated plasma concentration 
of free fatty acids (FFAs) (Bang, Dyerberg, and Hjoorne 1976). ω-3 fatty acids, 
which are found in fish oils, then became of interest to researchers as potential 
therapeutic compounds for cardiovascular disease and cardiac arrhythmia. In 
animal models, such as canine and rabbit models, PUFAs such as 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were shown to 
be antiarrhythmic because of their ability to terminate arrhythmic activity (Kang 
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and Leaf 2000; Pound, Kang, and Leaf 2001). Further work demonstrated that 
PUFAs have these anti-arrhythmic effects because they modulate the activity of 
voltage-gated ion channels expressed in the heart, particularly voltage-gated Na+ 
(Nav) and Ca2+ channels (Cav) (Elinder and Liin 2017; Kang and Leaf 1996; Xiao 
et al. 1997; Xiao et al. 1995; Xiao et al. 2001).  In the case of Nav and Cav 
channels, PUFAs reduce Na+ and Ca2+ currents, allowing them to behave anti-
arrhythmically (Elinder and Liin 2017; Kang and Leaf 1996; Xiao et al. 1997; Xiao 
et al. 1995).  
 
Our group has also demonstrated that PUFAs can promote the activation of 
voltage-gated K+ channels, including Kv7.1 and Kv7.1/KCNE1 (Figure 1.4C-D). 
PUFAs such as DHA promote the activation of voltage-gated K+ channels such 
as Shaker and Kv7.1 by causing a left-shift in the voltage-dependence of channel 
activation, meaning that these channels are activating at more negative 
potentials and the PUFA is acting to stabilize the open state of the channel 
(Figure 1.4C). PUFA-induced activation of K+ channels such as Shaker and 
Kv7.1 occurs through the lipoelectric hypothesis (Borjesson, Hammarstrom, and 
Elinder 2008; Yazdi et al. 2016; Kang and Leaf 1996). The lipoelectric hypothesis 
states that the PUFA molecule: 1) integrates into the membrane via its 
hydrophobic tail and 2) electrostatically attracts the positively charged residues of 
S4 by its negatively charged head group (Borjesson, Hammarstrom, and Elinder 
2008). This electrostatic interaction promotes the upward movement of the 
voltage-sensor which results in a conformational change in the channel protein, 
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opening the channel (Borjesson and Elinder 2011; Borjesson, Hammarstrom, 
and Elinder 2008). The lipoelectric hypothesis also suggests that a negatively 
charged head group, a long hydrocarbon tail, and at least two double bonds in 
the PUFA tail are necessary to promote activation of Kv channels (Borjesson, 
Hammarstrom, and Elinder 2008; Liin et al. 2015). Unsaturated and 
monounsaturated fatty acids do not produce a left-shift in the voltage 
dependence of activation in Kv channels (Borjesson, Hammarstrom, and Elinder 
2008; Liin et al. 2015). 
  
Figure 1.4. X-ray crystal structure of the Kv7.1 a-subunit with putative PUFA 
binding sites. X-ray crystal structure of the Kv7.1 α-subunit (PDB 5VMS; Sun and 
MacKinnon, 2018, Cell) from the side view (top) and the top-down view (bottom). 
Transmembrane α-helical segments S1-S6 are labeled. PUFA binding site R231 in the 
S4 segment (blue labeled amino acid) and K326 in the S6 segment (red labeled amino 
acid) are indicated in each subunit.
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Interestingly, co-expression of the KCNE1 subunit with Kv7.1 removes the 
activation induced by PUFAs such as DHA (Liin et al. 2015). However, the 
voltage-shifting effect of DHA on Kv7.1 can be recovered in Kv7.1/KCNE1 if 
experiments are performed at pH 9, which creates a pH environment that favors 
deprotonation of the PUFA head group (Liin et al. 2015). Interestingly, the 
association of KCNE1 with the Kv7.1 subunit alters the local pH near the binding 
site of the PUFA, altering the pKa of the PUFA molecule when bound to 
Kv7.1/KCNE1. KCNE1 does this by altering the conformation of the Kv7.1 turret 
region, which is made up by the S5-S6 linker (Larsson, Larsson, and Liin 2018). 
In the S5-S6 linker, there are negatively charged acidic amino acid residues 
(namely E290) which are moved closer to the binding site of the PUFA when 
KCNE1 is present (Larsson, Larsson, and Liin 2018). The negatively charged 
turret residues alter the pKa of the PUFA head group, resulting in the protonation 
of the head group, such that the PUFA head group will be uncharged at 
physiological pH. The effects of KCNE1 on the PUFA head group can be 
circumnavigated by using modified PUFAs (or PUFA analogues) that have a 
different functional group on the PUFA head that have a lower pKa value.  
 
Examples of PUFA analogues that have a lower pKa head group are DHA-
glycine and N-arachidonoyl taurine (N-AT) (Figure 1.4B). DHA-glycine and N-AT 
have both been demonstrated to promote the activation of Kv7.1/KCNE1 at 
physiological pH (7.5) by left-shifting the voltage-dependence of activation (Liin et 
al. 2015; Liin et al. 2016). Two other PUFA analogues that contain glycine and 
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taurine head groups are linoleoyl glycine (lin-glycine) and linoleoyl-taurine (lin-
taurine). When the effects of lin-glycine and lin-taurine on IKs current have been 
measured, they increase IKs current in a dose dependent manner with Hill 
coefficients of n = 2.7 and n = 1.5, respectively. This suggests that PUFA 
analogues exhibit some positive cooperativity in binding to the IKs channel. PUFA 
analogues have also been evaluated for their potential to treat LQTS and cardiac 
arrhythmia. N-AT has been shown in previous work to rescue the wild type 
activity of several diverse LQTS-causing mutations in Kv7.1 (Liin et al. 2016). In 
addition, when applied to neonatal rat cardiomyocytes, DHA-glycine application 
has been shown to restore normal action potential firing following drug-induced 
arrhythmia cause by the application of chromanol (Liin et al. 2015).  
 
In recent work, an PUFA analogues have been shown to participate in an 
additional electrostatic effect on the pore of the Kv7.1/KCNE1 channel which is 
measured as an increase in the maximal conductance (Gmax) (Liin, Yazdi, et al. 
2018) (Figure 1.4D). This dual effect on Kv7.1/KCNE1 activation occurs by a 
positively charged amino acid residues, K326, in the S6 segment of Kv7.1 (Liin, 
Yazdi, et al. 2018). The negatively charged head group of a PUFA analogue 
participates in an electrostatic interaction with the positively charged lysine to 
increase the Gmax, and this electrostatic effect can be eliminated if K326 is 
mutated (Liin, Yazdi, et al. 2018). Additionally, this Gmax effect is independent of 
the electrostatic effect on the S4 segment of Kv7.1/KCNE1 (Liin, Yazdi, et al. 
2018). Mutations that remove the left-shifting effect of PUFA analogues do not 
16 
 
 
 
disrupt the Gmax effect and mutations that remove the Gmax effect do not disrupt 
the left-shifting effect of PUFA analogues (Liin, Yazdi, et al. 2018). These data 
further suggest that modulation of the cardiac IKs channel by PUFA analogues is 
electrostatic in nature. 
  
Figure 1.5. Polyunsaturated fatty acid (PUFA) structure and the lipoelectric 
hypothesis. A-B) Structure of A) the PUFA docosahexaenoic acid (DHA) and B) the 
PUFA analogue N-arachidonoyl taurine (N-AT). C) Electrostatic interaction between 
the negatively charged PUFA head group (yellow) and positive charges in the voltage 
sensor segment (green) in Kv channels. D) Electrostatic interaction between the 
negatively charged PUFA head group (yellow) and positive charges (K326) in the Kv 
channel pore. 
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The work described here provides a comprehensive analysis of how the structure 
of PUFAs and PUFA analogues relate to activation of the cardiac Kv7.1/KCNE1 
(IKs) channel. In addition, we have demonstrated that PUFAs and PUFA 
analogues vary in their channel selectivity and that they modulate the activity of 
different voltage-gated ion channels through different mechanisms. 
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CHAPER 2. ω-6 and ω-9 polyunsaturated fatty acids with double bonds 
near the carboxyl head have the highest affinity and largest effects on the 
cardiac IKs potassium channel1 
Background 
Excitable tissues, such as brain, heart, and muscle, express a wide variety of 
voltage-gated ion channels that play a critical role in the firing and the shaping of 
action potentials (Hille 2001). Voltage-gated K+ channels (Kv channels) comprise 
an important family of channels that are involved in the repolarization phase of 
the cardiac action potential (Deal, England, and Tamkun 1996; Salata et al. 
1996; Lei and Brown 1996; Li et al. 1996; Veldkamp et al. 1995; Noble and Tsien 
1969a; Noble and Tsien 1969b). The Kv7.1/KCNE1 macromolecular complex, 
here forward referred to as the IKs channel (a slow delayed rectifier Kv channel) is 
important for the repolarization of the cardiac ventricular action potential. There 
are a variety of mutations in both the Kv7.1 and KCNE1 subunits that result in a 
LQTS phenotype and these mutations have been demonstrated to affect an array 
of processes including voltage sensing, channel opening/closing, and channel 
trafficking to the membrane (Alders and Christiaans 2003). 
 
Polyunsaturated fatty acids (PUFAs) are naturally occurring, amphipathic 
molecules that contain a hydrophilic, carboxyl head and hydrophobic 
 
1 Bohannon, BM., Perez, ME., Liin, SI., and Larsson, HP. (2019) w-6 and w-9 polyunsaturated fatty acids 
with double bonds near the carboxyl head have the highest affinity and largest effects on the cardiac IKs 
potassium channel. Acta Phyiologica. DOI: 10.1111/alpha.13186 
19 
 
 
 
hydrocarbon tail (Benatti et al. 2004). Early evidence from animal models 
suggested that PUFAs modulate the activity of voltage-gated Na+ and Ca2+ 
channels and therefore could act anti-arrhythmically at the ion channel level 
(Kang and Leaf 1996, 2000; Xiao et al. 1995; Xiao et al. 2001; Xiao et al. 1997). 
In our lab, we have investigated the potential therapeutic effect of PUFAs on the 
IKs channel and our data strongly suggests that modified PUFAs affect the 
cardiac IKs current by shifting the voltage-dependence of activation to more 
negative voltages (Liin et al. 2015). PUFAs have also been shown to reverse the 
loss-of-function of some LQT1 mutants in IKs channels expressed in Xenopus 
laevis oocytes and also to reverse drug-induced arrhythmia in cultured 
cardiomyocytes and a drug-induced prolongation of the QT interval in guinea pig 
hearts (Liin et al. 2015; Liin et al. 2016). However, the features of these PUFAs 
that are necessary for the effects on the IKs channel are not fully understood. This 
study investigates the properties of the PUFA tail with the goal of determining 
what features of the PUFA tail are important for the activating effects of PUFAs 
on the cardiac IKs channel.  
 
Previous data from our lab has shown that the most common PUFA in fish oil, 
docosahexaenoic acid (DHA), shifts the voltage dependence of activation (V0.5) 
of the Kv7.1 channel to more negative voltages by an electrostatic interaction 
between the negatively charged DHA head group and the positively charged 
voltage sensor of Kv7.1 (Liin et al. 2015), a mechanism demonstrated in Shaker 
K+ channels (Borjesson, Hammarstrom, and Elinder 2008; Borjesson and Elinder 
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2011). However, when DHA is applied to the physiological IKs channel (co-
expression of Kv7.1 and KCNE1), there is no effect on the V0.5. Interestingly, the 
left-shifting effect of DHA could be restored in the IKs channel by conducting 
experiments at pH 9 (rather than pH 7.5) (Liin et al. 2015). We have further 
shown that the presence of KCNE1 decreases the local pH near the DHA head 
group, so that DHA is less likely to be negatively charged in the presence of 
KCNE1 at physiological pH (Liin et al. 2015). By increasing the pH of the 
extracellular solution to pH = 9, we deprotonate the DHA head group and restore 
its negative charge, thereby restoring the left-shifting effects of DHA on the IKs 
channel (Liin et al. 2015). We have also shown that PUFAs with a lower pKa, 
such as N-arachidonoyl taurine (N-AT) that remains negatively charged when 
bound to IKs channels at pH 7.5, retain the ability to shift the voltage-dependence 
of Kv7.1 even when it is co-expressed together with KCNE1 (Liin et al. 2016; Liin 
et al. 2015). While our previous data show the importance of the PUFA head 
group charge for shifting the V0.5 of the IKs channel, little is known about the 
importance of PUFA tail properties for the affinity of PUFAs and the effects of 
PUFAs on the IKs channel. Due to the limited number of commercially available 
PUFAs with a permanently negatively-charged head group (such as N-AT), we 
here tested the importance of the tail properties in PUFAs with a carboxyl head 
group at pH 9.0 to maintain the negative charge on the head group even in the 
presence of KCNE1. 
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Here, we report that specific properties of the hydrocarbon tail are important for 
the effects of PUFAs on the IKs current and the apparent binding affinity of 
PUFAs to the IKs channel. The length and number of double bonds in the PUFA 
tail do not strongly correlate with the effects of PUFAs on IKs current or the 
binding affinity of PUFAs to the IKs channel. However, we find that the position of 
the first double bond strongly correlates with both the effect of PUFAs on IKs 
current and the apparent binding affinity of PUFAs for the IKs channel. PUFAs 
that have their first double bond close to the hydrophilic head group consistently 
demonstrate a larger effect on the IKs current and a higher apparent affinity for 
the IKs channel than PUFAs that have their first double bond further away from 
the PUFA head. In addition, PUFAs with a double bond close to the end of the 
PUFA tail (ω-3 PUFAs) are less effective compared to PUFAs with a double 
bond further away from the end of the PUFA tail (ω-6 and ω-9 PUFAs). 
  
Results  
To determine the effect of a specific PUFA (for example, eicosatrienoic acid 
5,8,11), we measured its effects on the current vs. voltage relationship of the IKs 
channel (Fig. 1A-C). The tail currents were measured after different activation 
voltages to generate the G-V curve from which we can determine both the shift in 
the V0.5 and the increase in Gmax (Fig.1C) once the current has reached 
saturation (Fig. 1D). We also measured the relative increase in K+ current (I/I0) at 
0 mV (Fig. 1C), a voltage close to the systolic plateau during a cardiac action 
potential. Both a shift in the V0.5 and an increase in the Gmax would increase the 
22 
 
 
 
currents at 0 mV, so by measuring the currents at 0 mV we get a rough estimate 
of the total expected physiologically-relevant, PUFA induced change in current 
during a ventricular action potential (O'Hara et al. 2011). Lastly, we determine Km 
values for I/I0, ΔV0.5, and Gmax to understand how different properties (i.e. 
different tail length, double bond number, and bond position) affect the apparent 
binding affinity of the PUFAs to the IKs channel (Fig.1E). The apparent binding 
affinity reported throughout the text is the Km corresponding to the increase in I/I0, 
as the apparent affinities of I/I0, ΔV0.5, and Gmax are comparable. 
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2.1. Increasing the length of the PUFA tail does not increase the effects on 
the IKs current. 
We first investigate the role of the carbon tail length by applying PUFAs of 
varying length to Xenopus oocytes expressing the wild type human IKs channel. 
16 PUFAs were tested that varied in total carbon tail length while maintaining the 
same (carboxyl) head group (Sup. Fig. 1; Table 1). The recordings were done in 
solutions at pH 9.0 to ensure a negatively charged head group (Liin et al. 2015). 
To make it easier to follow the discussion of the different PUFAs, we will refer to 
PUFAs using a shorthand nomenclature throughout the remainder of this paper: 
Carbon length: number of double bondsΔposition of double bonds. For example, 
the tail of docosahexaenoic acid (DHA) has 22 carbons and six double bonds at 
positions 4,7,10,13,16,19 where the numbering beginning at the carbonyl carbon 
of the PUFA head group. We will therefore call DHA 22:6Δ4,7,10,13,16,19. 
Figure 2.1. Example of raw and analyzed data from IKs recordings using 
20:3Δ5,8,11. A) K+ current in response to increasing depolarizing voltage steps in the 
absence of 20:3D5,8,11 (0 μM). Red trace occurs at 20 mV (Voltage protocol shown 
above) B) K+ current in response to increasing depolarizing steps in the presence of 
20 μM 20:3D5,8,11. C) Conductance vs. voltage (G-V) relationship for series of 
20:3D5,8,11 concentrations measured using IKs channel tail current (Arrow in panels 
A and B). D) Currents in response to a voltage step to 0 mV during application 
protocol. E) Dose dependent increase in relative current (I/I0), measured at 0 mV and 
fit using Equation 1.  
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If the length of the carbon tail is important for its effect on the IKs channel, we 
would expect that changing the length of the carbon tail would produce a 
subsequent change in K+ current amplitude. However, this is not obvious from 
the data. As an example, we compare four PUFAs that vary in the length of their 
carbon tail, but all have a carboxyl head group and have three double bonds in 
the same position from the end of the tail (22:3Δ13,16,19, 20:3Δ11,14,17, 
18:3Δ9,12,15, and 16:3Δ7,10,13). The PUFA with the longest carbon tail 
(22:3Δ13,16,19) does not increase the maximum I/I0 (0.7 ± 0.01) (Fig. 2A), 
produces no change in the Gmax (1.0 ± 0.1) (Sup. Fig. 2), and also produces no 
left-shift of the V0.5 (DV0.5 = 1.7 ± 0.3 mV) (Fig. 2B). Removing two carbons from 
Figure 2.2. All PUFA structures aligned. 
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the tail (20:3Δ11,14,17) increases the maximum I/I0 (1.6 ± 0.1) (Fig. 2A), but does 
not produce a change in the Gmax (1.0 ± 0.1) (Sup. Fig. 2) and produces a small 
shift in the V0.5 (ΔV0.5 = -4.4 ± 1.3 mV) (Fig. 2B). However, shortening of the 
PUFA by two additional carbons (18:3Δ9,12,15) produces a three-fold increase in 
maximum I/I0 (3.3 ± 0.004) (Fig. 2A), slightly increases the Gmax (1.6 ± 0.3) (Sup. 
Fig. 2), and drastically increases the left-shift of the V0.5 (ΔV0.5 = -21.9 ± 0.5 mV) 
(Fig. 2B). In contrast, further shortening of the PUFA by two more carbons 
(16:3Δ7,10,13), though it still produces a two-fold increase in maximum I/I0 (2.1 ± 
0.02) (Fig. 2A), decreases the left-shift of the V0.5 (ΔV0.5 = -13.4 ± 0.6 mV) (Fig. 
2B) and the change in the Gmax (0.9 ± 0.2) (Sup. Fig. 2). Overall, when we 
compare the effects of all 16 PUFAs tested, there is no correlation between the 
length of the carbon tail and I/I0 (Slope = 0.14 ± 0.12; R2 = 0.09; p = 0.26) (Fig. 
2C). There is no correlation between the length of the carbon tail and the left shift 
of the V0.5 (Slope = -0.61 ± 1.7; R2 = 0.01; p = 0.72) (Fig. 2D). There is a weak 
correlation between the length of the carbon tail and the maximal conductance 
(Gmax) (Slope = 0.08 ± 0.04; R2 = 0.25; p = 0.05) (Sup. Fig. 2B). Lastly, there is 
no correlation between the length of the carbon tail and the apparent binding 
affinity for I/I0 (Km) (Slope = -0.76 ± 1.3; R2 = 0.03; p = 0.56) (Fig. 2E).   
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  Figure 2.3. No role of carbon tail length on PUFA effect and 
affinity. A) Dose dependent I/I0 increase in the presence of PUFAs 
with varying carbon tail lengths. B) Dose dependent ΔV0.5. C-E) 
Correlation between carbon tail length and (C) I/I0 (Slope = 0.14 ± 
0.12; R2 = 0.09; p = 0.26), (D) ΔV0.5 (Slope = -0.61 ± 1.7; R2 = 0.01; p 
= 0.72), and (E) Km of I/I0 (Slope = -0.76 ± 1.3; R2 = 0.03; p = 0.56). 
27 
 
 
 
2.2. A greater number of double bonds in the PUFA tail does not increase 
the effects on IKs current. 
To determine whether the number of double bonds in the tail is important for the 
effects of PUFAs on the IKs channel, we look next at PUFAs with different number 
of double bonds while the head group and the tail length are constant. We first 
compare two PUFAs (22:5Δ4,7,10,13,16 versus 22:3Δ13,16,19) that both have 
22 carbons, but either have 5 or 3 double bonds in the tail. Decreasing the 
number of double bonds from 5 to 3 bonds (22:5Δ4,7,10,13,16 versus 
22:3Δ13,16,19) decreases the I/I0 (3.7 ± 0.02 to 0.7 ± 0.01) (Fig. 3A), removes 
the increase in Gmax (1.3 ± 0.02 to 1.0 ± 0.1) (Sup. Fig. 2), and removes the left-
shift of the V0.5 (ΔV0.5 = -44.4 ± 10 mV to 1.7 ± 0.3 mV) (Fig. 3B). In contrast, 
reducing the number of double bonds in PUFAs with 20-carbon tails 
(20:5Δ5,8,11,14,17 versus 20:3Δ5,8,11) increases the maximum I/I0 (2.4 ± 0.05 
to 4.0 ± 0.23) (Fig. 3A), slightly increases the Gmax (1.0 ± 0.1 to 1.3 ± 0.01) (Sup. 
Fig. 2), and increases the left-shift of the V0.5 by a factor of 2 (ΔV0.5 = -25 ± 4.6 
mV to -44.7 ± 4.3 mV) (Fig. 3B). Overall, when we compare the effects of all 16 
PUFAs tested, there is no correlation between the number of double bonds in the 
tail and I/I0 (Slope = 0.16 ± 0.29; R2 = 0.02; p = 0.59) (Fig. 3C) There is also no 
correlation between the number of double bonds and the shift in V0.5  (Slope = 
0.14 ± 3.8; R2 = 0.0001; p = 0.97) (Fig. 3D), the Gmax (Sup. Fig. 2C), or the 
apparent binding affinity of I/I0 (Km) (Slope = -4.2 ± 2.0; R2 = 0.28; p = 0.06) (Fig. 
3E).  
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Figure 2.4. No role of the number of double bonds on PUFA effect and 
affinity. A) Dose dependent I/I0 increase in the presence of PUFAs with 
varying number of double bonds. B) Dose dependent changes in ΔV0.5. C-E) 
Correlation between the number of double bonds and (C) I/I0 (Slope = 0.16 
± 0.29; R2 = 0.02; p = 0.59), (D) ΔV0.5 (Slope = 0.14 ± 3.8; R2 = 0.0001; p = 
0.97), and (E) Km of I/I0 (Slope = -4.2 ± 2.0; R2 = 0.28; p = 0.06). 
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2.3. Having the first double bonds closer to head group increases apparent 
affinity and effect of PUFA on IKs current. 
Because neither the tail length nor the number of double bonds in the tail 
correlate very strongly with the PUFA-induced effects on the IKs channel, we 
investigated whether the positions of the double bonds are important for the 
effects of PUFAs on the IKs channel. We first compare the compounds 
22:6Δ4,7,10,13,16,19 and 22:3Δ13,16,19 on the IKs channel (Fig. 4A-B). 
Application of 22:6Δ4,7,10,13,16,19 produces a dose dependent increase in 
maximum I/I0 (3.2 ± 0.1) (Fig. 4E), produces an increase in the Gmax (1.5 ± 0.2) 
(Sup. Fig. 2), and produces a significant shift in the V0.5 (ΔV0.5 = -20.2 ± 0.1 mV) 
(Fig. 4F). However, when the first three double bonds are removed 
(22:3Δ13,16,19), there is a decrease in maximum I/I0 (0.7 ± 0.01) (Fig. 4E), no 
change in the Gmax (1.0 ± 0.1) (Sup. Fig. 2), and the left-shifting effect on the V0.5 
is abolished (ΔV0.5 = 1.7 ± 0.3 mV) (Fig. 4F). This data show that some, or all, of 
the three initial double bonds in the 22:6Δ4,7,10,13,16,19 tail are necessary for 
its effects on the IKs channel. To determine whether reintroducing double bonds 
closer to the PUFA head improves the effects of 22:3Δ13,16,19, we test 
22:4Δ7,10,13,16 and 22:4Δ4,10,13,16 (Fig. 4C-D). 22:4Δ7,10,13,16 application 
compared to 22:4Δ4,10,13,16 produces a smaller increase in I/I0 (3.3 ± 0.01 and 
5.3 ± 0.09, respectively) (Fig. 4G), a smaller increase in the Gmax (1.5 ± 0.03 and 
2.4 ± 0.03, respectively) (Sup. Fig. 2), and produces a marginally smaller shift in 
the V0.5 (ΔV0.5 = -14.9 ± 2.2 mV and -18.2 ± 0.5 mV, respectively) (Fig. 4H). In 
addition, positioning the first double bond closer to the head group increased the 
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apparent affinity for the IKs channel, as 22:4Δ4,10,13,16 had a Km = 6.3 ± 0.3 μM, 
whereas 22:4Δ7,10,13,16 had a Km = 11.6 ± 0.1 μM (for I/I0) (t statistic = 32.2; 
degrees of freedom = 4; p < 0.0005). This suggests that the location of the first 
double bond close to the hydrophilic head group of the PUFA is important for 
improving the effects on and the apparent affinity for the IKs channel. 
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Next, we test three 20-carbon PUFAs (20:3Δ5,8,11, 20:3Δ8,11,14, and 
20:3Δ11,14,17) that all contain the same number of double bonds, but the double 
bonds start at different distances from the carboxyl head group (Fig. 5A-C). 
20:3Δ5,8,11, which has its first double bond closest in proximity to the head 
group, produced the largest increase in maximum I/I0 (4.0 ± 0.2) (Fig. 5D). 
20:3Δ8,11,14, in which the double bonds are shifted further away from the head, 
increased the maximum I/I0 less than 20:3Δ5,8,11 (2.5 ± 0.04) (Fig. 5D). 
20:3Δ11,14,17, in which the double bonds are located furthest away from the 
PUFA head, produced the smallest increase in maximum I/I0 (1.6 ± 0.1) (Fig. 5D). 
20:3Δ5,8,11 also slightly increased the Gmax of the IKs channel compared to 
20:3Δ8,11,14 and 20:3Δ11,14,17 (1.3 ± 0.01, 1.0 ± 0.2, and 1.0 ± 0.1, 
respectively) (Fig. 5E). 20:3Δ5,8,11 and 20:3Δ8,11,14 both produce a larger left-
shift the V0.5 (ΔV0.5 = -44.7 ± 4.3 mV and -42.5 ± 1.9 mV, respectively) compared 
to 20:3Δ11,14,17 (-4.4 ± 1.3 mV) (Fig. 5F). 20:3Δ5,8,11 and 20:3Δ8,11,14 bound 
to the IKs channel with comparable Km for I/I0 (9.2 ± 1.4 μM and 14.4 ± 2.5 μM, 
respectively) and exhibited better apparent affinity for I/I0 compared to 
20:3Δ11,14,17 (35.2 ± 0.1 μM) (Fig. 5G). The effects and apparent affinity of 
20:3Δ5,8,11 compared to those of 20:3Δ8,11,14 and 20:3Δ11,14,17 suggest that 
the location of the first double bond close to the hydrophilic head group of the 
Figure 2.5. Double bonds closer to the PUFA head rescues effect on 
IKs channel current and voltage shift. A) K+ current in 0 μM (Left) and 20 
μM (Right) for (A) 22:6Δ4,7,10,13,16,19. B) K+ current in 0 μM (Left) and 
70 μM (Right) for (B) 22:3Δ13,16,19, (C) 22:4Δ7,10,13,16 , and (D) 
22:4Δ4,10,13,16. E and G) Comparison of dose dependent I/I0 increase 
between (E) 22:6Δ4,7,10,13,16,19  and 22:3Δ13,16,19 and (G) 
22:4Δ4,10,13,16 and 22:4Δ7,10,13,16. F and H) Comparison of dose 
dependent shifts in ΔV0.5 of (F) 22:6Δ4,7,10,13,16,19  and 22:3Δ13,16,19 
and (H) 22:4Δ4,10,13,16 and 22:4Δ7,10,13,16.    
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PUFA is important for improving the effects on and the apparent affinity for the IKs 
channel.  
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To further test the importance of the location of double bonds relative to the head 
group, we compared three 18-carbon PUFAs (18:3Δ5,9,12, 18:3Δ6,9,12, and 
18:3Δ9,12,15) that all contain the same number of double bonds, but with the 
double bonds at different locations (Fig. 6A-C). 18:3Δ5,9,12 and 18:3Δ9,12,15 
both produce the largest increases in maximum I/I0 when compared to 
18:3Δ6,9,12 (2.9 ± 0.07 and 3.3 ± 0.004 compared to 2.2 ± 0.06) (Fig. 6D). Both 
18:3Δ5,9,12 and 18:3D9,12,15 increased the Gmax slightly (1.1 ± 0.01 and 1.6 ± 
0.3, respectively) (Sup. Fig. 2), however 18:3Δ6,9,12 did not increase Gmax (0.9 ± 
0.1) (Sup. Fig. 2). 18:3Δ5,9,12 application resulted in the greatest left-shift in the 
V0.5 of IKs channel activation, shifting the V0.5 by -38 ± 2.7 mV (Fig. 6E). In 
contrast, 18:3Δ9,12,15 and 18:3Δ6,9,12 both produced similar left-shifts of the 
V0.5 (ΔV0.5 = -21.9 ± 0.5 mV and -22.3 ± 0.5 mV, respectively) (Fig. 6E).  In 
addition, 18:3Δ5,9,12 has the highest apparent affinity (6.7 ± 0.4 μM), whereas 
18:3Δ6,9,12 and 18:3Δ9,12,15 exhibited lower apparent binding affinity for I/I0 
(10.0 ± 1.0 μM and 18.7 ± 0.1 μM, respectively) (Fig. 6F). These data further 
suggest that the location of the first double bond close to the hydrophilic head 
group of the PUFA is important for improving the effects on and apparent affinity 
for the IKs channel.  
  
Figure 2.6. Having a double bond closer to PUFA head improves effects on 
IKs channel. A-C) K+ current in 0 μM (Left) and 70 μM (Right) for (A) 20:3Δ5,8,11, 
(B) 20:3Δ8,11,14, and (C) 20:3Δ11,14,17. D-F) Comparison of dose dependent (D) 
I/I0 increase, (E) Gmax increase, and (F) ΔV0.5 between 20:3Δ5,8,11, 20:3Δ8,11,14, 
and 20:3Δ11,14,17. G) Correlation between the position of the first double bond 
and Km of I/I0 (Slope = 4.3 ± 1.5; Adjusted R2 = 0.89; p = 0.21). 
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Figure 2.7. Having the first double bond closer to PUFA head in linolenic acid 
analogues improves PUFA effects on I/I0 and ΔV0.5. A-C) K+ current in 0 μM (Left) 
and 70 μM (Right) for (A) 18:3Δ9,12,15, (B) 18:3Δ6,9,12, and (C) 18:3Δ5,9,12. D-E) 
Comparison of dose dependent (D) I/I0 increase and (E) ΔV0.5 between 18:3Δ9,12,15, 
18:3Δ6,9,12, and 18:3Δ5,9,12. F) Correlation between the position of the first double 
bond and Km of I/I0 (Slope = 3.0 ± 0.08; Adjusted R2 = 0.99; p = 0.02). 
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To corroborate our conclusion for the importance of the position of the first 
double bond, we compared three PUFAs (20:3Δ5,8,11, and 22:5Δ4,7,10,13,16, 
and 18:3Δ5,9,12) (Fig. 7A-C). These three PUFAs all have the first double bond 
at positions 4 or 5 but they have different carbon tails lengths, a different number 
of double bonds, and different positions of the other double bonds. The prediction 
is that PUFAs with the first double bond close to the head group will be similarly 
effective compounds and have similar apparent affinity for the IKs channel. 
18:3Δ5,9,12, 22:5Δ4,7,10,13,16, and 20:3Δ5,8,11 all increase the maximum I/I0 
(2.9 ± 0.07, 3.7 ± 0.02, and 4.0 ± 0.23, respectively) (Fig. 7D), and Gmax (1.1 ± 
0.01, 1.3 ± 0.02, and 1.3 ± 0.01, respectively) (Fig. 7E), and produce a similar 
shift in the V0.5 of the IKs channel (ΔV0.5 = -38 ± 2.7 mV, -44.4 ± 10 mV, and -44.7 
± 4.3 mV, respectively) (Fig. 7F). 18:3Δ5,9,12, 22:5Δ4,7,10,13,16, and  
20:3Δ5,8,11, though they are significantly different in their apparent binding 
affinities for I/I0, (Km = 6.7 ± 0.4 μM versus 3.7 ± 0.1 and 9.2 ± 1.4 μM, 
respectively; One-way ANOVA F statistic = 56.3; p < 0.001) are all among the 
PUFAs tested here that have the highest apparent binding affinity for the IKs 
channel. When we compared the effects of all 16 PUFAs tested, there was a 
significant correlation between the position of the first double bond and I/I0 (Slope 
= -0.24 ± 0.1; R2 = 0.27; p = 0.04) (Fig. 7G). There is not a significant correlation 
between the position of the first double bond and the ΔV0.5 (Slope = 2.6 ± 1.4; R2 
= 0.19; p = 0.09) (Fig. 7H). There is no correlation between the position of the 
first double bond and the maximal conductance (Gmax) (Supplemental Fig. 2D). 
However, there is a strong and significant correlation between the position of the 
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first double bond relative to the PUFA head and the apparent binding affinity for 
I/I0 (double bonds closer to the head group give lower Km) (Slope = 3.6 ± 0.49; R2 
= 0.83; p < 0.0001) (Fig. 7I). These data suggest that the location of the first 
double bond does indeed contribute to the ability of PUFAs to increase K+ current 
with high apparent affinity for the IKs channel. 
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Figure 2.8. Effects on and affinity for IKs channel can be predicted using 
the position of the first double bond, demonstrated using 18:3Δ5,9,12. A-C) 
K+ current in 0 μM (Left) and 70 μM (Right) for (A) 20:3Δ5,8,11, (B) 
22:5Δ4,7,10,13,16, and (C) 18:3Δ5,9,12. D-F) Comparison of dose dependent 
(D) I/I0 increase, (E) Gmax, and (F) ΔV0.5 between 20:3Δ5,8,11, 
22:5Δ4,7,10,13,16, and 18:3Δ5,9,12. G-I) Correlation between the position of 
the first double bond of all PUFAs and the (G) I/I0 (Slope = -0.24 ± 0.1; R2 = 
0.27; p = 0.04), (H) ΔV0.5 (Slope = 2.6 ± 1.4; R2 = 0.19; p = 0.09), and (I) Km of 
I/I0 (Slope = 3.6 ± 0.49; R2 = 0.83; p < 0.0001). 
 
Figure 2.9. Correlations between PUFA parameters and Gmax. A) 
Comparison of dose dependent increase in Gmax with all PUFAs. B) Correlation 
between the length of the PUFA tail and Gmax (Slope = 0.08 ± 0.04; R2 = 0.25; p 
= 0.05). C) Correlation between the number of double bonds and Gmax (Slope = 
0.12 ± 0.09; R2 = 0.11; p = 0.21). D) Correlation between the position of the first 
double bond and Gmax (Slope = -0.05 ± 0.04; R2 = 0.1; p = 0.22). E) Correlation 
between the position of the last double bond and Gmax (Slope = 0.05 ± 0.05; R2 = 
0.05; p = 0.42). 
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2.4. Hierarchical cluster analysis reveals distinct groupings of PUFAs 
according to their effects. 
We grouped PUFAs with similar effects using hierarchical cluster analysis to 
determine key differences between the PUFAs that were tested (Wessa 2017). 
All four effects on the IKs channel (i.e. I/I0, ΔV0.5, Gmax, and Km of I/I0) were input 
simultaneously to be clustered according to similarity in all of the effects. We then 
looked at the PUFAs that were clustered together to determine whether there are 
similarities between those PUFAs in their structures (i.e. tail length, number of 
double bonds, position of the first double bond, and the position of the last double 
bond). Our hierarchical cluster analysis revealed three distinct groupings of 
PUFAs based on dissimilarity of PUFA effects between the groups (denoted by 
the height of dendrogram branches) (Fig. 8A). The first grouping (Cluster 1) 
included 18:3Δ5,9,12, 22:5Δ4,7,10,13,16, 20:3Δ5,8,11 and 20:3Δ8,11,14. All of 
these PUFAs have their double bonds grouped closer to the PUFA head and 
they produce the largest left-shifts in the V0.5 of the IKs channel. Interestingly, all 
of these PUFAs are ω-6 and ω-9 PUFAs. The next grouping (Cluster 2) includes 
18:2Δ9,12, 22:4Δ4,10,13,16, 20:5Δ5,8,11,14,17, 22:6Δ4,7,10,13,16,19, 
18:3Δ6,9,12. The following grouping (Cluster 3) includes 18:3Δ9,12,15, 
22:5Δ7,10,13,16,19, 16:3Δ7,10,13, and 22:4Δ7,10,13,16. Clusters 2 and 3 both 
include PUFAs that have moderate effects on the IKs channel. The final grouping 
(Cluster 4) includes 20:3Δ11,14,17, 22:3Δ13,16,19, and 14:3Δ5,8,11, all of which 
have the majority of their double bonds grouped closer to the end of the PUFA 
tail and produce little to no change in the V0.5 of the IKs channel. Interestingly, all 
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of these PUFAs are ω-3 PUFAs. Clusters 1 and 4 demonstrated the greatest 
dissimilarity in their effects. The hierarchical cluster analysis suggests that the 
PUFAs with double bonds located closer to the PUFA head (Cluster 1) resulted 
in the greatest left-shift in the V0.5. In addition, the PUFAs with double bonds 
further from the PUFA head (Cluster 4) produced the smallest changes in the 
V0.5, which is in line with our single regression analysis and conclusions. Most 
PUFAs in Clusters 2 and 3 were either ω-3 PUFAs with a double bond close to 
the head group or ω-6 PUFAs with no double bond close to the head group. 
These PUFAs had intermediate effects on the IKs channel. The pattern that 
emerges from this analysis is that the most effective PUFAs on the IKs channel 
are PUFAs with a double bond close to the head group (position 4 or 5), but that 
lack a double bond close to the end of the PUFA tail (ω-6 and ω-9 PUFAs). For 
example, when the first and last double bonds are both shifted closer to the end 
of the tail (i.e. shifted closer to the omega carbon) by comparing 
22:5Δ4,7,10,13,16 (Cluster 1) to 22:5Δ7,10,13,16,19 (Cluster 3) the I/I0 is 
reduced by nearly half. (Fig. 8B). Because the cluster analysis suggests that the 
ω-6 and ω-9 PUFAs produce the largest shifts in the V0.5, we correlate the ω-
number with each of the effects on the IKs channel. There is a significant 
correlation between the ω-number and I/I0 (Slope = 0.39 ± 0.13; R2 = 0.40; p = 
0.009) (Fig. 8C). In addition, there is a strong correlation between ω-number and 
the ΔV0.5, which is consistent with our findings from the dendrogram grouping 
(Slope = -6.0 ± 1.5; R2 = 0.54; p = 0.001) (Fig. 8D).  However, there is no 
correlation between the ω-number and the maximal conductance (Gmax) (Sup. 
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Fig. 2E). There is also no correlation between the ω-number and apparent 
binding affinity (Slope = -1.0 ± 1.3; R2 = 0.05; p = 0.45) (Fig. 8E). 
 
  Figure 2.10. Hierarchical clustering suggests three distinct groups of PUFAs 
and suggests role of ω-number in effects on IKs. A) Dendrogram of all PUFAs 
tested grouped according to their effects on the IKs channel. B) Comparison of dose 
dependent I/I0 increase between 22:5Δ4,7,10,13,16 (Cluster 1) and 
22:5Δ7,10,13,16,19 (Cluster 3). C-E) Correlation between the position of the last 
double bond of all PUFAs and (C) I/I0  (Slope = 0.39 ± 0.13; R2 = 0.40; p = 0.009), (D) 
DV0.5 (Slope = -6.0 ± 1.5; R2 = 0.54; p = 0.001), and (E) Km of I/I0 (Slope = -1.0 ± 1.3; 
R2 = 0.05; p = 0.45). 
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2.5. Multivariable regression analysis. 
To test whether the PUFA effects – I/I0, ΔV0.5, Gmax, and Km of I/I0 – depend on a 
combination of the different parameters (Length, number of double bonds, and 
location of the first and last double bonds) of the PUFA tails, we conducted a 
multivariable regression of each PUFA effect using combinations of the four 
PUFA parameters simultaneously (Sup. Fig. 3). The multivariable regression 
using all four parameters improved the fit for I/I0 (Adjusted R2 increased from 
0.40 to 0.54) and Gmax (Adjusted R2 increased from 0.25 to 0.60).  According to 
the multivariable regression analysis I/I0 is significantly correlated to the location 
of the first double bond (Table 2). Gmax is significantly correlated to the length of 
the tail, the number of double bonds and the location of the first and last double 
bond (Table 2). However, the ΔV0.5 and Km (for I/I0) single regressions were not 
improved by the addition of more parameters of the PUFA. This suggests that the 
ΔV0.5 and Km (for I/I0) are highly dependent on single PUFA parameters (i.e. the 
position of the last double bond and first double bond, respectively). To show the 
quality of the fit of the multivariable analysis, we show in Sup. Fig. 3 the 
measured and the predicted values for the fits of I/I0 (Sup. Fig. 3A) and Gmax 
(Sup. Fig. 3B).  
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General Discussion 
Neither the length of the carbon tail nor the number of double bonds in the tail 
showed a strong correlation with the effects on the IKs currents or the affinity for 
the IKs channel. However, there were correlations between having the first double 
bond closer to the PUFA head and increasing I/I0 and improving the apparent 
binding affinity for I/I0 (lower Km). In contrast, having a double bond close to the 
end of the PUFA tail (i.e. an ω-3 PUFA) decreased the effect of the PUFA on the 
V0.5 of the IKs channel, whereas having a double bond further away from the end 
of the PUFA tail (i.e. an ω-6 or ω-9 PUFA) increases the effect of the PUFA on 
the V0.5. Using our data, the location of the first and the last double bonds, 
Figure 2.11. Multivariable regression model vs. experimental data. The 
experimental data (from Table 1) was sorted according to the sizes of the 
measured effects for: A) I/I0 and B) Gmax and compared to the predicted effects 
from the multivariable regression models (using parameters from Table 2). 
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relative to the PUFA head can therefore be used to develop effective PUFAs that 
bind with high affinity to the IKs channel.  
 
One of the main obstacles to the clinical use of PUFAs for cardiovascular 
diseases has been inconsistencies in clinical trials investigating the relationship 
between dietary fatty acids and cardiovascular disease risk. Two recent clinical 
studies report on correlation between ω-3 and ω-6 fatty acid supplements with 
cardiovascular disease risk (Aung et al. 2018; Virtanen et al. 2018). In a meta-
analysis of 10 clinical trials looking at the relationship between ω-3 fatty acid 
supplements and the risk for cardiovascular disease and negative disease 
outcomes, Aung et al, reported that there is no significant correlation between the 
use of ω-3 fatty acid supplements and cardiovascular disease risk (Aung et al. 
2018). In contrast, Virtanen et al. reported beneficial effects of ω-6 PUFAs on 
cardiovascular disease risk in the Kuopio Ischaemic Heart Disease Risk Factor 
Study (Virtanen et al. 2018). These findings are in agreement with our 
conclusions that ω-3 PUFAs have reduced left-shifting effects on the IKs voltage-
dependence whereas ω-6 PUFAs (along with ω-9 PUFAs) are the most 
beneficial for left-shifting the IKs voltage dependence and increasing IKs current. 
 
Tian et al., 2016, applied PUFAs, such as DHA (22:6Δ4,7,10,13,16,19), onto 
Slo1-β1 BK channels to determine the important features for PUFAs to interact 
with BK channels (Tian et al. 2016). They concluded that double bonds at least 
halfway through the PUFA tail (at carbons 9-12) are important for a high affinity 
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interaction of PUFAs with Slo1 BK channels. They proposed that these double 
bonds allow more curvature of the PUFA molecule and make it more compact, 
thus increasing the stability of the PUFA in its binding site (Tian et al. 2016). In 
contrast, we find here that the double bonds closer to the PUFA head groups (at 
carbons 4-5) are important for the effect on and apparent binding affinity for the 
IKs channel. However, how the PUFA tail specifically interacts with the IKs channel 
to increase the apparent binding affinity is not known from this data and will be 
the focus of futures studies.  
 
Tian et al., 2016, proposed that the PUFA head group takes part in an anion-pi 
interaction with a tyrosine residue in the S6 segment of Slo1 BK channels (Tian 
et al. 2016). In contrast, we previously showed that the effects on the IKs channel 
are mainly due to an electrostatic interaction between the PUFA head group and 
the positively charged S4 segment of the IKs channel (Liin et al. 2015). PUFA 
effects on the BK channels are believed to be due to PUFAs in the inner leaflet of 
the membrane, whereas our effects on IKs channels are believed to be due to 
PUFAs in the outer leaflet of the membrane. This fact, along with their different 
putative site of DHA interaction, is indicative of different mechanisms for the 
PUFA effects on BK and IKs channels (intracellular action on S6 versus 
extracellular action on S4). Different mechanisms for PUFA effects on various ion 
channels is also supported by the effects of PUFAs on cardiac Na+ and Ca2+ 
channels. For example, in contrast to the increase in currents shown here for 
DHA and EPA on IKs channels, DHA and EPA have been shown to reduce the 
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currents through voltage-gated Na+ and Ca2+ channels (Kang and Leaf 1996; 
Xiao et al. 1997; Xiao et al. 1995). This further suggests different mechanisms of 
action of PUFAs on different voltage-gated ion channels. Therefore, there is a 
possibility for channel-specific PUFA interactions which could be, in part, 
attributed to different features of the PUFA tail. Future studies would have to 
determine what PUFA features are important for other cardiac ion channels and 
whether channel-specific PUFAs could be developed. 
 
Our current model for how PUFAs affect the IKs channel is that 1) the PUFA tail 
inserts into the lipid bilayer, 2) the PUFA then diffuses in the membrane to the IKs 
channel, 3) the PUFA tail binds to the IKs channel and anchors the PUFA head 
group near the positively charged voltage sensor of the IKs channel, 4) the 
negatively charged head group of the PUFA electrostatically attracts the voltage 
sensor and activates the IKs channel (Liin et al. 2015). The presently reported 
changes in the apparent PUFA affinity for the IKs channel due to variations in the 
PUFA tail are consistent with this model. However, in addition to changing the 
apparent PUFA affinity to the IKs channel, we here show that the positions of the 
double bonds of the PUFAs also affects the size of the left shift of the voltage 
dependence of the IKs channel (e.g. the position of the last double bond in the 
tail) and, in some instances, also affects the maximal conductance of the IKs 
channel. The reasons for these additional effects are not clear. It is possible that 
the interactions between the last double bonds and the IKs channel alter the 
location of the negatively charged head group of the PUFAs relative to the 
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charges in S4 and thereby cause bigger or smaller shifts in the voltage 
dependence of activation. 
 
The PUFAs were tested at pH 9, a pH at which the carboxyl head group of the 
PUFA molecules interacting with the IKs channel are expected to be deprotonated 
and negatively charged, with no additional effects on normal wild type IKs function 
compared to pH 7.5 (Sup. Fig. 4). Our group has previously described that DHA 
(22:6Δ4,7,10,13,16,19) increases Kv7.1 K+ current at pH 7.5, but that this effect 
is abolished when Kv7.1 is co-expressed with the accessory β-subunit KCNE1 
(Liin et al. 2015). The head groups of N-AT and DHA-glycine are more 
efficacious than DHA on IKs channels, because they remain more deprotonated 
and negatively charged at physiological pH 7.5 Knowing that a PUFA head with a 
lower pKa increases IKs current at physiological pH = 7.5, we can now begin 
making modifications in the tails of these PUFA analogues to improve the binding 
affinity to the IKs channel based on the data reported here. Understanding the 
role of the double bonds for the PUFA tail in altering the binding affinity to the IKs 
channel will allow us to develop new PUFA analogues with better effect on IKs 
channels by attaching high affinity tails to head groups, such as taurine or 
glycine, that are more deprotonated and efficacious at physiological pH. 
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The work presented here was performed using the Xenopus laevis oocytes 
expression system. This poses some limitations to understanding the effects of 
PUFAs on the physiological IKs channel due to the absence of intrinsic factors in 
human cardiomyocytes that can influence the IKs macromolecular complex. 
Ongoing and future experiments will determine the effects of the PUFAs 
examined here on the IKs current present in human cardiomyocytes to further 
understand the therapeutic potential of PUFAs as anti-arrhythmic compounds. In 
addition, our experiments only shed light on the acute effects of PUFAs applied 
to the IKs channel. Further experiments are needed to determine the long-term 
effects of chronic application of PUFAs to the IKs channel. 
 
Figure 2.12. pH does not influence the G-V of wild type IKs channels. 
Comparison of the conductance vs. voltage relationship of IKs channels in ND96 
pH 7.5 and ND96 pH 9. (V0.5 pH 7.4: 28.6 ± 1.8 mV, n=23; V0.5 pH 9.0: 26.5 ± 1.8 
mV, n=23.)  
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The next step in understanding the important properties of PUFAs for increasing 
IKs current in LQTS is to test whether the PUFAs deemed effective here on wild 
type IKs channels are able to reverse Long QT mutation phenotypes in IKs 
channels. Mutations in the IKs channel that cause LQTS type 1 (LQT1) cause 
loss-of-function in the IKs channel by a variety of mechanisms, including a right-
shift in the voltage dependence of the IKs channel, changes in channel kinetics, or 
alterations in trafficking to the cell membrane (Bohnen et al. 2017; Huang et al. 
2018; Liin et al. 2016). Here, we showed that ω-6 (and ω-9) PUFAs with double 
bonds close to the PUFA head produce the largest increases in K+ current, shift 
the wild type G-V curve leftward the most, and activate the channel at more 
negative voltages. These data suggest that applying the same PUFAs to a 
mutated IKs channel would restore the wild type IKs current and, therefore, restore 
the normal ventricular action potential. A previous study from our group showed 
that a modified PUFA, N-arachidonoyl taurine (N-AT), could restore much of the 
defects of eight different LQTS-causing mutations, albeit at high N-AT 
concentrations (Liin et al. 2016). This presents a need for new PUFA analogues 
that can influence IKs currents in a lower concentration range which would be 
more therapeutically relevant and reduce potential side effects on other 
channels. The findings reported here provide a foundation for the design of 
higher affinity PUFA analogues that can be used for the treatment of LQTS. 
Future experiments need to be done to test the best compounds found here on 
IKs channels bearing LQT1-causing mutations. In addition, because different 
PUFAs shift the G-V curve by different amounts and different LQT1 mutations 
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shift the G-V curves by different amounts in the opposite direction along the 
voltage axis, one could develop mutation-specific therapeutics by matching each 
PUFA with each mutation depending on their relative effects on the G-V curves.  
Table 2.1: Summary of all PUFA properties and effects on the IKs channel  
Name IUPAC 
Name 
Tail 
Length 
Double 
Bond 
Number 
Double 
Bond 
Position 
ω Max 
I/I0 
Max 
ΔV0.5 
(mV) 
Max 
Gmax/
Gmax0 
Km 
(μM) 
of I/I0 
Km 
(μM) 
of 
ΔV0.5 
Km 
(μM) 
of 
Gmax/G
max0 
n 
Docosahexanoic 
acid 
(4,7,10,13,16,19) 
22:6Δ4,7,10,
13,16,19 
 
22 6 4, 7, 10, 
13, 16, 
19 
3 3.2 ± 
2.7E-
16 
 
-20.2 
± 0.1 
 
1.5 ± 
0.2 
 
3 ± 
0.1 
 
3.1 ± 
0.1 
 
1.8 ± 
0.0 
 
6 
Docosapentaenoic 
acid (4,7,10,13,16) 
 
22:5Δ4,7,10,
13,16 
 
  
22 5 4, 7, 10, 
13, 16 
6 3.7 ± 
0.02 
 
-44.4 
± 10 
 
1.3 ± 
0.02 
 
3.7 ± 
0.07 
 
8.8 ±  
4.8 
 
2.9 ± 
0.5 
 
3 
Docosapentaenoic 
acid 
(7,10,13,16,19) 
 
22:5Δ7,10,13
,16,19 
 
22 5 7, 10, 
13, 16, 
19 
3 1.6 ± 
0.05 
 
-4 ± 
0.13 
 
1.2 ± 
0.01 
 
8.72 
± 
1.25 
 
11.1 ± 
0.6 
 
1.2 ± 
1.7 
 
4 
Docosatetraenoic 
acid (4,10,13,16) 
 
22:4Δ4,10,13
,16 
22 4 4, 10, 
13, 16 
6 5.3 ± 
0.09 
 
-18.2 
± 0.5 
 
2.4 ± 
0.03 
 
6.3 ± 
0.27 
 
4.4 ± 
0.3 
 
4.4 ± 
0.3 
 
3 
Docosatetraenoic 
acid (7,10,13,16) 
 
22:4Δ7,10,13
,16 
 
22 4 7, 10, 
13, 16 
6 3.3 ± 
0.01 
 
-14.9 
± 2.2 
 
1.5 ± 
0.03 
 
11.6
5 ± 
0.1 
 
19.4 ±  
7.3 
 
2.7 ±  
0.6 
 
3 
Docosatrienoic 
acid (13,16,19) 
 
22:3Δ13,16,1
9 
22 3 13, 16, 
19 
3 0.69 
± 
0.01 
 
1.7 ± 
0.3 
 
1.02 
± 0.1 
 
NA 
 
NA 
 
NA 4 
Eicosapentaenoic 
acid (5,8,11,14,17) 
 
20:5Δ5,8,11,
14,17 
 
20 5 5 ,8, 11, 
14, 17 
3 2.4 ± 
0.05 
 
-25 ± 
4.6 
 
1.0 ± 
0.1 
 
4.9 ± 
0.49 
 
9.8 ±  
4.4 
 
NA 3 
Eicosatrienoic acid 
(5,8,11) 
 
20:3Δ5,8,11 20 3 5 ,8, 11 9 4.0 ± 
0.23 
 
-44.7 
± 4.3 
 
1.3 ± 
0.01 
 
9.24 
± 
1.44 
 
10.3 ± 
2.2 
 
6.0 ± 
0.8 
 
3 
Eicosatrienoic acid  
(8,11,14) 
 
20:3Δ8,11,14 20 3 8, 11, 
14 
6 2.5 ± 
0.04 
 
 
-42.5 
± 1.9 
 
0.95 
± 0.2 
 
14.4 
± 2.5 
 
16.1 ±  
1.6 
 
NA 
 
4 
Eicosatrienoic acid  
(11,14,17) 
 
20:3Δ11,14,1
7 
20 3 11, 14 
,17 
3 1.6 ± 
0.1 
 
-4.4 
± 1.3 
 
0.99 
± 0.1 
 
35.2 
± 0.1 
 
23.7 ± 
7.6 
NA 
 
4 
Linoleic acid (9,12) 
 
18:2Δ9,12 18 2 9, 12 6 3.6 ± 
0.6 
 
-29.8 
± 1.7 
 
1.06 
± 
0.02 
 
NA NA NA 3 
α-linolenic acid 
(9,12,15) 
 
18:3Δ9,12,15 
 
18 3 9, 12, 
15 
3 3.3 ± 
0.00
4 
 
-21.9 
± 0.5 
 
1.6 ± 
0.34 
 
18.7 
± 
0.05 
 
21.9 ± 
0.5 
 
14 ± 
2.4 
 
3 
γ-linolenic acid 
(6,9,12) 
 
18:3Δ6,9,12 18 3 6, 9 ,12 6 2.2 ± 
0.1 
 
-22.3 
± 0.5 
 
0.9 ± 
0.1 
 
10.0
4 ± 
0.97 
 
12.3  ± 
0.6 
 
NA 
 
5 
Pinolenic acid 
(5,9,12) 
 
18:3Δ5,9,12 
 
18 3 5, 9, 12 6 2.9 ± 
0.07 
 
-38 ± 
2.7 
 
1.1 ± 
0.01 
 
6.74 
± 
0.36 
 
10.5 ± 
1.6 
 
4.9 ± 
2.2 
 
7 
Hexadecatrienoic 
acid (7,10,13) 
 
16:3Δ7,10,13 16 3 7, 10 
,13 
3 2.1 ± 
0.02 
 
-13.4 
± 0.6 
 
0.90 
± 0.2 
 
8.11 
± 
0.21 
 
7.2  ± 
0.5 
 
NA 4 
Tetradecatrienoic 
acid (5,8,11) 
 
14:3Δ5,8,11 
 
14 3 5, 8 ,11 3 1.1 ± 
0.15 
 
0.80 
± 6.5 
 
0.84 
± 0.1 
 
NA NA NA 3 
*All values for I/I0, ΔV0.5, Gmax, and Km for I/I0,  V0.5, and Gmax represent the mean and standard error of the mean (SEM). 
  
50 
 
 
 
Table 2.2: Multiple regression analysis results. 
Variables I/I0 Gmax 
CL 0.62 ± 0.29 ns 0.39 ±0.09 *** 
C#B -1.6 ± 0.87 ns -0.97 ±0.27 ** 
CFB -0.65 ± 0.28 * -0.34 ±0.09 ** 
CLB -0.26 ± 0.33 ns -0.33 ±0.10 ** 
C0 2.7  1.22  
Adj. R2 0.54 0.6 
F 0.01 0.005 
The measured outcomes (I/I0 and Gmax) were fitted to the equation y = C0 + 
CL x (Tail length -  Average Tail Length) + C#B x (Number of double bonds - 
Average number of double bonds) + CFB x (Position of the first double bond 
- Average position of the first double bond) + CLB x (ω-number - Average ω-
number). C0 is the average response of all tested PUFAs. p < 0.05 *, p < 
0.01 **, p < 0.001 *** ns = not significant. 
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CHAPTER 3. Polyunsaturated fatty acids produce a range of activators for 
heterogeneous IKs channel dysfunction2 
Background 
The ventricular cardiac action potential is controlled by the activation of 
depolarizing and repolarizing ionic currents. One of the dominant repolarizing 
currents during the ventricular action potential is the slow delayed-rectifier 
potassium current (IKs), which is critical for the timing of action potential 
termination (Barhanin et al. 1996; Sanguinetti 1996; Salata et al. 1996). The IKs 
channel underlies the slow component of the delayed rectifier K+ current and is 
comprised of the voltage-gated K+ channel, Kv7.1, α-subunit and the KCNE1 
accessory β-subunit (Barhanin et al. 1996; Salata et al. 1996; Sanguinetti 1996). 
Kv7.1 forms a tetrameric Kv channel that associates with the β-subunit, KCNE1, 
which dramatically alters the voltage dependence and kinetics of Kv7.1 channel 
activation and is necessary to generate the physiological IKs current (Barhanin et 
al. 1996; Salata et al. 1996; Sanguinetti 1996; Barro-Soria et al. 2014; Osteen et 
al. 2010).  
 
Ion channel mutations, or channelopathies, are the root of many pathological 
conditions, including the arrhythmogenic disorder Long QT Syndrome (LQTS) 
(Bohnen et al. 2017; Alders and Christiaans 2003; Schwartz, Crotti, and Insolia 
2012). LQTS is an inherited disorder that is characterized by a prolonged QT 
 
2 Bohannon, BM., Wu, X., Wu, X., Perez, ME., Liin, SI., and Larsson, HP. (2019) Polyunsaturated fatty 
acids produce a range of activators for heterogenous IKs channel dysfunction. Journal of General 
Physiology (under review) 
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interval  –the time between ventricular depolarization and repolarization  – on the 
electrocardiogram (ECG) (Schwartz, Crotti, and Insolia 2012; Waddell-Smith and 
Skinner 2016). The most common form of LQTS (LQT1) is caused by mutations 
in the voltage-gated K+ channel known as the IKs channel (Alders and Christiaans 
2003; Roden 2008; Wu, Ding, and Horie 2016).  
 
Treatment options for Long QT Syndrome include pharmacological attenuation of 
β-adrenergic stimulation by β blockers or the implantation of a cardioverter 
defibrillator (Cho 2016; Schwartz, Crotti, and Insolia 2012; Waddell-Smith and 
Skinner 2016). Though these treatments help to prevent arrhythmia or stop 
arrhythmia, they do not work for all individuals (Chockalingam et al. 2012; 
Schwartz, Crotti, and Insolia 2012) and they do not directly target the underlying 
channelopathies that lead to LQTS (Schwartz, Ackerman, and Wilde 2017). 
Therefore, there is a need for new therapeutics that directly target the 
channelopathies that lead to LQTS. 
 
We have previously shown that the activity of the IKs channel can be modified by 
lipids, such as polyunsaturated fatty acids (PUFAs) (Liin et al. 2015; Liin et al. 
2016). PUFAs and PUFA analogues are amphipathic molecules that have two 
distinct structural regions that can participate in interactions with membrane 
proteins: 1) a charged hydrophilic head group, and 2) a long, hydrophobic tail 
with two or more double bonds. PUFAs and PUFA analogues influence the 
activation of K+ channels through a lipoelectric mechanism in which the 
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hydrophobic tail integrates into the cell membrane near the voltage sensing 
domain and electrostatically attracts the positively charged S4 through its 
negatively charged hydrophilic head group, thus facilitating channel activation 
(Fig. 1A,B). We have recently demonstrated that in PUFAs with a carboxyl head 
group the position of the double bonds in the tail correlates significantly with 
apparent binding affinity to the IKs channel (Bohannon et al. 2018). Specifically, 
having the first double bond close to the carboxyl head group is important for 
high apparent binding affinity for the IKs channel and PUFA-induced 
enhancement of IKs current (Bohannon et al. 2018). It is known that a negatively 
charged head group is necessary for activation of voltage-gated K+ channels (Liin 
et al. 2015; Borjesson, Hammarstrom, and Elinder 2008). Docosahexaenoic acid 
(DHA), which can bear a negative charge at its carboxyl head group, shifts the 
voltage dependence of Kv7.1 channel activation to more negative voltages, 
however co-expression of KCNE1 abolishes DHA sensitivity (Liin et al. 2015). 
KCNE1 has recently been shown to tune PUFA sensitivity by inducing a 
conformational change of the S5-P-helix loop that results in protonation of the 
PUFA head group (Liin, Yazdi, et al. 2018). This protonation can be 
circumvented by using PUFA analogues that are negatively charged at 
physiological pH (pH 7.4), such as DHA-glycine or N-arachidonoyl taurine (N-AT) 
(Liin et al. 2015; Liin et al. 2016). In addition to an electrostatic effect on the 
voltage sensor of the IKs channel, our group has also recently demonstrated that 
PUFA analogues have an additional effect on the pore of the IKs channel (Liin, 
Yazdi, et al. 2018): a lysine residue (K326) in the S6 helix of the IKs channel 
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electrostatically interacts with the negatively charged head group of PUFA 
analogues and this electrostatic interaction increases the maximal conductance 
(Gmax) of the cardiac IKs channel (Liin, Yazdi, et al. 2018) (Fig. 1B-D). 
 
A thorough characterization of PUFA analogues with a wide range of effects on 
the cardiac IKs channel provides a means to develop novel treatments for LQT1-
causing mutations of different severity. LQT1 is variable in its severity and can 
present with different symptoms based on the individual (Schwartz, Crotti, and 
Insolia 2012). For example, some patients carrying a mutation in KCNQ1 can 
have milder phenotypes associated with less severe prolongation of the QT 
interval. (Schwartz, Crotti, and Insolia 2012; Wu, Ding, and Horie 2016; Amin et 
al. 2011; Chouabe et al. 2000). For example, R533W, which causes a positive 
shift of approximately 15 mV in the voltage-dependence of activation, is 
associated with a milder cardiac phenotype (Chouabe et al. 2000). In other 
cases, such as for the KCNQ1 mutation A341V, that is one of the most severe 
presentations of LQT1,  >30% of patients experience cardiac arrest or sudden 
cardiac death (Crotti et al. 2007; Schwartz, Crotti, and Insolia 2012). These 
examples highlight extreme differences in the manifestation of LQT1 in the 
clinical population that occur in a mutation-specific manner. Treatment for such 
distinct phenotypes would require an individualized approach. For this reason, 
there is a need to find new ways in which the effects of PUFA analogues can be 
tuned, allowing for more personalized treatment options for patients with LQT1. 
The purpose of the present study is to evaluate different PUFA head groups to 
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determine if the activating effects of PUFA analogues can be enhanced or 
attenuated through modifications to the charged PUFA head group. 
 
Results 
3.1. Linoleoyl-taurine and linoleoyl-glycine increase the IKs current by 
differentially affecting the V0.5 and the Gmax. 
We have previously demonstrated that the negative charge of a PUFA with a 
carboxyl head group is neutralized by the presence of KCNE1 in IKs channels 
(Larsson, Larsson, and Liin 2018). For this reason, PUFAs with a carboxyl head 
group tend to have little effect on IKs channel activation at physiological pH. In 
this study, we investigate the effects of other head groups that are expected to 
promote IKs channel activation through the lipoelectric mechanism (Fig. 1A-B) 
with effects on the voltage sensor (Fig. 1A) and the pore (Fig. 1B). We compare 
the effects between PUFAs with varying functional groups of the hydrophilic 
PUFA head, but with the same hydrocarbon tail. To do this, we use two-electrode 
voltage clamp and a series of depolarizing voltage steps to measure the effects 
of PUFAs on IKs current (Fig. 1C). This allows us to measure the effects on the 
normalized current at 0 mV (I/I0), the shift in voltage dependence of IKs channel 
activation (ΔV0.5), and the maximal conductance (Gmax) (Fig. 1D).  
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  Figure 3.1. Illustration of the lipoelectric mechanism and measured effects on 
the cardiac IKs channel. A) Schematic side view of the IKs channel with S4 in green. 
Illustration of the electrostatic interaction of PUFA analogue (yellow) with the voltage 
sensor (green) of the cardiac IKs channel, which leads to potentiation of upward S4 
movement. B) Schematic top view of the IKs channel with Kv7.1 in blue KCNE1 in 
purple. Illustration of the electrostatic interaction of PUFA analogue (yellow) with the 
positively charged lysine residue K326 in the S6 segment of the cardiac IKs channel, 
which leads to an increase in the maximal conductance (Gmax) of the IKs channel. C) 
Activation protocol for the cardiac IKs channel using two-electrode voltage clamp and 
raw current traces in 0 μM PUFA analogue (left) and 20 μM PUFA analogue (right) 
with arrows indicating tail currents. Red trace occurs at 20 mV for visualization of 
PUFA-induced increases in current.  D) Representative current vs voltage 
relationship in 0 μM (black line) and 20 μM PUFA (blue line) highlighting increase in 
I/I0 at 0 mV, leftward shift in the V0.5, and increase in Gmax denoted by arrows. 
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We first compare three PUFAs and PUFA analogues that have a linoleic acid tail: 
linoleic acid, linoleoyl glycine (lin-glycine), and linoleoyl taurine (lin-taurine) (Fig. 
2A-C). Application of 20 μM linoleic acid (Fig. 2A), which has a carboxyl head 
group, does not increase in I/I0 (0.5 ± 0.1) (Fig. 2D), does not left-shift the V0.5 of 
IKs channel activation (4.7 ± 0.9 mV) (Fig. 2F), and does not increase the Gmax 
(0.7 ± 0.1) (Fig. 2H). Lin-glycine, when applied at 20 μM (Fig. 2B), produces a 
moderate increase in I/I0 (5.3 ± 0.5) (Fig. 2D) and a moderate shift in the V0.5 (-
26.4 ± 4.4 mV) (Fig. 2F), and produces the largest increase in the Gmax (2.4 ± 
0.2) (Fig. 2H). Lin-taurine, when applied at 20 μM, (Fig. 2C) produces the largest 
increase in I/I0 (10.4 ± 4.0) (Fig. 2D) and largest left-shift in the V0.5 (-73.1 ± 2.6 
mV) (Fig. 2F), and increases the Gmax (2.0 ± 0.6) (Fig. 2H). Statistical analysis of 
the fitted parameters of the dose response curves show that lin-taurine has the 
biggest increase in I/I0 (Fig. 2E) and V0.5 (Fig. 2G), whereas lin-glycine has the 
biggest increase in Gmax (Fig. 2I). The size of the voltage shifts caused by the 
three PUFAs correlates with the predicted protonation (i.e. charge) of the 
different head groups (from the pKa values estimated for carboxyl, glycine, and 
taurine head groups in the lipid bilayer) at physiological pH (Table 1). In contrast, 
the effects on Gmax did not correlate with the predicted charge of the PUFA head 
groups.   
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Table 3.1: PUFAs/PUFA analogues and their estimated pKa 
values 
PUFA pKa1 pKa2 pKa3 
Linoleic acid 8.5 NA NA 
Lin-glycine 7.6 NA NA 
Lin-taurine 2.7 NA NA 
Lin-glycine+1C 8.0 NA NA 
Lin-glycine+2C 8.0 NA NA 
Lin-aspartate 7.6 9.1 NA 
Lin-cysteic acid 2.6 7.1 NA 
Lin-AP3 5.0 7.7 11.8 
DHA 8.3 NA NA 
DHA-glycine 7.5 NA NA 
DHA-taurine 2.8 NA NA 
Pinolenic acid 8.4 NA NA 
Pinoleoyl glycine 7.5 NA NA 
Pinoleoyl taurine 2.8 NA NA 
Estimated pKa values for PUFAs and PUFA analogues associated with the 
cardiac IKs channel were calculated by adding a factor of 3.5 to the starting pKa 
value calculated in solution. 
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  Figure 3.2. Linoleoyl taurine produces the most potent activation of the IKs channel compared to linoleoyl glycine and linoleic acid. A-C) Structure of and raw current 
traces measured in 0 μM (left) and 20 μM (right) A) linoleic acid, B) linoleoyl glycine, and 
C) linoleoyl taurine. D) Dose dependent effects of linoleic acid (n = 5), lin-glycine (n = 4), 
and lin-taurine (n = 3) on IKs current (I/I0) (mean ± SEM at maximal concentration). E) 
Statistical differences on I/I0 effects (I/I0 fitted from the dose response curve) measured 
by one-way ANOVA followed by Tukey’s HSD post hoc analysis. F) Dose dependent 
effects of linoleic acid, lin-glycine, and lin-taurine on IKs voltage dependence (ΔV0.5). G) 
Statistical differences on ΔV0.5 effects (ΔV0.5 fitted from the dose response curve) 
measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. H) Dose 
dependent effects of linoleic acid, lin-glycine, and lin-taurine on IKs maximal conductance 
(Gmax). I) Statistical differences on Gmax effects (Gmax fitted from the dose response curve) 
measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. 
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3.2. The different effects of lin-glycine and lin-taurine on the V0.5 are not due 
to differences in the lengths of the PUFA head groups. 
One structural difference between the head groups of lin-glycine and lin-taurine is 
that the glycine group is shorter in length compared to the taurine group (Fig. 2B-
C). Therefore, we explored whether the different lengths of the head groups 
could explain the different activating effects of the two PUFAs on the IKs channel. 
To do so, we inserted additional carbons into the head group of lin-glycine to 
elongate the glycine head group and then compared the effects of lin-glycine, lin-
glycine+1C (Fig. 3A), and lin-glycine+2C (Fig. 3B). With the insertion of one 
additional carbon in the glycine head group, lin-glycine+1C has a similar length 
as lin-taurine. Application of lin-glycine produces an I/I0 increase of 5.3 ± 0.5, 
whereas lin-glycine+1C and+2C surprisingly produce a smaller increase in I/I0 
(1.7 ± 0.1 and 1.6 ± 0.1, respectively) (Fig. 3C and I). In addition, lin-glycine 
produced the largest shift in V0.5 (-26.4 ± 4.4 mV) compared to lin-glycine+1C (-
7.2 ± 2.5 mV) and lin-glycine+2C (-8.7 ± 0.5 mV) (Fig. 3D and J). Lin-glycine 
increases the Gmax of the IKs channel (2.4 ± 0.2), whereas lin-glycine+1C and lin-
glycine+2C produce no change in the Gmax (1 ± 0.1 and 0.9 ± 0.1, respectively) 
(Fig. 3E and K).  
 
One possible mechanism behind the decreased effects of lin-glycine+1C and lin-
glycine+2C, compared to lin-glycine, is that the addition of carbons in the glycine 
head group shifts the pKa of the head group, which thereby promotes protonation 
and loss of the negative charge in the head group. We therefore repeated the 
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experiments with lin-glycine, lin-glycine+1C, and lin-glycine+2C at pH 9. We have 
previously demonstrated, using PUFAs with a carboxyl head group, that 
conducting experiments at pH 9 can deprotonate the head group to restore the 
negative charge of the head group and allow PUFAs to activate the IKs channel 
(Bohannon et al. 2018; Liin et al. 2015). Changing the solution from pH 7.5 to pH 
9 does not alter the normal activation of the IKs channel (Supp. Fig. S1). At pH 9, 
lin-glycine, lin-glycine+1C, and lin-glycine+2C all produce a similar left-shift in the 
voltage-dependence of IKs channel activation at 20 μM (-43.6 ± 1.6 mV, -41.7 ± 
1.7 mV, and -47.9 ± 2.4 mV, respectively) (Fig. 3G and J). Note that, at pH 9, 
application of lin-glycine results in a larger left-shift in the voltage dependence of 
the IKs channel compared to the left-shifting effect of lin-glycine at pH 7.5 (Fig. 
3J). This is consistent with our estimated pKa = 7.6 for lin-glycine: at pH 7.5, 50% 
of lin-glycine will be negatively charged, whereas, at pH 9, lin-glycine is almost 
fully in its deprotonated and negatively charged form. Lin-glycine displays higher 
apparent affinity and begins to shift the V0.5 at lower concentrations compared to 
lin-glycine+1C and lin-glycine+2C (Fig. 3G). Although the left-shifting effects of 
lin-glycine, lin-glycine+1C, and lin-glycine+2C were improved at pH 9 (Fig. 3G 
and J), all three PUFA analogues decrease the maximal conductance (Gmax) of 
the channel (0.6 ± 0.1, 0.9 ± 0.1, and 0.5 ± 0.1, respectively) at pH 9 (Fig. 3H and 
K). The reason for this decrease in Gmax is unclear. At pH 9, lin-glycine, lin-
glycine+1C, and lin-glycine+2C all increase I/I0 (2.3 ± 0.1, 2.7 ± 0.3, and 1.8 ± 
0.04, respectively) (Fig. 3F and I).  
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Figure 3.3. Increasing the length of the linoleoyl glycine head group alters the 
pKa and reduces activating effect on the IKs channel. A-B) Structure of A) linoleoyl 
glycine with the addition of one carbon in the head group (lin-glycine+1C) and B) 
linoleoyl glycine with the addition of two carbons in the head group (lin-glycine+2C). C-
H) Dose dependent effects of lin-glycine (black dashed line) (n = 4), lin-glycine+1C (n = 
3), and lin-glycine+2C (n = 3) on C) IKs current (I/I0) at pH 7.5, D) IKs voltage 
dependence (ΔV0.5) at pH 7.5, E) IKs maximal conductance (Gmax) at pH 7.5, F) I/I0 at 
pH 9, G) ΔV0.5 at pH 9, and H) Gmax at pH 9 (mean ± SEM at maximal concentration). I-
K) Significant differences at 20 μM on I) I/I0 effect, J) ΔV0.5 effect, and K) Gmax effect 
measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. 
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The fact that the voltage-shifting effect of lin-glycine+1C and lin-glycine+2C are 
similar to that of lin-glycine at pH 9, but smaller at pH 7.5, suggest that the 
addition of 1 and 2 additional carbons in the glycine head group shifts the pKa of 
the glycine head group and reduces the likelihood that the glycine head will be 
deprotonated and negatively charged at pH 7.5. The size of the voltage shifts for 
lin-glycine+1C and lin-glycine+2C at pH 7.5 (50% smaller than for lin-glycine) are 
consistent with our estimated pKa values of lin-glycine+1C and lin-glycine+2C, 
which are both approximately 8.0 compared to 7.6 for lin-glycine (Suppl. Table 
1). That the voltage-shifting effect of lin-glycine, lin-glycine+1C, and lin-
glycine+2C at pH 9 are all similar suggests that is it not the length of the head 
group that renders lin-taurine more effective that lin-glycine, but mainly the 
protonation state of the PUFA head groups.  
 
 
 
 
 
Figure 3.4. Current vs. voltage relationship between pH 7.5 and pH 9. 
Current-voltage relationship of IKs channel in pH 7.5 (black squares; mean ± SEM; 
n = 4) and pH 9.0 (red circles; mean ± SEM; n = 4). 
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3.3. Increasing the number of potentially charged moieties on the PUFA 
head group did not further promote IKs channel activation. 
Because we previously found that the charge of the head group is important for 
activating the cardiac IKs channel, we tested whether it is possible to further 
improve the activating effects of PUFA analogues by increasing the charge 
available on the PUFA head group. To do so, we compared PUFA analogues 
that have 1 possible charge (lin-taurine and lin-glycine), 2 possible charges (lin-
aspartate and lin-cysteic acid) (Fig. 4A, B), and 3 possible charges (lin-AP3) (Fig. 
4C). Interestingly, increasing the number of potentially negatively charged groups 
on the PUFA head group did not further improve the effects on I/I0, V0.5, or Gmax. 
Lin-aspartate, which has 2 potentially charged moieties, moderately increases I/I0 
(4.0 ± 0.1) (Fig. 4D), moderately left-shifts the V0.5 (-34.5 ± 2.3 mV) (Fig. 4E), and 
moderately increases the Gmax (1.4 ± 0.1) (Fig. 4F). The effects of lin-aspartate 
were similar to the effects of lin-glycine, which has only one potentially charged 
moiety (Fig. 4G-I). Lin-cysteic acid (Fig. 4C), which also possesses two 
potentially charged moieties, increases substantially I/I0 (9.2 ± 0.4) (Fig. 4D), 
substantially left-shifts the V0.5 of IKs channel activation (-58.4 ± 2.8 mV) (Fig. 4E), 
and substantially increases the Gmax (2.0 ± 0.2) (Fig. 4F). The effects of lin-
cysteic acid were similar to the effects of lin-taurine, which has only one 
potentially charged moiety (Fig. 4G-I). Lastly, lin-AP3, which has 3 potential 
negative charges, produces the smallest increase in I/I0 (1.8 ± 0.3) (Fig. 4D and 
G), the smallest left-shift in the V0.5 (-5.7 ± 1.3 mV) (Fig. 4E and H), and produces 
no change in the Gmax (1.1 ± 0.1) (Fig. 4F and I). Together these data show that 
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having >1 potentially charged moiety of the head group does not necessarily 
improve the efficacy of PUFA analogues, leading us to concentrate on glycine 
and taurine head groups as potential therapeutics for LQTS.   
 
  
66 
 
 
 
  
67 
 
 
 
 
 
 
 
 
 
3.4. Taurine compounds have the largest current increase and left-shifting 
effect on the IKs channel. 
We next compare PUFAs and PUFA analogues that have a docosahexaenoic 
acid (DHA) or pinolenic acid tail group to determine if the efficacy of glycine and 
taurine head groups are consistent across PUFA tail groups. DHA, which has a 
carboxyl head group, produces little change in IKs current at 20 μM (Fig. 5A) and 
produces a slight increase in I/I0 (2.0 ± 0.6) (Fig. 5D). DHA-glycine, which has a 
glycine head group produces a larger increase in I/I0 (4.7 ± 1.3 at 20 μM) relative 
to DHA. DHA-taurine produces the most robust increases in IKs current at 7 μM 
compared to PUFA analogues with a DHA tail, increasing I/I0 by 5.1 ± 0.7 at 7 μM 
(Fig. 5D). Surprisingly, at concentrations higher that 7 μM (20 μM), DHA-taurine 
decreases the current for reasons that are unclear. For this reason, we report the 
effects observed at 7 μM. When measuring the effects on the V0.5 of the IKs 
channel, DHA does not left-shift the V0.5 (0.1 ± 1.4 mV) (Fig. 5F), DHA-glycine 
has a moderate left-shifting effect (-16.5 ± 1.3 mV at 20 μM), and DHA-taurine 
has a more robust left-shifting effect (-45.3 mV ± 2.9 mV at 7 μM) (Fig. 5F). DHA, 
Figure 3.5. Increasing the number of potentially charged moieties of the PUFA 
head group does not improve PUFA-induced IKs activation. A-C) Structure of and 
raw current traces measured in 0 μM (left) and 20 μM (right) A) lin-aspartate, B) lin-
cysteic acid, and C) lin-AP3. D-F) Dose dependent effects of lin-glycine (black dashed 
line) (n = 4), lin-taurine (red dashed line) (n = 3), lin-aspartate (n = 4), lin-cysteic acid 
(n = 5), and lin-AP3 (n = 3) on D) IKs current (I/I0). E) IKs voltage dependence (ΔV0.5), 
and F) IKs maximal conductance (Gmax) (mean ± SEM at maximal concentration). G-I) 
Statistical differences at 20 µM on G) I/I0 effect, H) ΔV0.5 effect, and I) Gmax effect 
measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. 
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DHA-glycine, and DHA-taurine all increase the Gmax (1.7 ± 0.3 at 20 μM, 2.0 ± 
0.2 at 20 μM and 1.7 ± 0.1 at 7 μM, respectively) (Fig. 5H). Statistical analysis of 
the fitted parameters of the dose response curves show that DHA-taurine has the 
biggest increase in V0.5 (Fig. 5G), whereas DHA-glycine has the biggest increase 
in I/I0 (Fig. 5E) and Gmax (Fig. 5I).  
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Application of 20 μM pinolenic acid (Fig. 6A), which has a carboxyl head group, 
increases I/I0 slightly (1.5 ± 0.3) (Fig. 6D), has little left-shifting effect on the V0.5 
of IKs channel activation (-6 ± 1.8 mV) (Fig. 6F), and produces a slight increase in 
the Gmax (1.4 ± 0.2) (Fig. 6H). Application of 20 μM pin-glycine (Fig. 6B), 
produces a moderate increase in I/I0 (Fig. 6D) (3.8 ± 0.2), has a moderate left-
shifting effect on the V0.5 of IKs channel activation (-21.1 ± 2.5) (Fig. 6F), and 
increases the Gmax (1.8 ± 0.1) (Fig. 6H). Application of 20 μM pin-taurine (Fig. 
6C) produces a robust increase in I/I0 (Fig. 6D) (9.0 ± 1.4), potently left-shifts the 
V0.5 of IKs channel activation (-51.6 ± 3.5 mV) (Fig. 6F), and increases the Gmax 
(1.9 ± 0.3) (Fig. 6H) relative to other PUFA analogues with a pinolenic acid tail. 
Statistical analysis of the fitted parameters of the dose response curves show 
that pin-taurine has the biggest increase in I/I0 (Fig. 6E) and V0.5 (Fig. 6G), 
Figure 3.6. DHA-taurine at 7 µM produces the most potent activation of the 
IKs channel compared to DHA-glycine and DHA at 20 µM. A-C) Structure of 
and raw current traces measured in 0 μM (left) and 20 μM (right) A) 
docosahexaenoic acid (DHA), B) docosahexanoyl glycine (DHA-glycine), and C) 
docosahexanoyl taurine (DHA-taurine, 0 μM (left) and 7 μM (right)). We report 
effects of DHA-taurine at 7 µM due to an unclear reduction in current caused by 
the application of 20 µM. D) Dose dependent effects of DHA (n = 4), DHA-glycine 
(n = 4), and DHA-taurine (n = 3) on IKs current (I/I0) (mean ± SEM at maximal 
concentration). E) Statistical differences on I/I0 effects (I/I0 fitted from the dose 
response curve) measured by one-way ANOVA followed by Tukey’s HSD post 
hoc analysis. F) Dose dependent effects of DHA, DHA-glycine, and DHA-taurine 
on IKs voltage dependence (ΔV0.5). G) Statistical differences on ΔV0.5 effects 
(ΔV0.5 fitted from the dose response curve) measured by one-way ANOVA 
followed by Tukey’s HSD post hoc analysis. H) Dose dependent effects of DHA, 
DHA-glycine, and DHA-taurine on IKs maximal conductance (Gmax). I) Statistical 
differences on Gmax effects (Gmax fitted from the dose response curve) measured 
by one-way ANOVA followed by Tukey’s HSD post hoc analysis.  
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whereas there were no significant differences in Gmax among the three 
compounds (Fig. 6I). 
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As previously mentioned, DHA-taurine produces an unexpected decrease in I/I0 
and Gmax at 20 μM. The largest effect on the Gmax induced by DHA-taurine on the 
IKs channel occurs at 7 μM, followed by a drastic decrease in Gmax at 20 μM. We 
have also observed a similar decrease in the Gmax at 20 μM with pin-taurine, 
however, this decrease in Gmax is not as pronounced as we see with 20 μM DHA 
taurine. The source of the reduction in Gmax with the application of some taurine 
compounds is not known. One possibility is that it is caused by a steric effect of 
the longer taurine head group resulting in obstruction of the IKs channel pore. To 
determine whether the reduction in Gmax is intrinsic to the taurine head group, we 
applied 100 μM taurine to the IKs channel. However, 100 μM taurine alone does 
not change I/I0, ΔV0.5, or the Gmax (Suppl. Fig. S2) suggesting that the taurine 
head group alone is not responsible for the reduction in Gmax. Therefore, PUFA-
induced decreases in Gmax at concentrations ≥ 20 μM must be due to a different 
mechanism that occur through the combination of the taurine head group and the 
PUFA tail.  
Figure 3.7. Pin-taurine produces the most potent activation of the IKs channel 
compared to pin-glycine and pinolenic acid. A-C) Structure of and raw current 
traces measured in 0 μM (left) and 20 μM (right) A) pinolenic acid, B) pinoleoyl 
glycine (pin-glycine), and C) pinoleoyl taurine (pin-taurine). D) Dose dependent 
effects of pinolenic acid (n = 3), pin-glycine (n = 3), and pin-taurine (n = 4) on IKs 
current (I/I0) (mean ± SEM at maximal concentration). E) Statistical differences on I/I0 
effects (I/I0 fitted from the dose response curve) measured by one-way ANOVA 
followed by Tukey’s HSD post hoc analysis. F) Dose dependent effects of pinolenic 
acid, pin-glycine, and pin-taurine on IKs voltage dependence (ΔV0.5). G) Statistical 
differences on ΔV0.5 effects (ΔV0.5 fitted from the dose response curve) measured by 
one-way ANOVA followed by Tukey’s HSD post hoc analysis. H) Dose dependent 
effects of pinolenic acid, pin-glycine, and pin-taurine on IKs maximal conductance 
(Gmax). I) Statistical differences on Gmax effects (Gmax fitted from the dose response 
curve) measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. 
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We directly compare the effects of PUFA analogue head groups across different 
PUFA tails to see if there were any differences in apparent binding affinity or 
effects on I/I0, ΔV0.5, or Gmax depending on the tail. Our previous data and the 
data in this study suggest that PUFA analogues with glycine head groups have a 
pKa of ~7.5-7.6 when associated with IKs channels, suggesting that half the 
PUFA molecules with a glycine head group will be deprotonated and negatively 
Figure 3.8. Reduction of IKs current by the application of DHA taurine is not 
intrinsically related to the taurine head group alone. A) Structure of taurine and raw 
current traces measured in 0 μM taurine (left) and 100 μM taurine (right). B) Current vs 
voltage relationship in control (0 μM taurine) and following the addition of 100 μM taurine 
(mean ± SEM; n = 4). 
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charged at pH 7.5. PUFA analogues with a glycine head group produce similar 
max effects on I/I0 (Fig. 7A) and ΔV0.5 (Fig. 7B), whereas Gmax was more varied 
(Fig. 7C). PUFA analogues with taurine head groups have an estimated pKa of 
~2.6, suggesting that all of the PUFA molecules with a taurine head group will be 
deprotonated and negatively charged at pH 7.5. PUFA analogues with a taurine 
head group all produced much larger effects on ΔV0.5 than those with glycine 
head groups (Fig. 7B), whereas the effects on Gmax were all in a relative similar 
range (Fig. 7C).  Lin-taurine and pinoleoyl-taurine produced much larger effects 
on I/I0 than those with glycine head groups, whereas DHA-taurine produced a 
similar effect on I/I0 as those with glycine head groups (Fig. 7A). In summary, the 
major difference between PUFAs with taurine and glycine head groups is in the 
effects on the ΔV0.5. This difference is mainly due to the pKa (i.e. the charge) of 
the PUFA head group, with little influence from the hydrophobic PUFA tail 
groups. 
 
  
Figure 3.9. Comparison of effects by glycine head groups and taurine head 
groups on IKs current (I/I0), voltage dependence (ΔV0.5), and maximal 
conductance (Gmax). A-C) Dose dependent effects of DHA-glycine (n = 4), lin-glycine 
(n = 4), pin-glycine (n = 3), DHA-taurine (n = 3), lin-taurine (n = 3), and pin-taurine (n = 
4)  on A) IKs current (I/I0), B) IKs voltage dependence (ΔV0.5), and C) IKs maximal 
conductance (Gmax) (mean ± SEM at maximal concentration).  
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3.5. Hierarchical cluster analysis groups PUFA analogues that have similar 
functional effects. 
We used hierarchical cluster analysis as an unbiased method to group PUFAs 
and PUFA analogues according to similarity of their effects on I/I0, ΔV0.5, and 
Gmax at 20 μM (Fig. 8 and Suppl. Table 2). The hierarchical cluster analysis 
resulted in three distinct clusters of PUFAs and PUFA analogues. The first 
branch point results in the most distinct cluster (Cluster 1) of PUFA analogues 
that include lin-taurine, lin-cysteic acid, pin-taurine, and DHA-taurine which have 
the largest effects on the V0.5. The second branch point divides clusters 2 and 3. 
Cluster 2 includes lin-aspartate, pin-glycine, DHA-glycine, and lin-glycine, which 
have intermediate effects on I/I0 and the Gmax. Cluster 3 includes linoleic acid, 
DHA, lin-AP3, and pinolenic acid, which have the smallest effects on IKs channel 
activation. The results of the hierarchical cluster analysis suggest that PUFA 
analogues with a glycine head group have the most consistent effects on 
increasing Gmax and PUFA analogues with a taurine head group are most 
consistent in left-shifting the voltage dependence of IKs channel activation. 
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  Figure 3.10. Hierarchical cluster analysis and heat map demonstrate that 
taurine head groups are most similar in their voltage-shifting effects and 
glycine head groups are most similar in their effects on Gmax. The dendrogram 
displays groupings of PUFAs and PUFA analogues according to similarity of their 
effects. The heat map displays the magnitude of the effects, with warmer colors 
representing PUFAs and PUFA analogues that have larger relative effects (closer 
to 1.0) on I/I0, Gmax, and ΔV0.5 and cooler colors representing PUFAs and PUFA 
analogues with smaller relative effects (closer to 0.0). 
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Table 3.2: Summary of effects of PUFA analogues on the 
cardiac IKs channel 
 
PUFA Name I/I0 DV0.5 (mV) 
 
GMAX/GMAX0 
 
N 
Linoleic acid 
 
0.5 ± 0.04 
 
4.7 ± 0.9 
 
0.7 ± 0.04 
 
5 
Lin-glycine 
 
5.3 ± 0.5 
 
-26.4 ± 4.4 
 
2.4 ± 0.2 
 
4 
Lin-taurine 
 
10.4 ± 4.0 
 
-73.1 ± 2.6 
 
2.0 ± 0.6 
 
3 
Lin-glycine+1C 
 
1.7 ± 0.2 
 
-7.2 ± 2.5 
 
1.3 ± 0.02 
 
3 
Lin-glycine+2C 
 
1.9 ± 0.4 
 
-8.7 ± 0.5 
 
1.1 ± 0.2 
 
3 
Lin-cysteic acid 
 
9.2 ± 0.4 
 
-58.4 ± 2.8 
 
2.0 ± 0.2 
 
5 
Lin-aspartate 
 
4.0 ± 0.1 
 
-34.5 ± 2.3 
 
1.4 ± 0.1 
 
4 
Lin-AP3 
 
1.8 ± 0.3 
 
-5.7 ± 1.3 
 
1.1 ± 0.1 
 
3 
DHA 
 
2.0 ± 0.6 
 
0.1 ± 1.4 
 
1.7 ± 0.3 
 
4 
DHA-glycine 
 
4.7 ± 1.3 
 
-16.5 ± 1.3 2.0 ± 0.2 
 
4 
DHA-taurine 
 
5.1 ± 0.7 
 
-45.3 ± 2.9 
 
1.7 ± 0.1 
 
3 
Pinolenic acid 
 
1.5 ± 0.3 
 
-6 ± 1.8 
 
1.4 ± 0.2 
 
3 
Pin-glycine 
 
3.8 ± 0.2 
 
-21.1 ± 2.5 
 
1.8 ± 0.1 
 
3 
Pin-taurine 
 
9.0 ± 1.4 
 
51.6 ± 3.5 
 
1.9 ± 0.3 
 
4 
Summary of the effects of PUFAs on IKs I/I0, DV0.5 (mV), and 
Gmax/Gmax0 with the number of experiments (N). Data is represented 
as mean ± SEM at the maximum concentration used (effects of 
DHA-taurine are reported at 7 µM due to a decrease in current 
observed at 20 µM).  
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3.6. Circulating concentrations of Lin-glycine with albumin and other fatty 
acids promotes the activation of the cardiac IKs channel by left-shifting the 
voltage dependence of activation. 
In the body, PUFAs circulate in complex with serum albumin but interact with 
channel proteins in the free fatty acid form. In addition, PUFAs in the 
bloodstream will be in circulation with other types of fatty acids, including 
monounsaturated fatty acids (MUFAs) and saturated fatty acids (SFAs). In order 
to emulate the effects of PUFAs under physiological conditions, we applied lin-
glycine in combination with the MUFA oleic acid, the SFA stearic acid, and 
albumin (Tsukamoto and Sugawara 2018; Abdelmagid et al. 2015). We applied 
0.2 mM albumin/ 0.7 mM lin-glycine/ 0.6 mM oleic acid/ 0.6 mM stearic acid 
which we refer to as albumin + fatty acids (Abdelmagid et al. 2015; Tsukamoto 
and Sugawara 2018). Following the application of albumin + fatty acids, we see 
an increase in IKs current (Fig. 9A). In the current vs voltage relationship, we 
observe that the application of albumin alone causes a slight, but not significant, 
decrease in the current (Fig. 9B). However, with the application of albumin + fatty 
acids, we observe an increase in the current (such that the current is restored to 
the current seen under control conditions), as well as a leftward shift in the 
voltage dependence of IKs activation (Fig. 9B). Lin-glycine in combination with 
MUFAs, SFAs, and albumin produces a significant increase in IKs current (3.4 ± 
0.6) compared to control (p = 0.007) and albumin alone (p = 0.004) (Fig. 9C). In 
addition, we observe a leftward shift in the voltage-dependence of IKs activation (-
20.1 ± 5.1 mV) compared to control (p = 0.007) and the application of albumin 
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alone (p = 0.006), however it does not significantly increase the maximal 
conductance of the IKs channel (0.94 ± 0.01) (p = 0.5) (Fig. 9D-E). These data 
together suggest that there is still a substantial concentration of lin-glycine in the 
free fatty acid form that is available to promote the activation of the cardiac IKs 
channel by left-shifting the voltage dependence of activation. 
 
  Figure 3.11. Lin-glycine, in combination with physiological concentrations of 
monounsaturated and saturated fatty acids and albumin, promotes the 
activation of the IKs channel. A) Raw current traces measured in control ND96 (left) 
and in the presence of 0.2 mM albumin + 0.7 mM Lin-glycine/0.6 mM Oleic acid/0.6 
mM Stearic acid (Fatty Acids) (right). B) Current-voltage relationship of cells in control 
ND96 (black squares), 0.2 mM albumin alone (red circles) and 0.2 mM albumin + 0.7 
mM Lin-glycine/0.6 mM Oleic acid/0.6 mM Stearic acid (green triangles) (mean ± 
SEM; n = 3). C) Statistical differences on I/I0 effects (I/I0 fitted from the dose response 
curve) measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. D) 
Statistical differences on ΔV0.5 effects (ΔV0.5 fitted from the dose response curve) 
measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. E) 
Statistical differences on Gmax effects (Gmax fitted from the dose response curve) 
measured by one-way ANOVA followed by Tukey’s HSD post hoc analysis. 
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3.7. PUFA analogues rescue LQT1 associated loss of function mutation 
Kv7.1 V215M + KCNE1 by left-shifting voltage dependence of IKs activation. 
To evaluate the therapeutic potential of the PUFA analogues as potential 
treatments for LQTS, we expressed the IKs channel bearing a mutation that 
causes Long QT Type 1 (LQT1) (V215M). V215M (in which a valine residue is 
replaced with methionine) is a loss-of-function mutation located in the S3 
segment of the Kv7.1 α-subunit of the cardiac IKs channel (Eldstrom et al. 2010). 
The V215M mutation causes a rightward shift in the voltage dependence of 
channel activation and alters the activation and deactivation kinetics compared to 
the wild type channel (Fig. 10A) (Eldstrom et al. 2010). In order to determine the 
ability of PUFA analogues to restore IKs channel loss-of-function, we applied both 
lin-glycine and lin-taurine to the IKs channel bearing the V215M mutation.  From 
the current vs voltage relationship, we found that the V215M mutation results in a 
significant rightward shift in the voltage-dependence of IKs channel activation 
relative to the wild type channel (V215M V0.5 = 40.2 ± 0.2 mV; Wild type V0.5 = 
16.6 ± 0.4 mV; ΔV0.5 = +24.2 ± 2.3 mV) (Fig. 10 B-C). However, the application of 
lin-glycine (at 10 μM) and lin-taurine (at 5 μM) both strongly left-shift the voltage-
dependence of activation compared to the V0.5 of V215M mutant channels (ΔV0.5 
= -23.8 ± 3.3 mV and -29.7 ± 0.8 mV, respectively), fully restoring the wild-type 
voltage dependence of the IKs channel (Fig. 10B-C). Lin-glycine and lin-taurine 
even shift the voltage-dependence to the left relative to the wild-type voltage 
dependence and increase the normalized tail current relative to wild-type (Fig. 
10B). These data demonstrating PUFA-induced effects on LQT1-causing 
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mutations suggest that PUFA analogues are potent enough activators of the IKs 
channel that they are capable of restoring the normal voltage dependence of 
LQT1 mutation-bearing IKs channels. 
 
 
 
  Figure 3.12. PUFA analogues Lin-glycine and Lin-taurine rescue LQT1-
associated loss-of-function mutation, V215M. A) B) Current-voltage relationship of 
the wild type IKs channel (black squares; mean ± SEM; n = 4), Kv7.1 V215M + KCNE1 
(red circles; mean ± SEM; n = 3), Kv7.1 V215M + KCNE1 with Lin-glycine (green 
triangles; mean ± SEM; n = 3), Kv7.1 V215M + KCNE1 with Lin-taurine (blue triangles; 
mean ± SEM; n = 3). C) Statistical differences on the voltage dependence (V0.5) effects 
(V0.5 fitted using the Boltzmann equation) measured by one-way ANOVA followed by 
Tukey’s HSD post hoc analysis. 
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General Discussion 
We have characterized several different head groups of PUFA analogues in 
order to determine the range of effects of PUFA analogues on the current, 
voltage dependence, and maximal conductance of the cardiac IKs channel. Our 
findings demonstrate that PUFA analogues with a glycine head group 
consistently produce moderate activation of the cardiac IKs channel. In addition, 
we have demonstrated that PUFA analogues with a taurine or cysteic acid head 
groups produce the most potent activation of the cardiac IKs channel. Lastly, we 
have shown that increasing the number of potentially charged moieties did not 
necessarily improve PUFA-induced activation of the cardiac IKs channel. This is 
most likely due to the pKa of the additional potentially charged moieties, as well 
as potential steric hindrance of PUFAs with multiple potentially charged groups. 
We have previously presented evidence that the charged head group of PUFAs 
electrostatically interact with S4 arginines or K326 in S6 the IKs channel (Liin, 
Yazdi, et al. 2018). We assume that the PUFAs and PUFA analogues tested 
here also interact by similar mechanisms with the IKs channel. As an example, we 
show here that neutralization mutations of charges in S4 or K326 in S6 decrease 
the effects of lin-glycine on the voltage shift and Gmax (Suppl. Fig. S3), as if lin-
glycine also interact with the S4 arginines and K326 in the pore.   
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Most of the variability in the effects of the different PUFA head groups on IKs 
channels can be explained by the predicted pKa of the different head groups, 
which determines their protonation state in the membrane bound to the IKs 
channel. Our group has previously demonstrated that the protonation state of the 
PUFA head group is influenced specifically by the presence of KCNE1 bound in 
the lipophilic cleft between adjacent Kv7.1 a-subunits (Larsson, Larsson, and Liin 
2018). When KCNE1 is present, acidic residues located in the S5-P-helix loop 
(and in particular, the residue E290) are brought closer to the PUFA head group 
and, promoting protonation of the PUFA head group (Larsson, Larsson, and Liin 
2018). When the pH dependence of IKs activation is measured, the 
experimentally determined pH dependence a PUFA with a carboxyl head group 
was consistent with a pKa ~ 8.5, suggesting that PUFAs with a simple carboxyl 
head group is protonated and neutral at pH 7.5. We, therefore, propose that 
PUFAs with a simple carboxyl head group are unable to participate in an 
electrostatic interaction with S4 arginines or K326 in S6 the IKs channel.  
 
Figure 3.13. Residues in the voltage sensor and pore are important for 
electrostatic activation of the cardiac IKs channel. A) Current-voltage 
relationship for Kv7.1 R231Q Q234R + KCNE1 with the application of Lin-glycine 
(mean ± SEM; n = 4). B-D) Dose dependent effects of Lin-glycine on Kv7.1 R231Q 
Q234R + KCNE1 (black squares) and the wild type IKs channel (red dashed line) 
on I/I0, C) ΔV0.5, and D) Gmax. E) Current-voltage relationship for Kv7.1 K326Q + 
KCNE1 with the application of Lin-glycine (mean ± SEM; n = 4).  F-H) Dose 
dependent effects of Lin-glycine on Kv7.1 K326Q + KCNE1 (black squares) and 
the wild type IKs channel (red dashed line) on I/I0, G) ΔV0.5, H) Gmax. 
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The experimental determined pKa value of PUFA analogues with a glycine head 
group associated with the IKs channel is ~ 7.6 (Borjesson and Elinder 2011; 
Elinder and Liin 2017; Liin et al. 2015). Therefore half of the PUFA molecules 
with a glycine head group will be deprotonated and able to participate in an 
electrostatic interaction with S4 arginines or K326 in S6. (Liin et al. 2015). Our 
data comparing the effects of lin-glycine at pH 7.5 and pH 9 supports the idea 
that half of the PUFA molecules with a glycine head group are able to have an 
electrostatic interaction with the S4 segment of IKs channels. Notably, the left-shift 
in the V0.5 of lin-glycine at pH 9 (Fig. 3H) is approximately doubled compared to 
the left-shift at pH 7.5 (Fig. 3E), consistent with our estimate of a pKa of ~7.5-7.6 
for PUFA analogues with glycine head groups (Suppl. Table 1). At pH 9, all of the 
lin-glycine molecules will be deprotonated and able to participate in an 
electrostatic interaction with the S4 segment, leading to a larger left-shift in the 
voltage-dependence of IKs channel activation.   
 
Finally, the predicted pKa for PUFA analogues with a taurine head group 
associated with IKs channels is ~ 2.6, so that all taurine head groups are able to 
participate in an electrostatic interaction with the S4 arginines or K326 in S6 even 
at pH 7.5. The predicted pKas for taurine and glycine compounds are consistent 
with the approximate half size of the voltage-shifting effect of glycine compounds 
compared to taurine compounds. Why lin-glycine gives a larger increase in Gmax 
than lin-taurine is not clear, but maybe due to different access for lin-glycine than 
lin-taurine to the PUFA binding site that promotes increase in Gmax.  
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We estimated pKa1 and pKa2 values of lin-aspartate and lin-cysteic acid, as well 
as the pKa3 of lin-AP3, to compare to estimated pKa values of lin-glycine and lin-
taurine (Suppl. Table 1). In lin-aspartate, the pKa1 is ~7.6, which is similar to the 
pKa value of lin-glycine, suggesting that the first potentially charged group is 
likely to reside in its deprotonated form 50% of the time at pH 7.5. The pKa2 of 
lin-aspartate is ~9.1, which means that the second potentially charged moiety 
would be protonated and uncharged at pH 7.5. Therefore, lin-aspartate has 
approximately the same functional charge on the hydrophilic head group as lin-
glycine. Indeed, the overall effect of lin-aspartate on I/I0 is not significantly 
different than the I/I0 effect of lin-glycine. In lin-cysteic acid, the pKa1 is ~2.4, 
which is very similar to the pKa value of lin-taurine, meaning lin-cysteic acid 
should be at least as potent as lin-taurine. pKa2 of lin-cysteic acid is ~7.1, 
meaning that the second group is likely to reside in its deprotonated form >50% 
of the time at physiological pH. However, lin-cysteic acid did not have a larger 
effect than lin-taurine, suggesting that the second charge group is not interacting 
with the channel or it is possible that nearby residues in the IKs channel protein 
modify the pKa2 so that this group remains protonated at pH 7.5. Lastly, in lin-
AP3, the pKa1 and pKa2 are ~5.0 and ~7.7 while the pKa3 is ~11.8, which would 
suggest that the first site would be deprotonated and the second site would be 
deprotonated 50% of the time while the third group is protonated and uncharged 
at pH 7.5. However, Lin-AP3 has little to no effect on I/I0, ΔV0.5, or Gmax, 
suggesting that lin-AP3 does not effectively interact with the voltage sensor/pore 
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or it is not effectively deprotonated/negatively charged. We observe small effects 
of lin-AP3 when applied at pH 9 (in an attempt to help unmask potentially 
charged groups) (Suppl. Fig. S4), suggesting that there may be steric hindrance 
preventing the bulky AP3 head group from interacting favorably with the IKs 
channel.  
 
 
 
 
  
Figure 3.14. Effects on lin-AP3 on IKs activation at pH 9. A-C) Dose dependent 
effects of lin-AP3 on A) IKs current (I/I0), B) IKs voltage dependence (ΔV0.5), and C) IKs 
maximal conductance (Gmax) at pH 9 (mean ± SEM at maximal concentration; n = 3). 
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Similar to our findings on the importance of the pKa of the PUFAs for shifting the 
voltage dependence of IKs channels, Ottosson and coworkers (2015) found that 
lowering the pKa of resin acid molecules resulted in greater left shift in the 
voltage dependence of the Shaker potassium channel (Ottosson et al. 2015). 
This further shows the importance of a deprotonated and charged compound for 
a strong activating effect on voltage-gated K+ channels by the lipoelectric 
mechanism. In addition, Ottosson et al. noted that some substitutions wherein a 
bulky group was added to the scaffold, the efficacy of these resin acid 
compounds were reduced (Ottosson et al. 2015). They suggest that adding a 
bulky group may impede the ability of the small molecule to interact with the 
voltage sensor of the Shaker K+ channel (Ottosson et al. 2015). This is similar to 
our data using the more bulky PUFA analogue lin-AP3. 
 
The pH dependence of PUFA head group ionization has also been shown in the 
Slo1 BK channel by Tian and colleagues (2016) (Tian et al. 2016). They found 
that DHA produces potent activation of Slo1 BK channels and that this effect can 
be reduced when the pH is decreased, leading to protonation of the PUFA head 
group, and that the effect can be potentiated when the pH is increase, leading to 
deprotonation of the PUFA head group (Tian et al. 2016). Similar to our results, 
Tian et al. found that the addition of a phosphate head group leads to an 
attenuated effect on BK channel activation compared to DHA and DHA-glycine, 
which is similar to the effects we see when applying lin-AP3 (Tian et al. 2016).  
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In addition to the charge of the PUFA head group, the degree of unsaturation in 
the PUFA tail also plays an important role in PUFA-induced activation of the IKs 
channel. We and others have found that the PUFA-induced activation of IKs 
channels and Shaker K channels requires that the PUFA tail structure has at 
least two double bonds in cis-configuration in the tail  (Liin et al. 2015; Liin et al. 
2016) (Borjesson, Hammarstrom, and Elinder 2008).  We recently conducted a 
systematic analysis of the PUFA tail (Bohannon et al. 2018) and found that 
neither the length of the carbon tail nor the number of double bonds in the tail 
correlated significantly with effects on or apparent binding affinity for the cardiac 
IKs channel (Bohannon et al. 2018). However, the position of the double bonds in 
the tail is strongly correlated with stronger activation of and better apparent 
affinity for the cardiac IKs channel (Bohannon et al. 2018).  
 
Lipophilic compounds have the ability to form micelles. The concentration at 
which micelle formation takes place is called the critical micellar concentration 
(CMC). If the critical micellar concentration for our compounds is reached, 
micelle formation has the potential to interfere with the efficacy of the PUFAs and 
PUFA analogues being applied. Some factors that contribute to the ability of 
PUFAs to form micellar structures include the degree of unsaturation of the 
PUFA tail, the length of the PUFA tail (Borjesson, Hammarstrom, and Elinder 
2008). In addition, the CMC could be influenced to some extend by pH (Rustan 
and Drevon 2005). However, the critical micellar concentration that is estimated 
for the majority of PUFAs and other unsaturated fatty acids is between 60-150 
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µM (Serth et al. 1991; Richieri, Ogata, and Kleinfeld 1992; Mukerjee and Mysels 
1971). The experiments reported here were done at concentrations between 0.2-
20 µM, which is well under the expected critical micellar concentration reported 
for unsaturated fatty acids. For this reason, we expect that the PUFAs applied in 
our preparation remain in the free fatty acid form, meaning that it is unlikely that 
any lack of effect from a PUFA could be attributed to the formation of micelles. 
 
A range of effective compounds that activate the cardiac IKs channel is useful in 
the design of personalized therapeutics for LQT1. Patients with different LQT1 
mutations have IKs channels with different degrees of channel malfunction (e.g. 
different size voltage shifts in their voltage dependence of activation) and present 
symptoms of varying severity. For this reason, individual LQT1 patients will not 
benefit from a one-size-fits-all treatment, producing a need for more personalized 
treatments. The findings presented here suggest that patients with more severe 
loss-of-function mutations of the cardiac IKs channel would most likely benefit 
from PUFA analogues with a taurine head group. In particular, PUFA analogues 
with a taurine or cysteic acid head group would be the most effective to rescue 
loss-of-function mutations in the IKs channel that lead to large shifts of the voltage 
dependence of IKs activation, because these head groups produce the most 
robust effects on the V0.5. Patients with a milder LQT1 phenotype, however, may 
benefit more from treatment with a glycine PUFA analogue that has more 
moderate effects on IKs channel activation, and especially loss-of-function 
mutations that alter the maximal conductance (Gmax) of the IKs channel. Effective 
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PUFA analogues can thus be selected for specific patients according to the 
severity of LQT1 pathology. 
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CHAPTER 4. Polyunsaturated fatty acid analogues have differential effects 
on cardiac NaV, CaV, and KV channels through unique mechanisms3 
Background 
The ventricular action potential is mediated by the coordinated activity of several 
different voltage-dependent ion channels (Mohrman and Heller 2010). The rapid 
upstroke of the ventricular action potential is mediated by the activation of the 
voltage-gated Na+ channel, Nav1.5, which then rapidly inactivates. The activation 
of L-type voltage gated Ca2+ channels, Cav1.2, and influx of Ca2+ leads to a 
sustained depolarization, or plateau phase, and the contraction of the cardiac 
muscle. Inactivation of Cav1.2 channels along with the activation of the slow 
delayed-rectifier K+ channels, Kv11.1 (which generates the IKr current) and 
Kv7.1/KCNE1 (which generates the IKs current), work to promote repolarization of 
the cell membrane (Nerbonne and Kass 2005). Mutations of any of these ion 
channels (or channelopathies) could lead to Long QT Syndrome (LQTS), which 
is an arrhythmogenic disorder that predisposes the individual to potentially fatal 
cardiac arrhythmias (Alders and Christiaans 2003; Bohnen et al. 2017). 
 
The Nav1.5 α-subunit contains four non-identical linked domains, DI-DIV. Each of 
these domains contain 6 transmembrane segments (S1-S6), where the S1-S4 
 
3 Bohannon, BM., Wu, X., Perez, ME., Liin, SI., and Larsson, HP. (2019) Polyunsaturated fatty acids have 
differential effects on cardiac Nav, Cav, and Kv channels through unique mechanisms. BioRxiv 772640; doi: 
https://doi.org/10.1101/772640 
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segments make up the voltage-sensing domains (VSD) and S5-S6 segments 
make up the pore domains (PD). The S4 helix of each of the four domains 
contains a motif with positively charged amino acid residues which allow the S4 
segment to detect and respond to changes in the membrane electric field, acting 
as the channel voltage sensor (Chanda and Bezanilla 2002). The movement of 
these voltage sensors determines the voltage dependence of activation and 
inactivation, where activation of the DI-III S4s are suggested to promote 
activation and activation of DIV S4 segment is sufficient to induce voltage-
dependent inactivation of Nav1.5 (Capes et al. 2013). The Nav1.5 α-subunit 
exists as a macromolecular complex with the accessory subunit β1 (Barro-Soria, 
Liin, and Larsson 2017; Xiao et al. 2000; Zhu et al. 2017). Gain-of-function 
mutations of Nav1.5 increase Na+ currents and lead to LQTS Type 3 (LQT3) 
(Fernandez-Falgueras et al. 2017; Calloe et al. 2013; Rivolta et al. 2002).  
 
Like Nav1.5, the Cav1.2 α-subunit contains four linked domains, DI-DIV, where 
each domain consists of 6 transmembrane segments S1-S6. S1-S4 form the 
VSD, where S4 acts as the voltage sensor, and S5-S6 form the PD. Cav1.2 
exists as a large macromolecular complex with the accessory subunits β3 and 
α2δ subunits that are important for membrane expression and alter channel 
activation and deactivation kinetics, respectively (Rougier and Abriel 2016; Chen 
et al. 2004). Cav1.2 undergoes both voltage-dependent inactivation and calcium-
dependent inactivation (Stotz, Jarvis, and Zamponi 2003; Zhang et al. 1994) 
which allows it to regulate Ca2+ influx into the cardiomyocyte. Gain-of-function 
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mutations of Cav1.2 increase Ca2+ currents and lead to Long QT Type 8 (LQT8) 
(Dick et al. 2016; Hoffman 1995).  
 
The voltage-gated K+ channel, Kv7.1, along with the auxiliary subunit KCNE1, 
mediates an important repolarizing K+ current, IKs (Noble and Tsien 1969a; Deal, 
England, and Tamkun 1996; Lei and Brown 1996). The Kv7.1 α-subunit contains 
6 transmembrane segments, S1-S6. S1-S4 comprise the VSD, where S4 
contains several positively charged amino acid residues that allow S4 to act as 
the voltage sensor of Kv7.1. S5-S6 segments comprise the channel PD. Kv7.1 
forms a tetrameric channel, where 4 Kv7.1 α-subunits arrange to form a 
functional channel. The auxiliary β-subunit KCNE1 drastically modulates Kv7.1 
channel voltage dependence, activation kinetics, and single-channel 
conductance (Barro-Soria et al. 2014; Osteen et al. 2010). Loss-of-function 
mutations in the Kv7.1 α-subunit and KCNE1 b-subunit lead to reductions in IKs 
and can lead to LQTS Type 1 (LQT1) and Type 5 (LQT5) (Huang et al. 2018; Ma 
et al. 2015; Schwartz, Crotti, and Insolia 2012; Sanguinetti 1999; Harmer et al. 
2009), respectively.  
 
Polyunsaturated fatty acids (PUFAs) are amphipathic molecules that have been 
suggested to possess antiarrhythmic effects (Endo and Arita 2016; Kang and 
Leaf 2000). PUFAs, such as DHA and EPA, have been shown to prevent cardiac 
arrhythmias in animal models and cultured cardiomyocytes by inhibiting the 
activity of Nav and Cav channels (Kang and Leaf 1996, 2000; Xiao 1997; Xiao et 
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al. 1995). Since the voltage sensors of Nav and Cav channels are relatively 
homologous, it has been suggested that PUFAs act on the voltage-sensing S4 
segments that control inactivation in these channels (Kang and Leaf 1996, 2000). 
Our group has demonstrated that PUFAs and PUFA analogues also modulate 
the activity of the Kv7.1/KCNE1 channel and work to promote voltage-dependent 
activation of the IKs current through a mechanism referred to as the lipoelectric 
hypothesis (Borjesson, Hammarstrom, and Elinder 2008; Liin et al. 2015; Liin et 
al. 2016). Our group has also demonstrated that PUFAs and modified PUFAs 
exert a second effect on the pore of Kv7.1 through an additional electrostatic 
interaction with a lysine residue (K326) in the S6 segment (Liin, Yazdi, et al. 
2018). This electrostatic interaction between the negatively charged PUFA head 
group and K326 leads to an increase in maximal conductance of the channel 
(Gmax) (Liin, Yazdi, et al. 2018).  
 
Some groups have suggested that PUFAs could modify Nav channels by causing 
a leftward shift in voltage dependent inactivation through an electrostatic effect 
on the voltage-sensing domains involved in inactivation (Kang and Leaf 1996, 
2000). It is possible that PUFAs modulate Kv7.1/KCNE1, Nav, and Cav channels 
by a similar mechanism by integrating next to the S4 voltage sensors and 
electrostatically attracting the voltage sensors toward their outward position. If 
PUFAs integrate preferentially next to the S4 that controls inactivation in Nav and 
Cav channels but next to all S4s in Kv7.1/KCNE1 channels, PUFAs would 
promote activation in Kv7.1/KCNE1 channels but promote inactivation in Nav and 
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Cav channels. Though both PUFAs and PUFA analogues are known to modulate 
different ion channel activities (i.e. processes underlying activation and 
inactivation), it is unclear whether specific PUFAs and PUFA analogues are 
selective for certain ion channels or if they broadly influence the activity of 
several different ion channels simultaneously.  
 
In this work, we characterize the channel-specific effects of different PUFAs and 
PUFA analogues in order to further understand which PUFAs and PUFA 
analogues would be the most therapeutically relevant in the treatment for 
different LQTS subtypes. We have found that PUFA analogues modulate 
Kv7.1/KCNE1, Cav1.2, and Nav1.5 through different mechanisms instead of 
through a shared mechanism. In addition, we demonstrate that PUFA analogues 
exhibit a broad range of differences in selectivity for Kv7.1/KCNE1, Cav1.2, and 
Nav1.5. Lastly, PUFA analogues that are more selective for Kv7.1/KCNE1 are 
able restore a prolonged ventricular action potential and prevent arrhythmia in 
simulated cardiomyocytes. 
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Results 
4.1. PUFA analogues modulate Kv7.1/KCNE1, Cav1.2, and Nav1.5 through 
distinct mechanisms. 
There are several studies supporting electrostatic activation of Kv7.1/KCNE1 
channels by PUFA analogues (Larsson, Larsson, and Liin 2018; Liin et al. 2015; 
Liin et al. 2016; Liin, Yazdi, et al. 2018). PUFAs are known to inhibit Nav and Cav 
channels, but there is little evidence on the mechanism of channel inhibition 
using a diverse set of PUFA analogues. Previous groups have suggested that 
PUFAs may inhibit Nav and Cav channels by interacting with S4 voltage sensors 
and stabilizing the inactivated state since there are similarities between the 
voltage sensor profiles of Nav and Cav channels. (Xiao 1997; Kang and Leaf 
1996, 2000; Xiao et al. 1995). For this reason, we hypothesize that PUFA 
analogues inhibit Cav1.2 and Nav1.5 through a shared electrostatic mechanism 
on S4 voltage sensors, similar to that reported with Kv7.1/KCNE1 channels. But 
in the case of Nav and Cav channels, PUFAs would left-shift the voltage 
dependence of inactivation instead of activation which is seen in Kv7.1/KCNE1. 
To compare the effects of different PUFA analogues on these three different 
channels, we here measure the currents from Kv7.1/KCNE1, Cav1.2, and Nav1.5 
expressed in Xenopus oocytes using two-electrode voltage clamp. 
 
We first illustrate the effects of a representative PUFA analogue Linoleoyl taurine 
(Lin-taurine) on the voltage dependence of activation and the conductance of 
Kv7.1/KCNE1 (Fig. 1A-C). These effects are reflected in the tail current-voltage 
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relationship where the effects on the voltage sensor are measured as a leftward 
shift in the voltage dependence of activation and the effects on the conductance 
are measured as a relative increase in the maximal conductance upon PUFA 
application (Fig. 1C).  
 
 
  Figure 4.1. PUFAs activate Kv7.1/KCNE1 channels through an electrostatic 
mechanism on voltage sensor and pore. A) Simplified membrane topology of a 
single Kv7.1 α-subunit (blue) and a single KCNE1 β-subunit (grey). B) Voltage protocol 
used to measure voltage dependence of activation and representative Kv7.1/KCNE1 
current traces in control (0 μM) and 20 μM Lin-taurine. Arrows mark tail currents. C) 
Current-voltage relationship demonstrating PUFA induced left-shift in the voltage-
dependence of activation (V0.5) and increase in maximal conductance (Gmax) (mean ± 
SEM; n = 3). 
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We also measure the effect of Lin-taurine on Cav1.2 and Nav1.5 channels 
(Figure 2-3). When we apply Lin-taurine to the Cav1.2 macromolecular complex 
(Fig. 2A), we see that Lin-taurine reduces Ca2+ currents in a dose-dependent 
manner (Fig. 2B-C). However, Lin-taurine reduces Ca2+ current without shifting 
the voltage-dependence of Cav1.2 activation (Fig. 2B-C; Supplemental Fig. 1). 
We use a depolarizing pre-pulse protocol to measure changes in voltage-
dependent inactivation (Fig. 2D-E). When we measure the effects of PUFA 
analogues on voltage-dependent inactivation, we see again a decrease in Ca2+ 
currents, but surprisingly no shift in voltage-dependent inactivation (Fig. 2D-E). 
This suggests that PUFA analogues do not inhibit Cav1.2 channels through a 
shared electrostatic mechanism on S4 voltage sensors that shifts the voltage 
dependence of S4 movement, but rather through a mechanism that reduces 
either the number of conducting channels (potentially through an effect on the 
pore) or the maximum conductance of each channel.  
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  Figure 4.2. PUFAs inhibit Cav1.2 channels without altering channel voltage 
dependence. A) Simplified membrane topology of the Cav1.2 pore-forming α-subunit 
(light gray) and auxiliary β- (mint) and α2δ-subunits (yellow and green). B) Voltage 
protocol used to measure voltage dependence of activation and representative Cav1.2 
current traces in control (0 μM) and 20 μM Lin-taurine. C) Current-voltage relationship 
demonstrating dose-dependent inhibition of Cav1.2 currents measured from activation 
protocol (mean ± SEM; n = 3). D) Voltage protocol used to measure voltage 
dependence of inactivation and representative Cav1.2 current traces in control (0 μM) 
and 20 μM Lin-taurine measured at arrow. E) Current-voltage relationship 
demonstrating dose-dependent inhibition of Cav1.2 currents measured from 
inactivation protocol (mean ± SEM; n = 3). 
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When we apply Lin-taurine to Nav1.5 (Figure 3A) and measure voltage-
dependent activation, we see a dose-dependent inhibition of Na+ currents with no 
shift in the voltage dependence of activation (Fig. 3B-C; Supplemental Fig. 1). 
However, when we measured voltage-dependent inactivation of Nav1.5, we 
observed that PUFA analogues left-shift the voltage dependence of inactivation 
(Fig. 3D-E). In addition to the left-shift in voltage-dependent inactivation, we also 
observe a dose-dependent decrease in Nav1.5 currents (Fig. 3E). This suggests 
that PUFA analogues, while they do influence the voltage dependence of 
inactivation, may also have an additional effect on the conductance of Nav1.5, 
leading to the dose-dependent decrease in Na+ currents seen on top of the 
leftward shift of the voltage dependence of inactivation. 
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Figure 4.3. PUFAs inhibit Nav1.5 by shifting the voltage dependence of 
inactivation. A) Simplified membrane topology of the Nav1.5 pore-forming α-subunit 
(light blue) and auxiliary β-subunit (green). B) Voltage protocol used to measure 
voltage dependence of activation and representative Nav1.5 current traces in control 
(0 μM) and 20 μM Lin-taurine. C) Current-voltage relationship demonstrating dose-
dependent inhibition of Nav1.5 currents measured from activation protocol (mean ± 
SEM; n = 5). D) Voltage protocol used to measure voltage dependence of inactivation 
and representative Nav1.5 current traces in control (0 μM) and 20 μM Lin-taurine 
measured at arrow. E) Current-voltage relationship demonstrating dose-dependent 
inhibition of Nav1.5 currents and leftward shift in the voltage dependence of 
inactivation measured from inactivation protocol (mean ± SEM; n = 5). 
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Figure 4.4. PUFA-induced changes in I/I0 normalized by concentration show no 
changes in voltage-dependent activation of Cav1.2 and Nav1.5 channels. A-B) 
Voltage-dependent activation of Cav1.2 in the presence of A) N-AT and B) DHA-
glycine. Peak currents are normalized to each concentration to clearly visualize that 
there is no shifts in voltage-dependent activation. C-D) Voltage-dependent activation 
of Nav1.5 in the presence of C) N-AT and D) DHA-glycine. Peak currents are 
normalized to each concentration to clearly visualize that there are no shifts in 
voltage-dependent activation. 
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Through these data, we observe that PUFA analogues modulate cardiac voltage-
gated ion channels through non-identical mechanisms. PUFA analogues promote 
the activation of Kv7.1/KCNE1 through electrostatic effects that left-shift the 
voltage dependence of activation and an increase in the maximal conductance. 
PUFA analogues inhibit Cav1.2 channels through an apparent effect on the pore 
leading to a reduction in Ca2+ current but without producing any leftward shift in 
the voltage dependence of inactivation. In addition, PUFA analogues inhibit 
Nav1.5 through a combination of a leftward shift in the voltage dependence of 
inactivation and an effect on the maximum conductance, which leads to a dose-
dependent decrease in Na+ current. Together these findings show that PUFA 
analogues affect Kv7.1/KCNE1, Nav1.5, and Cav1.2 channels through different 
mechanisms. 
 
4.2. PUFA analogues with taurine head groups are non-selective and 
broadly modulate multiple cardiac ion channels, with preference for Cav1.2 
and Nav1.5. 
We have found through previous work that PUFA analogues with taurine head 
groups are good activators of the Kv7.1/KCNE1 channels due to the low pKa of 
the taurine head group (Liin et al. 2015; Liin et al. 2016). Having a lower pKa 
allows the taurine head group to be fully negatively charged at physiological pH 
so that it has maximal electrostatic effects on Kv7.1/KCNE1 channels (Liin et al. 
2016). We tested a set of PUFA analogues with taurine head groups on 
Kv7.1/KCNE1, Cav1.2, and Nav1.5 channels to determine if these effects are 
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selective for the Kv7.1/KCNE1 channel or if taurine analogues also modulate 
Cav1.2 and Nav1.5 channels. Lin-taurine is a PUFA analogue with a taurine 
head group (Figure 4A) that promotes the activation of the cardiac Kv7.1/KCNE1 
channel, by promoting a leftward shift in the voltage-dependence of activation by 
-39.9 ± 3.6 mV at 7 μM (p = 0.008) (Fig 4B). In addition, the application of Lin-
taurine produces a slight, but not statistically significant increase in the maximal 
conductance of the Kv7.1/KCNE1 channel at 7 μM (1.9 ± 0.6; p = 0.26) (Fig. 4C).  
Lin-taurine inhibits Cav1.2 current in a dose-dependent manner without left-
shifting the voltage dependence of inactivation for Cav1.2 (2.8 ± 1.4 mV; p = 
0.17), but instead by significantly decreasing the Gmax at 7 μM (0.4 ± 0.1; p = 
0.03) (Fig. 4D-E). Lastly, Lin-taurine inhibits Nav1.5 current by left-shifting the 
voltage dependence of inactivation (-23.5 ± 1.9 mV; p = 0.001) and also 
decreasing the Gmax at 7 μM (0.5 ± 0.07; p = 0.005) (Fig 4F-G).  
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Figure 4.5. Linoleoyl taurine has broad selectivity for Kv7.1/KCNE1, Cav1.2, and 
Nav1.5. A) Structure of Linoleoyl taurine (Lin-taurine). B, D, F) Dose response of the 
shift in voltage dependent B) activation (ΔV0.5) of Kv7.1/KCNE1 channels (mean ± 
SEM; n = 3), D) inactivation (ΔV0.5) of Cav1.2 channels (mean ± SEM; n = 3), F) 
inactivation (ΔV0.5) of Nav1.5 channels (mean ± SEM; n = 5) in the presence of lin-
taurine. C, E, G) Dose response of the change in maximal conductance (Gmax) of C) 
Kv7.1/KCNE1 channels E) Cav1.2 channels, G) Nav1.5 channels in the presence of 
lin-taurine. 
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N-arachidonoyl taurine (N-AT) is a PUFA analogue with a taurine head group 
that has been demonstrated by our group to promote activation of Kv7.1/KCNE1, 
left-shifting the voltage-dependence and increasing the Gmax at 70 μM (Fig. 5A) 
(Liin et al. 2016). Here, we used lower concentrations (0.2, 0.7, 2, 7, and 20 μM) 
with the goal of understanding the selectivity of N-AT for cardiac ion channels 
and at more therapeutically feasible concentrations. Application of N-AT does not 
promote activation of Kv7.1/KCNE1 in this lower concentration range, does not 
left-shift of the voltage-dependence of activation (-1.8 ± 2.6 mV; p = 0.5), and 
does not increase the Gmax at 7 μM (0.9 ± 0.03; p = 0.98) (Fig. 5B-D). However, 
N-AT causes a dose-dependent decrease in Cav1.2 current, though does not 
cause a significant shift in the voltage dependence of inactivation (13.5 ± 3.8 mV; 
p = 0.07), nor does it cause a significant reduction in the overall Gmax (0.6 ± 0.1; p 
= 0.06) at 7 μM (Fig. 5E-G). In addition, N-AT decreases Nav1.5 current, 
produces a leftward shift in voltage-dependent inactivation (-16.7 ± 3.5 mV; p = 
0.04), and significantly reduces the Gmax at 7 μM (0.3 ± 0.04; p = 0.004) (Fig. 5H-
J). This data suggests that N-AT is more selective for Cav1.2 and Nav1.5, 
compared to Kv7.1/KCNE1. 
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  Figure 4.6. N-arachidonoyl taurine is more selective for Cav1.2 and Nav1.5 than 
for Kv7.1/KCNE1. A) Structure of N-arachidonoyl taurine (N-AT). B) Current-voltage 
relationship of N-AT on Kv7.1/KCNE1 channels (mean ± SEM; n = 5). C) Dose 
response of the shift in voltage dependent activation (ΔV0.5) of Kv7.1/KCNE1 channels 
in the presence of N-AT. D) Dose response of the change in maximal conductance 
(Gmax) of Kv7.1/KCNE1 channels in the presence of N-AT. E) Current-voltage 
relationship of N-AT on Cav1.2 channels (mean ± SEM; n = 4). F) Dose response of 
the shift in voltage dependent inactivation (ΔV0.5) of Cav1.2 channels in the presence 
of N-AT. G) Dose response of the change in maximal conductance (Gmax) of Cav1.2 
channels in the presence of N-AT. H) Current-voltage relationship of N-AT on Nav1.5 
channels (mean ± SEM; n = 3). I) Dose response of the shift in voltage dependent 
inactivation (ΔV0.5) of Nav1.5 channels in the presence of N-AT. J) Dose response of 
the change in maximal conductance (Gmax) of Nav1.5 channels in the presence of N-
AT. 
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Pinoleoyl taurine (Pin-taurine) promotes the activation of Kv7.1/KCNE1 in a 
dose-dependent manner (Fig. 6A-B). Pin-taurine, like Lin-taurine, promotes a 
leftward shift in the voltage dependence of activation (-23.8 ± 2.7 mV; p = 0.003) 
and increases the Gmax of Kv7.1/KCNE1 at 7 μM with a trend towards 
significance (2.2 ± 0.4; p = 0.06) (Fig. 6C-D).  Pin-taurine also inhibits Cav1.2 
current, but does not significantly shift the voltage-dependence of inactivation 
(4.1 ± 2.2 mV; p = 0.13) and does not significantly decrease the Gmax at 7 μM 
(0.8 ± 0.1; p = 0.2) (Fig. 6E-G). Pin-taurine inhibits Nav1.5 currents and does so 
by significantly left-shifting the voltage dependence of inactivation (-16 ± 2.7 mV; 
p = 0.01) and decreasing the Gmax at 7 μM (0.4 ± 0.09; p = 0.005) (Fig. 6H-J).  
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Figure 4.7. Pinoleoyl taurine has broad selectivity for Kv7.1/KCNE1, Cav1.2, and 
Nav1.5. A) Structure of Pinoleoyl taurine (Pin-taurine). B) Current-voltage relationship 
of pin-taurine on Kv7.1/KCNE1 channels (mean ± SEM; n = 4). C) Dose response of 
the shift in voltage dependent activation (ΔV0.5) of Kv7.1/KCNE1 channels in the 
presence of pin-taurine. D) Dose response of the change in maximal conductance 
(Gmax) of Kv7.1/KCNE1 channels in the presence of pin-taurine. E) Current-voltage 
relationship of pin-taurine on Cav1.2 channels (mean ± SEM; n = 5). F) Dose response 
of the shift in voltage dependent inactivation (ΔV0.5) of Cav1.2 channels in the presence 
of pin-taurine. G) Dose response of the change in maximal conductance (Gmax) of 
Cav1.2 channels in the presence of pin-taurine. H) Current-voltage relationship of pin-
taurine on Nav1.5 channels (mean ± SEM; n = 4). I) Dose response of the shift in voltage 
dependent inactivation (ΔV0.5) of Nav1.5 channels in the presence of pin-taurine. J) 
Dose response of the change in maximal conductance (Gmax) of Nav1.5 channels in the 
presence of pin-taurine. 
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DHA-taurine promotes the activation of Kv7.1/KCNE1 channels in a dose-
dependent manner, left-shifting the voltage-dependence of activation (-45.3 ± 2.9 
mV; p = 0.004) and significantly increasing the Gmax at 7 μM (1.7 ± 0.1; p = 0.03) 
(Fig. 7A-C). DHA-taurine application results in dose-dependent inhibition of 
Cav1.2 current (Fig. 7E), but does not significantly left-shift the voltage-
dependence of inactivation at 7 μM (0.2 ± 0.8 mV; p = 0.85) (Fig. 7F). Instead, 
DHA-taurine causes a significant decrease in the Gmax of Cav1.2 at 7 μM (0.4 ± 
0.01; p < 0.001) (Fig. 7G). Lastly, DHA-taurine inhibits Nav1.5 by inducing a 
significant left-shift in the voltage-dependence of inactivation (-28.5 ± 0.6 mV; p < 
0.001) and decreasing the Gmax at 7 μM (0.05 ± 0.01; p < 0.001) (Fig. 7H-I). 
These results suggest that PUFA analogues with taurine head groups exhibit 
broad selectivity for multiple ion channels.  
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  Figure 4.8. Docosahexanoyl-taurine has broad selectivity for Kv7.1/KCNE1, 
Cav1.2, and Nav1.5. A) Structure of docosahexanoyl taurine (DHA-taurine). B) 
Current-voltage relationship of DHA-taurine on Kv7.1/KCNE1 channels (mean ± SEM; 
n = 3). C) Dose response of the shift in voltage dependent activation (ΔV0.5) of 
Kv7.1/KCNE1 channels in the presence of DHA-taurine. D) Dose response of the 
change in maximal conductance (Gmax) of Kv7.1/KCNE1 channels in the presence of 
DHA-taurine. E) Current-voltage relationship of DHA-taurine on Cav1.2 channels 
(mean ± SEM; n = 3). F) Dose response of the shift in voltage dependent inactivation 
(ΔV0.5) of Cav1.2 channels in the presence of DHA-taurine. G) Dose response of the 
change in maximal conductance (Gmax) of Cav1.2 channels in the presence of DHA-
taurine. H) Current-voltage relationship of DHA-taurine on Nav1.5 channels (mean ± 
SEM; n = 3). I) Dose response of the shift in voltage dependent inactivation (ΔV0.5) of 
Nav1.5 channels in the presence of DHA-taurine. J) Dose response of the change in 
maximal conductance (Gmax) of Nav1.5 channels in the presence of DHA-taurine. 
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4.3. PUFA analogues with glycine head groups tend to be more selective 
for Kv7.1/KCNE1 with lower affinity for Cav1.2 and Nav1.5. 
PUFA analogues with glycine head groups have also been shown to effectively 
activate the Kv7.1/KCNE1 channel (Liin et al. 2015). The glycine head group has 
a lower pKa than regular PUFAs with a carboxyl head group (Liin et al. 2015), 
thereby allowing the head group to be more deprotonated and partially negatively 
charged at physiological pH. For this reason, PUFA analogues with glycine head 
groups are able to electrostatically activate Kv7.1/KCNE1 channels (Liin et al. 
2015).  We here tested several glycine compounds on Kv7.1/KCNE1, Cav1.2, 
and Nav1.5 channels to determine whether they have selective or non-selective 
effects on cardiac ion channels.  
 
We first examined Linoleoyl glycine (Lin-glycine). Lin-glycine promotes the 
activation of the cardiac Kv7.1/KCNE1 channel by left-shifting the voltage 
dependence of channel activation to more negative voltages at 7 μM (-23.8 ± 1.6 
mV; p < 0.001). Application of Lin-glycine also increases the Gmax of 
Kv7.1/KCNE1 at 7 μM (2.3 ± 0.2; p = 0.008) (Fig. 8A-D). Lin-glycine inhibits 
Cav1.2 in a dose-dependent manner (Fig. 8E), but does not left shift the voltage 
dependence of inactivation (0.6 ± 2.3 mV; p = 0.65). Instead, Lin-glycine 
produces a decrease of the Gmax at 7 μM, but this decrease is not statistically 
significant (0.3 ± 0.2; p = 0.07) (Fig. 8F-G). Lin-glycine causes a dose-dependent 
decrease of Nav1.5 current, left-shifts the voltage dependence of inactivation (-
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15.2 ± 2.8 mV; p = 0.01), and reduces the Gmax at 7 μM (0.5 ± 0.1; p = 0.007) 
(Fig. 8H-J).  
  Figure 4.9. Linoleoyl glycine has broad selectivity for Kv7.1/KCNE1, Cav1.2, and 
Nav1.5. A) Structure of Linoleoyl glycine (Lin-glycine). B) Current-voltage relationship 
of lin-glycine on Kv7.1/KCNE1 channels (mean ± SEM; n = 4). C) Dose response of 
the shift in voltage dependent activation (ΔV0.5) of Kv7.1/KCNE1 channels in the 
presence of lin-glycine. D) Dose response of the change in maximal conductance 
(Gmax) of Kv7.1/KCNE1 channels in the presence of Lin-glycine. E) Current-voltage 
relationship of lin-glycine on Cav1.2 channels (mean ± SEM; n = 4). F) Dose response 
of the shift in voltage dependent inactivation (ΔV0.5) of Cav1.2 channels in the presence 
of lin-glycine. G) Dose response of the change in maximal conductance (Gmax) of 
Cav1.2 channels in the presence of lin-glycine. H) Current-voltage relationship of Lin-
glycine on Nav1.5 channels (mean ± SEM; n = 4). I) Dose response of the shift in 
voltage dependent inactivation (ΔV0.5) of Nav1.5 channels in the presence of lin-
glycine. J) Dose response of the change in maximal conductance (Gmax) of Nav1.5 
channels in the presence of lin-glycine. 
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Pinoleoyl glycine (Pin-glycine) promotes the activation of Kv7.1/KCNE1 channels 
in a dose-dependent manner (Fig. 9A-B). Pin-glycine induces a left-shift in the 
voltage-dependence of activation (-8.7 ± 1.8 mV; p = 0.04) and increases the 
Gmax at 7 μM (1.7 ± 0.1; p = 0.03) (Fig. 9C-D). Pin-glycine, however causes little 
inhibition of Cav1.2 current (Fig. 9E). Pin-glycine produces no shift in the voltage 
dependence of inactivation (-3.1 ± 4.2 mV; p = 0.54) and does not significantly 
reduce the Gmax of Cav1.2 channels at 7 μM (0.8 ± 0.1; p = 0.34) (Fig. 9F-G). 
Pin-glycine inhibits Nav1.5 channels in a dose-dependent manner, but does not 
produce a significant left-shift in the voltage dependence of inactivation at 7 μM (-
4.7 ± 1.9 mV; p = 0.09). However, there is a statistically significant reduction in 
the Gmax at 7 μM (0.7 ± 0.08; p = 0.03) (Fig. 9I-J). 
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  Figure 4.10. Pinoleoyl glycine is more selective for Kv7.1/KCNE1 and Nav1.5 
channels than for Cav1.2. A) Structure of Pinoleoyl glycine (Pin-glycine). B) Current-
voltage relationship of pin-glycine on Kv7.1/KCNE1 channels (mean ± SEM; n = 3). C) 
Dose response of the shift in voltage dependent activation (ΔV0.5) of Kv7.1/KCNE1 
channels in the presence of pin-glycine. D) Dose response of the change in maximal 
conductance (Gmax) of Kv7.1/KCNE1 channels in the presence of Pin-glycine. E) 
Current-voltage relationship of pin-glycine on Cav1.2 channels (mean ± SEM; n = 3). F) 
Dose response of the shift in voltage dependent inactivation (ΔV0.5) of Cav1.2 channels 
in the presence of pin-glycine. G) Dose response of the change in maximal conductance 
(Gmax) of Cav1.2 channels in the presence of Pin-glycine. H) Current-voltage 
relationship of pin-glycine on Nav1.5 channels (mean ± SEM; n = 4). I) Dose response 
of the shift in voltage dependent inactivation (ΔV0.5) of Nav1.5 channels in the presence 
of pin-glycine. J) Dose response of the change in maximal conductance (Gmax) of 
Nav1.5 channels in the presence of pin-glycine. 
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DHA-glycine promotes the dose-dependent activation of Kv7.1/KCNE1 channels 
(Fig. 10A-B), left-shifting the voltage-dependence of activation (-10.5 ± 1.0 mV; p 
0.002), and increasing the Gmax at 7 μM (1.9 ± 0.2; p = 0.03) (Fig. 10C-D). 
However, DHA-glycine does not result in a dose-dependent decrease in Ca2+ 
currents (Fig. 10E). DHA-glycine does not left-shift the voltage dependence of 
inactivation (7.6 ± 3.1 mV; p = 0.13) and does not significantly decrease the Gmax 
of Cav1.2 at 7 μM (1.0 ± 0.1; p = 0.98) (Fig. 10G). In addition, DHA-glycine 
produces some inhibition of Nav1.5, but only when applied at 20 µM (Fig. 10H). 
While DHA-glycine produces a small, but significant left-shift in voltage 
dependent inactivation at 7 μM (-4.8 ± 1.9 mV; p = 0.01), it does not significantly 
reduce the Gmax at 7 μM (0.7 ± 0.08; p = 0.84) (Fig. 10H-J). 
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  Figure 4.11. Docosahexanoyl glycine is more selective for Kv7.1/KCNE1 
channels. A) Structure of docosahexanoyl glycine (DHA-glycine). B) Current-voltage 
relationship of DHA-glycine on Kv7.1/KCNE1 channels (mean ± SEM; n = 4). C) Dose 
response of the shift in voltage dependent activation (ΔV0.5) of Kv7.1/KCNE1 channels 
in the presence of DHA-glycine. D) Dose response of the change in maximal 
conductance (Gmax) of Kv7.1/KCNE1 channels in the presence of DHA-glycine. E) 
Current-voltage relationship of DHA-glycine on Cav1.2 channels (mean ± SEM; n = 3). 
F) Dose response of the shift in voltage dependent inactivation (ΔV0.5) of Cav1.2 
channels in the presence of DHA-glycine. G) Dose response of the change in maximal 
conductance (Gmax) of Cav1.2 channels in the presence of DHA-glycine. H) Current-
voltage relationship of DHA-glycine on Nav1.5 channels (mean ± SEM; n = 7). I) Dose 
response of the shift in voltage dependent inactivation (ΔV0.5) of Nav1.5 channels in the 
presence of DHA-glycine. J) Dose response of the change in maximal conductance 
(Gmax) of Nav1.5 channels in the presence of DHA-glycine. 
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These results suggest that PUFA analogues with glycine head groups tend to be 
more selective for the cardiac Kv7.1/KCNE1 channel and tend to have lower 
apparent affinity for Cav1.2 and Nav1.5 channels. Pin-glycine and DHA-glycine 
both have more selective effects on the Kv7.1/KCNE1 channel and lower 
apparent affinity for Cav1.2 and Nav1.5 channels compared to PUFA analogues 
with taurine head groups. Lin-glycine, however, is less selective for 
Kv7.1/KCNE1 channels compared to Pin-glycine and DHA-glycine. Lin-glycine 
modulates Kv7.1/KCNE1 and Cav1.2 at similar concentrations, while the 
modulatory effects of Lin-glycine on Nav1.5 take place at higher concentrations. 
This suggests that the combination of a glycine head group and linoleic acid tail 
boosts the apparent affinity for Cav1.2 and Nav1.5 channels.  
 
4.4. PUFA analogues with glycine head groups activate IKs with higher 
apparent affinity compared to ICa and INa. 
We have observed that PUFA analogues have several different effects on the 
same channel (e.g. they alter voltage dependence and conductance at the same 
time). To evaluate the totally effects of PUFA analogues on channel currents at 0 
mV (I/I0), we compared the dose response curves for IKs (Kv7.1/KCNE1), ICaL 
(Cav1.2), and INaV (Nav1.5) (Table 1). At 0 mV, 7 μM N-AT does not increase IKs 
currents, but instead inhibits ICaL currents and almost completely inhibits INaV 
currents (Fig. 11A; Table 1). By comparing the dose response curves and Km (a 
measure of apparent binding affinity) for each channel current, we find that N-AT 
has similar apparent affinity for IKs, ICaL, and INaV. At 7 μM, Lin-taurine increases 
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IKs (though not significantly) while significantly inhibiting ICaL and INaV, and exhibits 
higher apparent affinity for ICaL and INaV than for IKs (Fig. 11B; Table 1). Similar to 
Lin-taurine, Pin-taurine and DHA-taurine increase IKs but it also inhibit ICaL and 
INaV with higher apparent affinity for ICaL and INaV than for IKs (Fig. 11C-D; Table 
1). At 7 μM, Lin-glycine increases IKs, but also inhibits ICaL and INaV with higher 
apparent affinity for ICaL than for IKs and INaV (Fig. 11E; Table 1). At 7 μM, Pin-
glycine increases IKs, but does not significantly inhibit ICaL or INaV. When we 
compare the Km from the dose response curves of each channel current, we find 
that Pin-glycine has higher apparent affinity for IKs compared to INaV (Fig. 11F; 
Table 1). Lastly, at 7 μM, DHA-glycine increases IKs with little effect on ICaL and 
INaV, exhibiting higher apparent affinity for IKs and ICaL than for INaV (Fig. 11G; 
Table 1). Overall, when we compare the effects of different PUFA analogues on 
IKs, INaV, and ICaL, PUFA analogues with taurine head groups tend to have higher 
apparent affinity for INaV and ICaL, whereas PUFA analogues with glycine head 
groups tend to have higher apparent affinity for IKs. 
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  Figure 4.12. Dose response curves for PUFAs on IKs, ICaL, and INaV at 0 mV. Dose 
response of A) N-AT, B) lin-taurine, C) pin-taurine, D) DHA-taurine, E) lin-glycine, F) pin-
glycine, and G) DHA-glycine on IKs, ICaL, and INaV currents (I/I0) at 0 mV.  
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Table 4.1: Summary of PUFA effects on current and apparent affinity 
PUFA IKs I/I0 (at 
7 μM) 
(mean ± 
SEM) 
Km IKs 
(μM) 
(mean ± 
SEM) 
ICa I/I0 (at 
7 μM) 
(mean ± 
SEM) 
Km ICa 
(μM) 
(mean ± 
SEM) 
INa I/I0 (at 7 
μM) (mean 
± SEM) 
Km INa 
(μM) 
(mean ± 
SEM) 
N-AT 1.12 ± 0.1 
(p = 0.27) 
9.8 ± 3.3 0.5 ± 0.1 
(p = 0.04) 
3.4 ± 2.5 0.2 ± 0.01 
(p = 0.001) 
3.1 ± 
0.3 
Lin-
taurine 
7.7 ± 2.9 
(p = 0.14) 
11.4 ± 
0.4  
0.3 ± 0.1 
(p = 0.02) 
0.1 ± 
0.01 
0.1 ± 0.02 
(p = 0.0001) 
2.4 ± 
0.04 
Pin-
taurine 
6.8 ± 1.0 
(p = 0.01) 
4.5 ± 0.2 0.7 ± 0.1 
(p = 0.02) 
NA 0.5 ± 0.1 
(p = 0.01) 
5.8 ± 
1.7 
DHA-
taurine 
5.1 ± 0.7 
(p = 0.03) 
5.9 ± 0.3 0.3 ± 0.05 
(p = 0.02) 
0.9 ± 0.6 0.07 ± 0.01 
(p = 0.0001) 
2.3 ± 
0.1 
Lin-
glycine 
5.1 ± 0.4 
(p = 
0.002) 
5.4 ± 0.2 0.4 ± 0.2 
(p = 0.07) 
2.2 ± 0.5 0.5 ± 0.1 
(p = 0.02) 
5.6 ± 
0.5 
Pin-
glycine 
2.5 ± 0.2 
(p = 0.02) 
3.8 ± 0.4 0.8 ± 0.1 
(p = 0.26) 
NA 0.7 ± 0.1 
(p = 0.09) 
7.1 ± 
1.2 
DHA-
glycine 
3.7 ± 1.0 
(p = 0.07) 
9.4 ± 0.5 0.9 ± 0.1 
(p = 0.19) 
0.9 ± 
0.03 
1.1 ± 0.05 
(p = 0.24) 
16.7 ± 
0.1 
I/I0 represents the relative current of the specified channel. The Km indicates the 
concentration at which half the maximal effect on I/I0 occurs and is used as a 
measure of the apparent affinity of the PUFA analogue. Data is represented at the 
mean ± SEM. Comparisons were made using One-way ANOVA and Student’s t t-
test. Significance level is set to p = 0.05.  
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4.5. Selective Kv7.1/KCNE1 channel activators have antiarrhythmic effects 
in the simulated cardiomyocyte. 
We next tried to understand what kind of compound is the most effective at 
shortening the action potential duration. To determine whether selective PUFA 
analogues or non-selective PUFA analogues can shorten the action potential 
duration, we simulated the effects of applying the PUFA analogues on human 
cardiomyocyte using the O’Hara-Rudy dynamic (ORd) model (O'Hara et al. 2011) 
while modifying parameters for the voltage dependence and conductance for 
individual channels to reflect our experimental PUFA-induced effects. We 
simulated the effects of PUFA analogues that are non-selective modulators for 
cardiac ion channels (i.e. N-AT, Lin-taurine, Pin-taurine, DHA-taurine, and Lin-
glycine) at concentrations of 0.7 μM, 2 μM, and 7 μM (Fig. 12A-E). In most 
cases, we saw little change in the ventricular action potential until we reached 7 
μM where we were unable to elicit an action potential (Fig. 12A-E). One 
exception was the effect of applying DHA-taurine, in which case we observed a 
small shortening of the action potential at 0.7 μM, but then an abnormal action 
potential upstroke and prolongation of the action potential at 2 μM (Fig 12D). This 
is likely due to the potent block of Nav1.5 channels, causing the action potential 
to be largely calcium dependent. But again, at 7 μM DHA-taurine, we were 
unable to elicit an action potential (Fig. 12D). However, the PUFA analogues that 
were more selective for Kv7.1/KCNE1, such as Pin-glycine and DHA-glycine (at 
7 μM) induce a slight shortening of the wild type ventricular action potential (Fig. 
12F-G). For Pin-glycine and DHA-glycine, we induced Long QT Type 2 by 
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simulating 25% block of the hERG channel, which generates the rapid 
component of the delated rectifier potassium current (IKr). 25% hERG block 
prolongs the ventricular action potential by 50 ms. Application of Pin-glycine or 
DHA-glycine at 7 µM in the simulation partially restores the duration of the 
ventricular action potential. In addition to simulating the effects of PUFA 
analogues on the ventricular action potential duration, we also simulated the 
ability of 7 µM DHA-glycine (the most selective Kv7.1/KCNE1 activator) to 
prevent arrhythmia by simulating early afterdepolarizations using 0.1 μM 
dofetilide. Dofetilide is a blocker of the hERG channel and increases the 
susceptibility for early afterdepolarizations (O'Hara et al. 2011) (Fig. 12H). When 
we simulate 0.1 μM dofetilide + 7 μM DHA-glycine, we are able to suppress early 
afterdepolarizations, suggesting that the application of 7 µM DHA-glycine would 
be anti-arrhythmic (Fig. 12H). 
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General Discussion 
We show here that PUFAs have different mechanisms of action on 
Kv7.1/KCNE1, Cav1.2, and Nav1.5 channels. We have previously shown that 
PUFAs promote the activation of Kv7.1/KCNE1 channels through the lipoelectric 
mechanism where the negatively charged PUFA head group electrostatically 
attracts both the S4 voltage sensor (facilitating its upward movement and 
channel opening) and K326 in S6 (increasing the maximal conductance) (Liin, 
Yazdi, et al. 2018; Borjesson and Elinder 2011; Borjesson, Hammarstrom, and 
Elinder 2008). In both Cav1.2 and Nav1.5 channels, PUFAs inhibit channel 
currents. We have found that PUFAs cause a dose-dependent reduction in the 
currents through in Cav1.2 channels, surprisingly with no effect on the voltage 
dependence of either activation or inactivation. In Nav1.5 channels, PUFAs 
cause inhibition through a dose-dependent decrease in currents, with both a left-
shifting effect on the voltage dependence of inactivation and a decrease in 
conductance. We also demonstrate that PUFA analogues vary in their selectivity 
for voltage-gated ion channels. The selectivity depends on the specific 
concentration of PUFA applied, because several compounds have non-
Figure 4.13. PUFAs that are selective for Kv7.1/KCNE1 channels partially restore 
prolonged ventricular action potential and suppress early afterdepolarizations. 
A-G) Simulated ventricular action potential in wild type cardiomyocytes (black) and in 
the presence of A) 0.7 (red), 2 (green), and 7 μM N-AT (blue), B) 0.7 (red), 2 (green), 
and 7 μM lin-taurine (blue), C) 0.7 (red), 2 (green), and 7 μM pin-taurine (blue), D) 0.7 
(red), 2 (green), and 7 μM DHA-taurine (blue), E) 0.7 (red), 2 (green), and 7 μM lin-
glycine (blue), F) 7 μM pin-glycine (blue solid), following 25% hERG block (red) and in 
the presence of 7 μM pin-glycine under 25% hERG block (blue dashed), and G) 7 μM 
DHA-glycine (blue solid), following 25% hERG block (red) and in the presence of 7 μM 
DHA-glycine under 25% hERG block (blue dashed). H) Early afterdepolarizations 
induced by dofetilide application (red) and suppression of early afterdepolarizations by 
7 μM DHA-glycine in the presence of dofetilide (black). 
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overlapping dose response curves for their effects on the three different channels 
(Fig. 11). We also found that PUFAs with taurine head groups tend to have broad 
modulatory effects on Kv7.1/KCNE1, Nav1.5 and Cav1.2 channels, with higher 
apparent affinity for Cav1.2 and Nav1.5 channels. Conversely, PUFAs with 
glycine head groups tend to be more selective for Kv7.1/KCNE1 channels and 
display lower apparent affinity for Cav1.2 and Nav1.5 channels. By 
understanding the effects of PUFA analogues on individual channels, it opens up 
the possibility to target specific forms of LQTS in which specific channels are 
mutated.  
 
In this work, we have demonstrated that PUFA analogues modulate several 
different voltage-gated ion channels, including those underlying the ventricular 
action potential: Kv7.1/KCNE1, Nav1.5, and Cav1.2. The effects of PUFAs on 
Kv7.1/KCNE1, Cav1.2, and Nav1.5 individually are anticipated to have anti-
arrhythmic effects and would potentially be beneficial for patients with Long QT 
Syndrome. In the case of IKs (Kv7.1/KCNE1) currents, PUFAs would be anti-
arrhythmic by rescuing loss-of-function mutants of Kv7.1/KCNE1 (IKs) channels in 
Long QT Type 1 (KCNQ1 mutations) or 5 (KCNE1 mutations). In the case of Nav 
and Cav currents, PUFAs would be anti-arrhythmic by inhibiting gain-of-function 
mutants of Nav1.5 and Cav1.2 channels in Long QT Type 3 or 7, respectively. 
We used the O’Hara-Rudy Dynamic model to simulate the ventricular action 
potential in the presence of different PUFAs. In our simulations, PUFAs that are 
non-selective (i.e. that activate Kv7.1/KCNE1 while inhibiting Cav1.2 and Nav1.5) 
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prevent the generation of an action potential. However, when we simulate the 
effects of Pin-glycine and DHA-glycine, which are both more selective for 
Kv7.1/KCNE1, we see a shortening in the action potential duration and the 
suppression of early afterdepolarizations. This suggests that selectively boosting 
IKs (Kv7.1/KCNE1) current would be important for shortening and terminating the 
ventricular action potential. However, evaluating PUFA-induced effects on 
Kv7.1/KCNE1, Cav1.2, and Nav1.5 channels bearing LQTS-causing mutations 
would be the next step in understanding the therapeutic potential for PUFA 
analogues as treatments for different forms of LQTS. 
 
In our experiments using PUFA analogues on Nav1.5, we observed both a shift 
in the voltage dependence of inactivation and a dose-dependent decrease in Na+ 
currents. Extensive work has been done to characterize how each of the different 
voltage-sensing domains in Nav channels contribute to voltage-dependent 
activation and inactivation, many implicating DIV S4 in fast inactivation (Ahern et 
al. 2015; Capes et al. 2013). Recent work by Hsu and colleagues (2017) has also 
shown using voltage clamp fluorometry, the importance of both DIII and DIV in 
Nav channel inactivation (Hsu et al. 2017). Our data suggest that PUFAs may 
interact with S4 segments involved in voltage-dependent inactivation, allowing 
PUFA analogues to left-shift the voltage dependence of inactivation. However, 
this does not completely explain the additional dose-dependent decrease in Na+ 
currents we observe on top of the leftward shifted voltage dependence of 
inactivation. Recent work by Nguyen and colleagues (2018) has uncovered a 
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mechanism of Nav channel inhibition through a new pathway, allowing a 
hydrophobic molecules to permeate a fenestration between domains III and IV 
(DIII and DIV) in the human cardiac Nav1.5 channel (Nguyen et al. 2019). It is 
possible that the hydrophobic PUFA analogue also block Nav1.5 channels 
through this fenestration between DIII and DIV, causing the voltage-independent 
decrease in sodium currents. 
 
The molecular mechanism of action of PUFA analogues on Cav1.2 is still 
unclear, though we have shown that it does not occur through a shift in the 
voltage dependence of inactivation. In each case of Cav1.2 inhibition by PUFA 
analogues, we observe a dose-dependent decrease in the Ca2+ currents that 
appears as a linear decrease in I/I0 and Gmax. There is evidence that some Cav 
channel antagonists, such as dihydropyridines (DHPs) inhibit Cav channels 
through an allosteric mechanism (Tang et al. 2016). Pepe and colleagues (1994) 
found that DHA alters the effectiveness of dihydropyridines, suggesting a shared 
binding site, or nearby binding sites, for DHPs and PUFAs (Pepe et al. 1994). 
Tang and colleagues (2016) found that dihydropyridines bind in a hydrophobic 
pocket near the pore of the bacterial CavAb channel and cause an allosteric 
conformational change that leads to disruption of the selectivity filter and thus 
inhibition of Ca2+ currents (Tang et al. 2016). In addition, they observed that in 
the absence of DHPs a phospholipid occupies the DHP binding site (Tang et al. 
2016). This would suggest that it is possible that PUFA analogues inhibit Cav1.2 
by binding to, or near, the DHP binding site and causing an allosteric 
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conformational change that leads to a collapse of the pore and thus explaining 
the inhibition of Cav1.2 currents without any changes in the voltage dependence 
of inactivation. 
 
Work from several groups has demonstrated a shared electrostatic mechanism of 
action on voltage-gated K+ channels (Liin, Lund, et al. 2018) and voltage-gated 
Na+ channels (Ahuja et al. 2015) by biaryl sulfonamides. Liin and colleagues 
(2018) showed that biaryl sulfonamides promote the activation of the Shaker K+ 
channel through an electrostatic effect on the voltage sensing domain. In addition, 
Ahuja and colleagues (2015) showed that aryl sulfonamides inhibit Nav channels 
through an electrostatic “voltage sensor trapping” mechanism that is specific for 
the Nav1.7 isoform. The work by Ahuja et al. supports the ability to 
pharmacologically target different ion channels with a high degree of selectivity 
(Ahuja et al. 2015). This is in agreement with our findings using PUFA analogues 
that show that PUFA analogues are variable in their channel selectivity, allowing 
us to target particular ion channels involved in the ventricular action potential. 
 
Our experiments were conducted using the Xenopus laevis oocyte expression 
system, where voltage-clamp recordings were performed at room temperature. It 
is possible that there may be temperature differences in the ways PUFA 
analogues modify different ion channels that we are unable to capture by 
conducting experiments at 20ºC. There is also the possibility that the membrane 
composition may differ between Xenopus oocytes and mammalian cells or 
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cardiomyocytes. However, using Xenopus oocytes, we are able to measure 
distinct differences between mechanisms of PUFA modulation in Kv7.1/KCNE1, 
Cav1.2, and Nav1.5 in isolation. To further confirm our findings, experiments 
should be conducted in mammalian cells or cardiomyocytes to determine the 
effects of different PUFA analogues on individual ion channels and the duration 
of the ventricular action potential at physiological temperatures. 
 
The work presented here demonstrates that PUFA analogues exert diverse 
modulatory effects on different types of voltage-gated ion channels through non-
identical mechanisms. Because PUFA analogues modulate Kv7.1/KCNE1 
channels through electrostatic effects, we hypothesized they would have similar 
effects on Cav1.2 and Nav1.5 channels. However, our data suggests that PUFA 
analogues can exert various modulatory effects on the activity of different ion 
channels, and that the mechanism depends on the ion channel that is being 
modulated. In addition, we have shown that PUFA analogues exhibit a range of 
selectivity for different ion channels, which depends both on the PUFA head group 
and the combination of PUFA head and tail groups. Using simulations of the 
ventricular action potential, we have shown that selective Kv7.1/KCNE1 channel 
activators are the most effective at shortening a prolonged ventricular action 
potential and suppressing early afterdepolarizations induced by hERG block. This 
suggests that boosting Kv7.1/KCNE1 currents by using selective Kv7.1/KCNE1 
channel activators can aid in restoring a normal action potential duration and 
possess antiarrhythmic potential.
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CHAPTER 5. Discussion 
The work presented here expands the current knowledge of interactions between 
polyunsaturated fatty acids and voltage-gated ion channels. PUFAs have been 
shown in the past to modulate the activity of voltage-gated ion channels including 
Nav, Cav, and Kv channels (Borjesson, Hammarstrom, and Elinder 2008; Elinder 
and Liin 2017; Kang and Leaf 1996; Xiao 1997; Liin et al. 2015; Liin et al. 2016). 
However, there has not been a systematic evaluation of the functional regions of 
the PUFA molecule (i.e. the head and tail groups of the PUFA) or the effects of 
the same PUFA on many voltage-gated ion channels expressed in a specific cell 
type. Here, I have presented systematic analysis of the role of PUFA tail group, 
head group, and the channel selectivity of different PUFAs.  
 
Through this work, I have demonstrated that the PUFA tail group is important for 
the apparent binding affinity of the PUFA for the cardiac IKs channel. I evaluated 
the length of the PUFA tail, the number of double bonds in the tail, and the 
position of the double bonds in the tail. Neither the length of the PUFA tail, nor 
the number of double bonds in the tail, significantly correlated with the effects on 
or the apparent binding affinity for the cardiac IKs channel. However, the position 
of the double bonds in the tail relative to the PUFA head group does significantly 
correlate with the apparent binding affinity for the cardiac IKs channel. 
Specifically, PUFAs that have double bonds closer to the PUFA head group 
promote the activation of the IKs channel with higher apparent binding affinity. In 
addition, the position of the double bonds closer to the PUFA head group can be 
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used to predict effective and high affinity PUFAs that promote the activation of 
the cardiac IKs channel. 
 
I have also demonstrated the importance of the pKa of the hydrophilic PUFA 
head group in the activation of the cardiac IKs channel, specifically that the pKa of 
the head group is related to the magnitude of activation of the cardiac IKs 
channel. In past studies, our group has observed that PUFAs with a carboxyl 
head group, under physiological conditions (pH 7.5), are protonated and 
uncharged when they are bound to the cardiac IKs channel. This prevents them 
from participating in an electrostatically activating the IKs channel through 
interactions with positively charged residues. However, when we apply PUFA 
analogues with lower pKa head groups, we are again able to promote the 
activation of the cardiac IKs channel. This is because the lower pKa value of the 
PUFA head group allows the PUFA to remain either partially or fully negatively 
charged and participate in electrostatic interactions with the IKs channel and 
promote channel activation. 
 
Lastly, I have demonstrated that PUFAs can have selective effects on voltage-
gated ion channels expressed in the heart. I looked at the effects of different 
PUFAs on the cardiac Nav1.5, Cav1.2, and IKs channels. Unlike the activating 
effects of PUFAs on the IKs channel, PUFAs inhibit Nav1.5 and Cav1.2 channels. 
The results presented here demonstrate that PUFAs with a glycine head group 
tend to have more selective effects on the IKs channel. However, PUFAs that 
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have a taurine head group tend to have broad effects on Nav1.5, Cav1.2, and IKs 
channels. When the cumulative effects of the different PUFAs were simulated 
using the O’Hara-Rudy Dynamic, we observed that PUFAs that are more 
selective for the IKs channel can partially restore a prolonged ventricular action 
potential and can also prevent early afterdepolarizations that can lead to cardiac 
arrhythmia. On the other hand, PUFAs that have more broad effects on Nav1.5, 
Cav1.2, and IKs channels prevent the generation of the ventricular action potential 
in our simulations. This suggests that PUFAs have are more selective for the 
cardiac IKs channel may be more effective at preventing cardiac arrhythmia. 
 
The causes of Long QT Syndrome involve mutations in various ion channels that 
are expressed in the heart. Patients with LQTS are generally treated using beta 
blockers to reduce adrenergic tone of the heart and prevent arrhythmia or 
through the surgical implantation of a cardioverter defibrillator. This means that 
the underlying ion channel dysfunction that leads to LQTS is not being addressed 
directly using traditional treatment methods. Polyunsaturated fatty acid 
analogues provide a means to directly modulate cardiac ion channels and 
potentially treat cardiac arrhythmia. We have observed in our own studies (and 
previous work) that PUFA analogues can restore loss-of-function of the cardiac 
IKs channel bearing LQTS-causing mutations (Liin et al. 2016). In addition, I have 
demonstrated in this work that PUFA analogues applied in solutions intended to 
mimic the normal physiological circulation of fatty acids in the body (ie. In 
combination with serum albumin and monounsaturated and saturated fatty acids) 
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are able to promote the activation of the cardiac IKs channel by left-shifting the 
voltage-dependence of activation. These data further suggest that PUFA 
analogues have therapeutic potential for the treatment of cardiac arrhythmia in 
patients with LQTS. 
 
The work presented here has provided a broad, systematic assessment of PUFA 
analogues and their effects on voltage-gated ion channels. By evaluating the 
functional role of the different structural regions of the PUFA, we have gained a 
foundation upon which new PUFA analogues could be synthesized. I have found 
that the position of the double bonds in the hydrophobic tail of the PUFA is 
important for the apparent binding affinity of PUFAs to the cardiac IKs channel. 
With this information, it would be possible to make modifications to the PUFA tail 
in order to boost the apparent affinity for the IKs channel. In addition, I found that 
the magnitude of PUFA-induced activation of the IKs channel depends on a low 
pKa head group, allowing us to tune the potency of different PUFA analogues. 
Finally, I found that the selectivity of different PUFAs for cardiac ion channels 
(Nav1.5, Cav1.2, and Kv7.1/KCNE1 (IKs)) also depends on the PUFA head 
group. In this case, PUFA analogues with a glycine head group are more 
selective for the IKs channels, whereas PUFA analogues with a taurine head 
group are more selective for Nav1.5 and Cav1.2 channels. With this information, 
it would be interesting to evaluate the role of the PUFA tail in apparent binding 
affinity of PUFAs to other voltage-gated ion channels, further promoting selective 
modulation of specific ion channels by altering the PUFA structure. So far, we 
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have looked only at the role of the hydrophobic tail in PUFAs that have a 
carboxyl head group, which we know is not negatively charged or effective at 
activating the IKs channel at physiological pH (7.5). An important next step would 
be to determine whether the double bonds in the PUFA tail have the same role in 
apparent binding affinity in PUFA analogues with glycine or taurine head groups 
(that are effective at activating the IKs channel at physiological pH). In addition, 
since the apparent affinity strongly influences the selectivity of different PUFA 
analogues for the voltage-gated ion channels expressed in the heart, it is 
important to know how the apparently affinity for Cav1.2 and Nav1.5 channels is 
influenced by the PUFA structure. In order to understand how the PUFA tail 
influences the apparent affinity of PUFA analogues for Cav1.2 and Nav1.5 
channels, it is necessary to conduct a similar systematic analysis of the 
properties of the PUFA tail and how they correlate to the effects on and affinity 
for Cav1.2 and Nav1.5 channels. With this information, it would be possible to 
make modifications to newly synthesized PUFA analogues in order to tailor them 
to become more selective for specific cardiac voltage-gated ion channels. 
 
One necessary step in the development of PUFA analogues as therapeutic 
compounds for LQTS is to screen new PUFA analogues against multiple ion 
channels. In this work, I have described that PUFA analogues that are more 
selective for the cardiac IKs channel are able to partially restore a prolonged 
ventricular action potential and prevent the initiation of early afterdepolarizations 
in simulated cardiomyocytes. However, PUFA analogues that activate the IKs 
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channel, but inhibit Nav1.5 and Cav1.2, prevent the initiation of the simulated 
ventricular action potential, likely due to extensive Nav1.5 channel block. This 
means that PUFA analogues should either be channel-selective or that the 
concentrations applied should maximize activation of the IKs channel while 
minimizing Nav1.5 block so that there are no disruptions of action potential 
initiation or conduction velocity. Another critical repolarizing current in the 
ventricular action potential is mediated by the IKr channel. However, PUFAs do 
not alter IKr and IK1 currents (unpublished data). In this preparation, the Kv11.1 
channel was expressed alone, without the auxiliary subunit KCNE2 which 
associates with Kv11.1. A critical step in understanding how PUFA analogues 
alter action potential repolarization is to test newly developed PUFA analogues 
on Kv11.1/KCNE2 channels in order to fully characterize the selectivity of PUFA 
analogues. 
 
In this work, I have shown that PUFA analogues can exert their modulatory 
effects on voltage-gated ion channels through a variety of mechanisms. Despite 
the similar architecture of Kv, Nav, and Cav channels, PUFA analogues 
modulate each of these channels through unique mechanisms rather than 
through a common, shared electrostatic mechanism. We have seen that PUFA 
analogues inhibit Nav1.5 by left-shifting the voltage dependence of inactivation, 
on top of a reduction in Na+ currents. Preliminary data from our group has shown 
that mutations of the gating charges in the S4 segment of domain IV (DIV) in 
Nav1.5 removes part of the voltage-shifting effect of PUFA analogues. However, 
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the mutation of these residues does not completely abolish the left-ward shift in 
the voltage dependence of inactivation induced by PUFA analogues. There is 
evidence that the DIII S4 is also involved in voltage dependent inactivation of 
Nav1.5 (Ahern et al. 2015; Capes et al. 2013; Muroi et al. 2010). Future studies 
should include the mutagenesis of gating charge residues in DIII-DIV S4 
segments in order to identify potential PUFA binding sites. Recent work has also 
shown that there is a lipophilic cleft in Nav channels that hydrophobic compounds 
can penetrate and exert modulatory effects. It is possible that hydrophobic PUFA 
analogues are able to bind in this lipophilic cleft and thus alter channel 
conductance, explaining the additional decrease in current observed in Nav1.5 
block by PUFAs (Gamal El-Din et al. 2018). In Cav1.2 channels, we did not 
observe any voltage-shifting effects of the PUFA analogues tested, rather we 
observe a dose-dependent decrease in current. There is evidence using 
dihydropyridines (DHPs), that there is an allosteric mechanism if Cav channel 
block in which one DHP molecule binds and the subsequent conformational 
change disrupts the symmetry of the selectivity filter, leading to Cav channel 
block (Tang et al. 2016). There is also evidence that DHPs and PUFAs share a 
common binding side in the cardiac Cav channel (Pepe et al. 1994). It is possible 
that PUFAs modulate Cav1.2 by a similar allosteric mechanism as DHPs. In 
order to determine whether our PUFA analogues inhibit Cav1.2 by a similar 
mechanism as DHPs, it would be necessary to conduct experiments applying 
both DHPs and PUFA analogues to determine if these compounds compete for 
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the same binding site of the Cav1.2 channel, providing further insight into the 
mechanism of PUFA-induced block of Cav1.2 channels. 
 
It is important to address that there are critical differences that could occur 
between the application of PUFA analogues to ion channels expressed in 
Xenopus laevis oocytes and the channels found in the human cardiomyocyte. 
For example, there may be differences in the phospholipid constituents of the 
membrane that could alter the incorporation of and/or the effects of exogenously 
applied PUFA analogues. In addition, many ion channels undergo 
posttranslational modification, including glycosylation. Glycosylation can have 
many effects on voltage-gated ion channels, including alterations to channel 
gating behavior, channel trafficking, and potential disruptions of interactions with 
small molecules/ligands and with other proteins. For example. Glycosylation is 
important for the trafficking of the b2 subunit associated with Nav1.5 channels to 
the cell membrane, which thus effects membrane expression of Nav1.5 (Cortada, 
Brugada, and Verges 2019). In addition, glycosylation has been shown to alter 
the gating kinetics of the Shaker Kv channel (Lopez-Rodriquez and Holmgren 
2018).  There is evidence that even exogenously expressed proteins can 
undergo posttranslational modifications, even when expressed in Xenopus laevis 
oocytes (Colman, Bhamra, and Valle 1984). However, in order for PUFA 
analogues to move forward as potential therapeutics for the treatment of LQTS, it 
is critical for them to be tested using mammalian systems to fully understand the 
potential of PUFA analogues when applied to the human body. To study the 
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effects of new PUFA analogues on different ion channels in a lipid environment 
specific to mammalian systems, ion channels can be expressed in a mammalian 
heterologous expression system such as HEK293 cells. Doing so will provide 
both information regarding the mechanism of action for different PUFA analogues 
on voltage-gated ion channels in a context that more accurately reflects the 
membrane composition and can also recapitulate physiological temperatures 
(37°C).  
 
Given that PUFAs have an ionizable, hydrophilic head group and a long 
hydrophobic, hydrocarbon tail they have the ability to behave as detergents. It is, 
therefore, possible that PUFAs could form micelles which could lead to changes 
in the properties of the lipid bilayer. It is also possible for exogenously applied 
PUFAs to cause changes in membrane elasticity that modulate the activity of 
membrane proteins, including ion channels (Lee 2006). For example, the length 
of the fatty acid acyl chain that incorporates into the membrane can lead to 
changes in the thickness of the membrane, which could indirectly alter ion 
channel activity (Lee 2006). For example, the PUFA DHA is able to modulate the 
activity of gramicidin channels via changes in membrane fluidity (Bruno, Koeppe 
III, and Andersen 2007). One basis for the membrane fluidity hypothesis is that 
PUFAs alter the activity of different ion channels at similar concentrations 
suggesting a similar mechanism (Bruno, Koeppe III, and Andersen 2007). 
However, in this work, I found significant differences in apparent binding affinity 
for different voltage-gated ion channels expressed in the heart and can modulate 
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some channels selectively while having little to no effect on other cardiac ion 
channels. These data suggest that it is likely a direct effect on voltage-gated ion 
channel activity rather than an indirect effect through changes in membrane 
fluidity. 
 
PUFAs are fatty acids that must be obtained through the diet. Linoleic acid is the 
precursor molecule of arachidonic acids, whereas a-linolenic acid is the 
precursor molecule of DHA and EPA (Anderson and Ma 2009). Linoleic acid and 
a-linolenic acid are found in vegetable oils, and the dietary sources of 
arachidonic acid, DHA, or EPA are fats (in the case of arachidonic acid) and fish 
oil (in the cases of DHA and EPA) (Anderson and Ma 2009). PUFAs (namely 
arachidonic acid and EPA) can be metabolized to molecules known as 
eicosanoids, a family of compounds involved in inflammation that include 
leukotrienes, thromboxanes, and prostaglandins (Anderson and Ma 2009). It is 
unclear, however, whether PUFA analogues (such as those tested in this work) 
would be further broken down into active molecules similar to the eicosanoid 
byproducts of EPA and arachidonic acid. Many of the PUFA analogues tested in 
the latter chapters of this work differ from EPA and arachidonic acid in that they 
have different chemical moieties on the PUFA head group and also have 
different tail structures (i.e different lengths, number of double bonds, and 
position of double bonds). It is possible that PUFA analogues could be broken 
down in the body, however there would likely be dissimilarities between the 
metabolic byproducts of PUFAs compared to those of PUFA analogues. To 
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understand the ramifications of long-term application of PUFA analogues, and 
the potential for the production of active PUFA analogue metabolites, PUFA 
analogues could be applied chronically in hiPSC-derived cardiomyocytes.  
 
In addition, it is important understand the effects of PUFA analogues specifically 
on cardiomyocytes and the ventricular action potential. To do this, PUFA 
analogues can be applied first to human-induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CMs). The duration of the ventricular action potential can 
be measured either using optical dyes (voltage sensing or calcium sensing) or 
using whole-cell patch-clamp electrophysiology. In LQTS, the ventricular action 
potential is prolonged, correlating to a prolongation of the QT interval measured 
by the electrocardiogram. The goal of finding PUFA analogues as potential 
therapeutics for LQTS is to find PUFA analogues that shorten the duration of the 
ventricular action potential. To determine if PUFA analogues can shorten a 
prolonged ventricular action potential, one could either prolong the ventricular 
action potential pharmacologically (using blockers such as chromonol or E4031) 
and apply PUFA analogues. Using hiPSC-CMs it is also possible to use lines of 
cardiomyocytes derived from LQTS patient cells and measure the effects of 
PUFA application on a prolonged ventricular action potential caused by and 
LQTS-causing mutation.  
 
Eventually, PUFA analogues will need to be tested using animal models. 
Zebrafish offer a simple animal model where PUFA analogues can be tested on 
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the isolated zebrafish heart. The zebrafish heart can be dissected out and the 
action potential duration measured using optical dyes. Zebrafish also allow 
simple genetic manipulation which can be used to generate lines of zebrafish 
harboring LQTS-causing mutations (Leong et al. 2010). Additionally, in previous 
work, our group has applied PUFA analogues to whole guinea pig hearts 
following pharmacological prolongation of the ventricular action potential (Liin et 
al. 2015). Once strong candidates of PUFA analogues are determined, these 
compounds can be tested in isolated guinea pig hearts to probe further their 
therapeutic relevance in animal models. Eventually, there target compounds 
need to be tested in intact animals to determine their therapeutic potential in vivo. 
The ideal route of drug administration of PUFA analogues for the treatment of 
LQTS in humans, would be oral administration. Therefore, the effects of PUFA 
analogues in vivo could be tested using a supplemented food source given to 
animals harboring LQTS-causing mutations (such as zebrafish, guinea pigs, or 
rabbits).  
 
Overall, the work presented here demonstrates that PUFA analogues offer 
promising pharmacological candidates for the treatment of Long QT Syndrome 
and cardiac arrhythmia. 
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CHAPTER 6. Materials and Methods 
Molecular biology 
cRNA encoding Kv7.1, KCNE1, Nav1.5 and β1, and Cav1.2, β3, and α2δ were 
transcribed using the mMessage mMachine T7 kit (Ambion). 50 ng of cRNA was 
injected into defolliculated Xenopus laevis oocytes (Ecocyte, Austin, TX): For IKs 
channel expression, we injected a 3:1, weight:weight (Kv7.1:KCNE1) cRNA ratio. 
For Nav1.5 channel expression, we injected a 2:1, weight:weight (Nav1.5:β1) 
cRNA ratio.  for Cav1.2 channel expression, we injected a 2:1:1, weight:weight 
(Cav1.2:β3:α2δ) cRNA ratio. Site-directed mutagenesis was performed using the 
Quickchange II XL Mutagenesis Kit (QIAGEN Sciences, Maryland, USA) for 
mutations in the Kv7.1 a-subunit. Injected cells were incubated for 72-96 hours in 
standard ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 
mM HEPES; pH = 7.5) containing 1 mM pyruvate at 16ºC prior to 
electrophysiological recordings.  
 
Two-electrode voltage clamp (TEVC) 
Xenopus laevis oocytes were recorded in the two-electrode voltage clamp 
(TEVC) configuration. Recording pipettes were filled with 3 M KCl. The recording 
chamber was filled with ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM 
CaCl2, 5 mM HEPES; pH 7.5). For Cav1.2 channel recordings, Xenopus oocytes 
were injected with 50 nl of 100 mM EGTA and incubated at 10ºC for 30 minutes 
prior to electrophysiological recordings in order to sequester cytosolic calcium. In 
addition, Cav1.2 channel recordings were done in solutions lacking Ca2+, using 
Ba2+ as the charge carrier to prevent calcium-dependent inactivation of Cav1.2
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channels. PUFAs were obtained from Cayman Chemical (Ann Arbor, MI.) or 
synthesized in house through methods previously described (Linköping, Sweden) 
and kept at -20˚ C as 100 mM stock solutions in ethanol. Serial dilutions of the 
different PUFAs were prepared from stocks to make 0.2 μM, 0.7 μM, 2 μM, 7 μM, 
and 20 μM concentrations in ND96 solutions (pH = 7.5). PUFAs were perfused 
into the recording chamber using the Rainin Dynamax Peristaltic Pump (Model 
RP-1) (Rainin Instrument Co., Oakland, CA. USA).  
 
Electrophysiological recordings were obtained using Clampex 10.3 software 
(Axon, pClamp, Molecular Devices). To measure Kv7.1/KCNE1 currents we 
apply PUFAs as the membrane potential is stepped every 30 sec from -80 mV to 
0 mV for 5 seconds before stepping to -40 mV and back to -80 mV to ensure that 
the PUFA effects on the current at 0 mV reached steady state. A voltage-step 
protocol was used to measure the current vs. voltage (I-V) relationship before 
PUFA application and after the PUFA effects had reached steady state for each 
concentration of PUFA. Cells were held at -80 mV followed by a hyperpolarizing 
prepulse to -140 mV. The voltage was then stepped from -100 to 60 mV (in 20 
mV steps) followed by a subsequent voltage step to -20 mV to measure tail 
currents before returning to the -80 mV holding potential. For Cav1.2 channel 
recordings, PUFAs are applied as the membrane potential is stepped from -80 
mV to -30 mV and then 10 mV before returning to the holding potential of -80 
mV. This allows the PUFA effects to reach steady state before recording voltage 
dependent activation and inactivation. To measure voltage-dependent activation 
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of Cav1.2, cells are held again at -80 mV and then stepped from -70 mV to 40 
mV (in 10 mV steps). Voltage-dependent inactivation was measured by holding 
cells at -80 mV, applying a 500-ms conditioning prepulse at voltages between -80 
mV and 20 mV (in 10 mV steps) before stepping to a test pulse of 10 mV to 
measure the remaining current and returning to -80 mV holding potential. For 
Nav1.5 channel recordings, PUFAs are applied as the membrane potential is 
stepped from -80 mV to -90 mV for 480 ms before stepping to 30 mV for 50 ms 
and returned to a holding potential of -80 mV. This allows the PUFA effects to 
reach steady state before recording voltage-dependent activation and 
inactivation. To measure voltage-dependent activation of Nav1.5, cells are held 
at -80 mV and then stepped from -90 mV to 40 mV (in 10 mV steps) and then 
returning to -80 mV holding potential. Voltage-dependent inactivation was 
measured by holding cells at -80 mV, applying a 500-ms conditioning prepulse at 
voltages between -140 mV and -30 mV (in 10 mV steps) and measuring the 
remaining current at a test pulse of -30 mV before returning to -80 mV holding 
potential. 
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Data analysis 
Tail currents from Kv7.1/KCNE1 measures were analyzed using Clampfit 10.3 
software in order to obtain conductance vs. voltage (G-V) curves. The V0.5, the 
voltage at which half the maximal current occurs, was obtained by fitting the G-V 
curves from each concentration of PUFA with a Boltzmann equation: 
𝐺(𝑉) = 𝐺𝑚𝑎𝑥1 + 𝑒(,-./,)/1 
where Gmax is the maximal conductance at positive voltages and s is the slope 
factor in mV. The current values for each concentration at 0 mV (I/I0) were used 
to plot the dose response curves for each PUFA. These dose response curves 
were fit using the Hill equation in order to obtain the Km value for each PUFA:  
  𝐼𝐼3 = 1 +	 𝐴1 + 𝐾𝑚7𝑥7  
 
where A is the fold increase in the current caused by the PUFA at saturating 
concentrations, Km is the apparent affinity of the PUFA, and n is the Hill 
coefficient. The maximum conductance (Gmax) was calculated by taking the 
difference between the maximum and minimum current values (using the G-V 
curve for each concentration) and then normalizing to control solution (0 μM). In 
Cav1.2 and Nav1.5 channels, peak currents (normalized to the peak values in 
control ND96) were used to determine PUFA induced changes in I/I0, ΔV0.5 of 
inactivation, and Gmax. Graphs plotting I/I0, ΔV0.5, Gmax, and Km were generated 
using the Origin 9 software (Northampton, MA.). 
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Simulations  
The effects of individual PUFA analogues were simulated on each ion channel 
using Berkeley Madonna modeling software and equations from the MATLAB 
code in the O’Hara and Rudy Dynamic (ORd) model (O'Hara et al. 2011). We 
individually simulated the Kv7.1/KCNE1, Cav1.2, and Nav1.5 channels in 
Madonna and altered the parameters suggested to be modulated by PUFA 
binding to recapitulate our voltage clamp data from Xenopus oocytes. For 
example, to model the effects observed on the cardiac IKs channel, we modified 
the voltage dependence of channel activation by shifting the V0.5 as well as 
multiplying the IKs conductance by the factor increase we observed in our 
experiments at a given PUFA concentration. 
 
MATLAB simulations of the ventricular action potential in the epicardium of the 
heart were performed using the ORd model (O'Hara et al. 2011). To simulate the 
effects of PUFAs, we introduced the same modified parameters in the MATLAB 
code as we used to model the PUFA effects on the ionic currents in Berkeley 
Madonna. We made simultaneous changes to Kv7.1/KCNE1, Cav1.2, and 
Nav1.5 for a given PUFA and specific PUFA concentration to model the effects of 
different PUFA analogues on the ventricular action potential under wild type and 
LQTS conditions. To simulate susceptibility to early afterdepolarizations, hERG 
block by 0.1 µM dofetilide was simulated which previously has been shown to 
cause spontaneous early afterdepolarizations (O'Hara et al. 2011). To simulate 
the ability of PUFA analogues to suppress early afterdepolarizations, we altered 
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the activity of Kv7.1/KCNE1, Cav1.2, and Nav1.5 channels according to the 
PUFA-induced effects observed during experiments.  
 
Estimated pKa values 
pKa for each of the PUFA head groups are calculated using the structure-based 
Marvin Software (ChemAxon). However, studies of PUFAs in lipid bilayers and 
our previous studies on PUFA-IKs channel interactions have shown that there is a 
large difference in the pKa values in solution (calculated according to the 
structure) compared to the measured pKa of PUFAs in the lipid bilayer (Elinder 
and Liin 2017; Borjesson and Elinder 2011) and in close contact with the IKs 
channel (Elinder and Liin 2017; Liin et al. 2015). The average difference between 
the calculated pKa values (of PUFA in solution) and experimentally determined 
pKa values for PUFAs associated with the IKs channel is ~3.5 (82). We therefore 
add this value (3.5) as a correction factor to the calculated solution pKa values to 
generate out estimated pKa value for PUFAs associated with the IKs channel. It is 
this estimated pKa value (calculated solution pKa from Marvin Software + 3.5) 
that is reported throughout this work. For example, the starting pKa value for 
linoleic acid in solution, generated using the Marvin Software is 5.0. This 
calculated pKa value (5.0) + the correction factor (3.5) is equal to 8.5, leading us 
to report the estimated pKa value for linoleic acid as 8.5. 
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Hierarchical Cluster Analysis 
Hierarchical cluster analysis was performed using either R-based software 
available from wessa.net or using Biovinci data visualization software (Biovinci, 
Bioturing). Effects on I/I0, ΔV0.5, and Gmax were normalized to the PUFA analogue 
with the largest influence on each of the three effects so that these effects were 
now scaled from 0.0 – 1.0, 1.0 being the largest effect. Each parameter (I/I0, 
ΔV0.5, and Gmax) was then used as input for clustering to generate the 
dendrogram and heat map. The dendrogram displays groupings of PUFAs and 
PUFA analogues according to similarity of their effects. The heat map displays 
the magnitude of the effects, with warmer colors representing PUFAs and PUFA 
analogues that have larger relative effects (closer to 1.0) on I/I0, Gmax, and ΔV0.5 
and cooler colors representing PUFAs and PUFA analogues with smaller relative 
effects (closer to 0.0). 
Statistics 
Single and multivariable regression statistics were computed using GraphPad 
Prism (GraphPad Software, La Jolla, CA) and Origin 9 software, respectively. We 
conducted single linear regression on each of the PUFA parameters with each of 
the effects we were interested in (i.e. I/I0, V0.5, Gmax, and Km) to determine the 
slope of the fit, the adjusted R2, and t-values. In addition, we conducted 
multivariable regression for all of the PUFA parameters simultaneously with each 
of the effects to determine again the slope, the adjusted R2, and F-values. To 
determine if there were significant differences between PUFA-induced effects on 
I/I0, ΔV0.5, and Gmax we conducted One-way ANOVA followed by Tukey’s HSD for 
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multiple comparisons. Significance α-level is set at p < 0.05 – asterisks denote 
significance: p < 0.05*, p < 0.01**, p < 0.001***. 
 
Multivariable regression analysis 
To test whether the PUFA effects – I/I0, ΔV0.5, Gmax, and Km of I/I0 – depend on a 
combination of the different parameters (Length, number of double bonds, and 
location of the first and last double bonds) of the PUFA tails, we conducted a 
multivariable regression of each PUFA effect using combinations of the four 
PUFA parameters simultaneously. The multivariable regression using all four 
parameters improved the fit for I/I0 (Adjusted R2 increased from 0.40 to 0.54) and 
Gmax (Adjusted R2 increased from 0.25 to 0.60).  According to the multivariable 
regression analysis I/I0 is significantly correlated to the location of the first double 
bond (Table 2). Gmax is significantly correlated to the length of the tail, the 
number of double bonds and the location of the first and last double bond (Table 
2). However, the ΔV0.5 and Km (for I/I0) single regressions were not improved by 
the addition of more parameters of the PUFA. This suggests that the ΔV0.5 and 
Km (for I/I0) are highly dependent on single PUFA parameters (i.e. the position of 
the last double bond and first double bond, respectively). 
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